var title_f16_21_16720="Pulmonary hypertension MS angio";
var content_f16_21_16720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriogram in pulmonary hypertension secondary to mitral stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pulmonary arteriogram performed in a patient with mitral stenosis demonstrates marking shunting of blood to the pulmonary vasculature of the upper lobes, away from the left and right lower lobes, as a result of constriction of the lower lobe vessels secondary to pulmonary venous hypertension. Also seen is dilation of the left atrium (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16720=[""].join("\n");
var outline_f16_21_16720=null;
var title_f16_21_16721="Banded gastroplasty";
var content_f16_21_16721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74191&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic appearance of vertical banded gastroplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retroflexed endoscopic appearance of a normal vertical banded gastroplasty.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher S Huang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16721=[""].join("\n");
var outline_f16_21_16721=null;
var title_f16_21_16722="Bullous pemphigoid IIF";
var content_f16_21_16722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Serum IgG basement membrane zone antibodies localizing to the epidermal side of split skin substrate in bullous pemphigoid by indirect immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear IgG antibody staining on the epidermal side of basement membrane zone-split skin substrate characteristic of bullous pemphigoid. This pattern also is referred to as staining the roof of the blister.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16722=[""].join("\n");
var outline_f16_21_16722=null;
var title_f16_21_16723="Patient information: C-section (cesarean delivery) (The Basics)";
var content_f16_21_16723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15611\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/10/30880\">",
"         Illustration of cesarean delivery",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/57/42897\">",
"         Patient information: Amniocentesis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/62/18402\">",
"         Patient information: Breech pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1732\">",
"         Patient information: Having twins (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/2/19490\">",
"         Patient information: Shoulder dystocia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/60/20418\">",
"         Patient information: Vaginal birth after cesarean delivery (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/28/14785\">",
"         Patient information: Amniocentesis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/33/27155\">",
"         Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: C-section (cesarean delivery) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/c-section-cesarean-delivery-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H197175630\">",
"      <span class=\"h1\">",
"       What is a c-section?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A c-section is a type of surgery used for having a baby (",
"      <a class=\"graphic graphic_figure graphicRef63791 \" href=\"UTD.htm?30/10/30880\">",
"       figure 1",
"      </a>",
"      ). If you have a c-section, you will be given anesthesia so that you won&rsquo;t feel pain. Then the doctor will make an incision (cut) in your belly and remove the baby from your uterus (womb). About 1 in 3 babies in the United States is born this way. Most babies come out of their mothers&rsquo; vaginas. This is called &ldquo;vaginal delivery.&rdquo; C-sections are also called &ldquo;cesarean deliveries.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175637\">",
"      <span class=\"h1\">",
"       Will I know in advance if I need a c-section?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. The most common reasons women have a cesarean delivery before they go into labor are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The mother had a baby by cesarean in the past",
"       </li>",
"       <li>",
"        The baby is not coming out head first",
"       </li>",
"       <li>",
"        The baby needs to be delivered weeks before the due date",
"       </li>",
"       <li>",
"        The baby is very large",
"       </li>",
"       <li>",
"        The mother has an infection, such as herpes or HIV. These can spread to the baby during a vaginal birth.",
"       </li>",
"       <li>",
"        The mother is carrying 2 or more babies",
"       </li>",
"       <li>",
"        The mother has a condition called &ldquo;placenta previa.&rdquo; The placenta is the organ that brings the baby nutrients and oxygen and carries away waste. In placenta previa, this organ blocks the way to the vagina. As a result, the baby can&rsquo;t get out on its own.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women choose to have cesareans even if they don&rsquo;t need to. You should talk to your doctor if you think you want to have your baby this way. Surgery brings real risks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175644\">",
"      <span class=\"h1\">",
"       When should planned c-sections happen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, you should wait until the 39th week of pregnancy or later. (A normal pregnancy lasts about 40 weeks.) If you need to have the surgery before then, your doctor might suggest a test called &ldquo;amniocentesis.&rdquo; This test can show if your baby&rsquo;s lungs are ready to breathe on their own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175651\">",
"      <span class=\"h1\">",
"       Why do some women end up having c-sections after labor begins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A common reason is that labor doesn&rsquo;t move along like it should. This can happen if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Contractions (the tightening of the uterus that happens during labor) are not strong enough to get the baby out",
"       </li>",
"       <li>",
"        The baby is too big",
"       </li>",
"       <li>",
"        The mother&rsquo;s pelvis is too small (the pelvis is the set of bones around your hips and vagina)",
"       </li>",
"       <li>",
"        The baby is in an odd position, such as sideways or chin-first",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other reasons that c-sections are done are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The baby&rsquo;s life is in danger; for example, because its heart rate is too slow.",
"       </li>",
"       <li>",
"        The mother&rsquo;s life is in danger; for example, because she is bleeding too much.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175658\">",
"      <span class=\"h1\">",
"       If my labor is moving slowly, will I need to have a c-section?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not necessarily. First, your doctor or nurse might offer a medicine called oxytocin (sold as Pitocin&reg;). The medicine should make your contractions stronger. If that doesn&rsquo;t help within a few hours, your doctor might suggest surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175665\">",
"      <span class=\"h1\">",
"       How is a c-section done?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Here are the main steps:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        First, you will get anesthesia to keep you from feeling what happens during the surgery. There are 2 kinds of anesthesia. With regional anesthesia, you stay awake. Under general anesthesia, you are asleep.",
"       </li>",
"       <li>",
"        Next, the doctor will make an incision on your lower belly. There are two ways of making the incision:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Most of the time, the incision goes across your belly, from left to right, an inch or two above your pubic hair.",
"       </li>",
"       <li>",
"        If you are bleeding a lot or your baby is in danger, the incision will go up and down. This kind of incision might cause more pain while it is healing. It also takes longer to heal. But it is the fastest way to get the baby out.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        After opening your belly, the doctor will make an opening in your uterus and remove the baby. Then the doctor will cut the umbilical cord and take out the placenta.",
"       </li>",
"       <li>",
"        Finally, the doctor will close your uterus and belly with stitches and staples.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175672\">",
"      <span class=\"h1\">",
"       How long does it take to get better after the surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Within a few hours, you will be able to move around, and eat and drink. Most women go home after 3 days, but will have some pain. Women who work can go back to work in about 6 weeks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175679\">",
"      <span class=\"h1\">",
"       Are there risks of having a c-section?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Compared to a vaginal delivery, c-sections are more likely to cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Harm to the bladder, blood vessels, intestines, and other nearby organs",
"       </li>",
"       <li>",
"        Infection",
"       </li>",
"       <li>",
"        Blood clots that can block blood vessels",
"       </li>",
"       <li>",
"        Lost bonding time between mother and baby",
"       </li>",
"       <li>",
"        A longer time for the mother to heal after the birth",
"       </li>",
"       <li>",
"        Problems with the placenta and uterus in later pregnancies",
"       </li>",
"       <li>",
"        Trouble breathing for the newborn. This usually lasts for just a short time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor can help you decide if the risks of surgery are worth taking for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175686\">",
"      <span class=\"h1\">",
"       What symptoms will I have while I&rsquo;m getting better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For the first few weeks, it is common to have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Mild cramps in your belly",
"       </li>",
"       <li>",
"        Light bleeding and yellowish fluids coming out of your vagina",
"       </li>",
"       <li>",
"        Pain where the incision was made",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Call your doctor if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have a fever higher than 100.4&deg;F (38&deg;C)",
"       </li>",
"       <li>",
"        Your pain gets worse",
"       </li>",
"       <li>",
"        Your vaginal bleeding gets heavier",
"       </li>",
"       <li>",
"        The incision in your belly gets more sore or red, or is bleeding or leaking fluid",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175693\">",
"      <span class=\"h1\">",
"       If I have a c-section, will all of my future deliveries have to be c-sections?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not anymore. Today, many women have vaginal births after c-sections. This is called a &ldquo;VBAC.&rdquo; If the cut in your uterus in the first c-section went from left to right (instead of up to down), you have a good chance of being able to have a vaginal birth with your next baby. Ask your doctor if a vaginal delivery is possible for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H197175700\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"       Patient information: Amniocentesis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/2/19490?source=see_link\">",
"       Patient information: Shoulder dystocia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=see_link\">",
"       Patient information: Vaginal birth after cesarean delivery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"       Patient information: Having twins (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/62/18402?source=see_link\">",
"       Patient information: Breech pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"       Patient information: Amniocentesis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=see_link\">",
"       Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/21/16723?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15611 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16723=[""].join("\n");
var outline_f16_21_16723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175630\">",
"      What is a c-section?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175637\">",
"      Will I know in advance if I need a c-section?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175644\">",
"      When should planned c-sections happen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175651\">",
"      Why do some women end up having c-sections after labor begins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175658\">",
"      If my labor is moving slowly, will I need to have a c-section?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175665\">",
"      How is a c-section done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175672\">",
"      How long does it take to get better after the surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175679\">",
"      Are there risks of having a c-section?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175686\">",
"      What symptoms will I have while I&rsquo;m getting better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175693\">",
"      If I have a c-section, will all of my future deliveries have to be c-sections?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H197175700\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/10/30880\">",
"      Illustration of cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=related_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=related_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/62/18402?source=related_link\">",
"      Patient information: Breech pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/2/19490?source=related_link\">",
"      Patient information: Shoulder dystocia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/60/20418?source=related_link\">",
"      Patient information: Vaginal birth after cesarean delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/33/27155?source=related_link\">",
"      Patient information: Vaginal birth after cesarean delivery (VBAC) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_21_16724="Rilonacept: Drug information";
var content_f16_21_16724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rilonacept: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/6/24676?source=see_link\">",
"    see \"Rilonacept: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/9/14484?source=see_link\">",
"    see \"Rilonacept: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5726811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arcalyst&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5931785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interleukin-1 Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5931822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cryopyrin-associated periodic syndromes:",
"     </b>",
"     SubQ: Loading dose 320 mg given as 2 separate injections (160 mg each) on the same day at 2 different sites, followed a week later by 160 mg, then once weekly.",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer more frequently than once weekly.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5931821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/9/14484?source=see_link\">",
"      see \"Rilonacept: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cryopyrin-associated periodic syndromes:",
"     </b>",
"     Children &ge;12 years: SubQ: Loading dose 4.4 mg/kg (maximum dose: 320 mg) given as 1-2 separate injections (maximum: 2 mL/injection) on the same day, followed by 2.2 mg/kg (maximum dose: 160 mg) once weekly.",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer more frequently than once weekly.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5931823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5931890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arcalyst&reg;: 220 mg [contains sucrose 2%; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5931783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5931886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Rotate injection sites (thigh, abdomen, upper arm); injections should never be made at sites that are bruised, red, tender, or hard",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5931786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5931806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (48%; majority mild-moderate; typically lasting 1-2 days; characterized by erythema, bruising, dermatitis, inflammation, pain, pruritus, swelling, urticaria, vesicles, warmth, and hemorrhage)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (48% during winter months; 18% during summer months), antibody formation to rilonacept (35%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Hypoesthesia (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (9%), sinusitis (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): HDL cholesterol increased, LDL cholesterol increased, neutropenia (transient), triglycerides increased, total cholesterol increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5931792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5931793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: May cause rare hypersensitivity, anaphylaxis, or anaphylactoid reactions; medications for the treatment of hypersensitivity reactions should be available for immediate use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infections: Caution should be exercised when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with latent or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued. Therapy should not be initiated in patients with active or chronic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy: Use may impair defenses against malignancies; impact on the development and course of malignancies is not fully defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperlipidemia: Use may increase total cholesterol, HDL, LDL, and triglycerides. Periodic assessment of lipid profile should occur. Initiation of lipid-lowering therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tumor necrosis factor (TNF)-blocking agents: Should not be used in combination with TNF-antagonists (eg, etanercept). There is an increased risk of serious infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use caution due to the potential higher risk for infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Safety and efficacy has not been established in patients &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations including pneumococcal and influenza vaccines before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy. Administration of inactivated (killed) vaccines while on therapy may not be effective.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5931812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Interleukin-1 Inhibitors may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5931787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5931788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects and fetal loss. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit to the mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5931790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5931791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown whether or not rilonacept is excreted in human breast milk. Use with caution in breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Arcalyst Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     220 mg (1): $6000.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5931888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, lipid profile, C-reactive protein (CRP), serum amyloid A; signs of infection",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arcalyst (FR, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5931883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates interleukin-1 beta (IL-1&beta;) activation. Deficiency of cryopyrin results in excessive inflammation. Rilonacept reduces inflammation by binding to IL-1&beta; (some binding of IL-1&alpha; and IL-1 receptor antagonist) and preventing interaction with cell surface receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5931818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Steady state reached by 6 weeks",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9483 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-78FC411DA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16724=[""].join("\n");
var outline_f16_21_16724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5726811\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931785\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931822\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931821\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931823\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931890\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931783\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931886\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931786\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931806\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931792\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931793\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299999\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931812\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931787\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931788\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931790\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931791\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321814\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931888\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992805\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931883\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931818\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/6/24676?source=related_link\">",
"      Rilonacept: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/9/14484?source=related_link\">",
"      Rilonacept: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_21_16725="Left phrenic nerve course";
var content_f16_21_16725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Course of the left phrenic nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 604px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16725=[""].join("\n");
var outline_f16_21_16725=null;
var title_f16_21_16726="Brain MRI 4 year old with Krabbe disease";
var content_f16_21_16726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Brain MRI of a 4 year old girl with Krabbe disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAkgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwR/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+LoIZbieOG3jeWaRgiRopZmY8AADqa95+Hf7Oer6gn9pePblfDujoN7I7r57j3ydsY9259qAPWP+GqvBH/AECvEv8A4Dwf/Hq1rD9obRdQRWsPCHje6Vuhh0xHB/KWuXtPE3wM+HVuF0W1g1e9Hyl4oDdSkjuXf5R/wHFQ3X7VWnxkrY+FLt414UyXaJx9ApxQB36/GqFunw/+If8A4J1/+OUyX43W0QzL4B+ISj1Ojr/8cryW8/ap1tnzZeGtOjj/AOm07uf0ArN0j9pbxVZz3slxptjfR3Nx5yI8jDyEwB5aY7cZyc9TQB6feftP+EbKYxXmheKreUdUltIUP5GWoP8AhqvwR/0CvEn/AIDwf/HqZpH7QHgXxLZi18a6O9i0gCut1bi6gOf9oAnH1FS3vwb+E/xCtXuPCd3DaTkZEml3IYD/AHomyAPoFoAb/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49Xi3xA/Zz8YeGEkutJWPX7BASWtFKzKPeI8n/gJavFXRo3ZJFKupwysMEH0NAH2n/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49Xp+h/EDStZ+Gknji1t75NJjtbi7MUiIJ9kJcOMBiuT5Zx83pnFfm3X2r8NP+TNrz/sC6t/6HcUAH/DVfgf/oFeJP8AwHg/+PUf8NV+B/8AoFeJP/AeD/49Xz1+z18P9K+I/jS90jXLi+gtodPe7VrN0Ry6yRqASysMYc9vSu58OfDb4Xa7d6LFGPH9rb6xcy2lldXEtl5cksf3lIQM6/UqBQB6Z/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8wfGbwpY+CPiTrHh7Spbmays/J8t7llaQ74Uc5KgDqx7DiuJoA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4qooA+1f+Gq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAer4rqW1tp7y4jgtIZZ55DtSOJCzMfQAcmgD7P/wCGq/A//QK8Sf8AgPB/8eo/4ar8D/8AQK8Sf+A8H/x6vnjTPgd46u7Zrq90yHR7NRlp9VuUt1X6gncPyqxJ8LdAsiE1X4m+F4ZVGZFtfMugp9AVHNAHv/8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8+J8N/C9z8tj8UPDrSHoLmCaBfxZhxTX+B/jCaKSXRV0nXIlG7dpmowy7h6gbgT+VAH0L/AMNV+B/+gV4k/wDAeD/49R/w1X4H/wCgV4k/8B4P/j1fHmtaFq2hzmHWdMvbCXJXbcwNGSR6ZHNZ1AH2p/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VUUAfav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9Xf/Cj4q6H8Tf7U/sG11K3/s7yvN+2xom7zN+3btds/wCrOc47V+ddfVX7DH/M7f8Abj/7cUAd34h/aV8HaDr+p6Reab4ge50+6ltJWighKF43KkqTKDjIOMgVn/8ADVfgf/oFeJP/AAHg/wDj1fOHiHSoNe/aH1PSLxpUttQ8Uy2krREB1SS7KkqSCM4JxkGvX9W+CHw+tPE934f05fHWs6pZ2y3dzFYT2QEKNnGTKqAseDtGTyPfAB2H/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49Xh37Qfwy0L4e2fha58PT6xIurpPJImplQ8ewRFRtCKVP7w5B9O1eN0Afav/DVfgf8A6BXiT/wHg/8Aj1H/AA1X4H/6BXiT/wAB4P8A49XxVRQB9q/8NV+B/wDoFeJP/AeD/wCPUf8ADVfgf/oFeJP/AAHg/wDj1fFVFAH2r/w1X4H/AOgV4k/8B4P/AI9R/wANV+B/+gV4k/8AAeD/AOPV8VVf0rSL7VrlINPtnnlboBgD8zwKAPsb/hqvwP8A9ArxJ/4Dwf8Ax6j/AIar8D/9ArxJ/wCA8H/x6vliLwHqiyMNRmsNORV377i5XDL6rgnd+FRPoGl20gFzr1tIh4zApbH1oA+rP+Gq/BH/AECvEv8A4Dwf/HqP+GqvBH/QK8S/+A8H/wAer5cii8GQzwee2sXEK/64Q7VZz/sk8AfXmr1xrXghX3af4RvAQAVFxqBkGR1zgDIP4Y7UAfSv/DVfgj/oFeJP/AeD/wCPUf8ADVfgj/oFeJf/AAHg/wDj1fNDeLdEW88238EaQkPyt5DyySAMOvJOcH0NXG8c6JNbyRz/AA78Nkvuy8TTxlSem3D8Y/GgD6L/AOGqvBH/AECvEv8A4Dwf/HqP+GqvBH/QK8S/+A8H/wAer5qttf8ACrn/AImfgiJ8FebS/kh+UdRjkZPrWnbXnwpvEuRfaJ4r0t3B8r7Jex3Cx+n31BP60AfQX/DVfgj/AKBXiX/wHg/+PUf8NV+B/wDoFeJP/AeD/wCPV89W/hL4f6hZBbX4gy2eo7N2zUdKeOFm/u71Y7cdMmsbVPhn4jtLGS/tLWLVtOQhWu9MmW4QE8gED5gce1AH09/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFroVJB6jgg9RTKAPtX/hqvwP/ANArxJ/4Dwf/AB6j/hqvwP8A9ArxJ/4Dwf8Ax6viqigD7V/4ar8D/wDQK8Sf+A8H/wAeo/4ar8D/APQK8Sf+A8H/AMer4qooA/ST4X/EDSviPoFxq+h299BbQ3TWjLeIiuXVEYkBWYYw47+tFeYfsU/8ks1X/sNS/wDoiCigA/bW/wCSWaV/2Gov/RE9cf8AATQdZ8Ufs3+J9D8O3Fpa3d/rDwSTXLMqrCYbfzMbVJJK5GPc812H7a3/ACSzSv8AsNRf+iJ6+KqAPv8A8CfDLUPA/wAQpdS0rVFu/D93pkVndRXWxJxLCAsTKsUaoVCALzzySc18AUUUAFW9L0+71XUbaw063kuby5kEUMMYyzsTgAVWVSzBVBLE4AHJJr6X8L6fZfAXwGPEOu20E/xA1eMrp9nLybOMjqw7Y6sevRR3NAF3RbPwv+z1o63WtpDrfxEu4d8drGcraKe27+Eer9W6AYzXnWuz+MfiXfNqPiq/eG0HzRQMCsSD0jj/AKnk+tWPA+nS6zqWoeJPE0stzrEtwCFuUyWLDJkweMDoB0Fdtcyqs7hB8rZILDJPtQB5mvgWAhhFJLIFbBlIwMewFVF8LCPWLa28rMMhJZ2/uj0HrXpMkojaMOp8s+2B+NVNRmj8pHhX99u2oy84z2oAbdaRYvpcGnra26xnDoyj5iO4ryTxJp0en6nPFCWVQ/yj29K9S1H7XbvFAsqNGnLSqeW9hXDazElx4hsbdlJ898sp9PrQBzkFjdznESO65Az2rfg8N65pF3Be6VctDdqN6SW0pjkT8RXbQQwxB7eAbHAwu0cY9qtRSpHHEJ13E52k9yPagCz4K/aC8YeFrn7N4riOt2Q4PmgRzp9HAw34j8a9H1fQfh1+0Fpkt7oVwmmeKY0+Z9gSYH0ljz+8XtuHI9e1eXSWtpfWrJNCnlHOPMGd59fauO1Lw3e6HN/bOg3kttc2hEqmFyHU+qMOuO4oA5Pxx4S1fwV4huNH162MNzEcqw5SVM8Oh7qf/rHBBFc/X014f8X6f8c9E/4Q7xyLSz8UIhbSNWVdvmS91I7E4GVHDdhkCvn3xX4d1Twprt1o+u2rW19bthkPII7Mp7qeoNAGPRRRQAV9q/DT/kza8/7Aurf+h3FfFVfavw0/5M2vP+wLq3/odxQB5V+xT/yVPVf+wLL/AOj4K9S8G/BjXtHk8OLKnh+wn0zVW1C41ewmka7u4ixP2cgwp8hBAOXYcdO1fFtFAHqv7Uf/ACXbxN/26/8ApLFXlVFFABRRXovw/wDhVq3ie1OsapNFoHhaIbp9Wv8A5E2/9MwSC57DHGeM54oA87AJIHrXpPhj4O+JNUhW91pYPDWjbBIdQ1hvIQqem0Hkk9ccV0Uvj/wb4DZrf4YeH4r7UEGw+INYXzHLD+OKI8JzyDx7g15n4l8Ua34nvDdeINVvNRnLFgbiQlVJ/up91R7AAUAd4YvhP4TmAaTVPHN2vJ8sGwtFI7EnLtk+nGKiuvjN4kjtTa+FLDR/C1kBjbpNkiOw/wBqRstn3GK80tYHuZtiD3Y+g9a6nT9AjUI7iY/MD0z+fYCgDC1a91TV7lrjWL27vpz8xkuZmlY/iSazgQOgFdbL4edtRcw3To4bMQ4Yj3+lYN+00M4S5hiDxZRdq4DHP3j60AV4PIId7oOwxhFjIB3e/tToFaOaKSwef7SDnbGpV09wRWp4dsPtEpcoWcHkjGQPaurjs4lnW5jQeaFwrR/KT9fWgBdI+Jnj7S7RoL6eXWtMOA9prMH22IgdjvywH0Iq2mp/DLxiNmsaVc+C9UkGPt2mk3FkX9WgPzKPZT+NaJtH+zxTWrIgVNzKSdxb8P61xXinSd9xLPbwhZsbzsGBJ68etAFfxX4D1PQoxeWzw6vosnMOp2B8yFx790I7hgK5Guj8L6/qnhnVYdQ0a+l026jO4NjMb+zKeCD6EGvSxfeCfihILfxJDaeDPFb8RanZpiwu27CVM/IT/ez9T0FAHiFFdR498Da74F1c6f4gtDEWyYZ0O6G4X+8j9x046jPIFcvQAUUUUAFfVX7DH/M7f9uP/txXyrX1V+wx/wAzt/24/wDtxQB5V/zdP/3Of/t9X11ceE9f0b4ka14q8MDS7xNZtYYbq01C4ktykkS7UdHSOTI24ypA+tfDfxY/5Kn4y/7DV7/6PeuUoA+pP22hcCz8BC+aJ7oJeec0KlUL4t8lQSSBnpkmvluiigAooroPBvhTUfFeotb2HkwW8Q33N7dP5dvap/fkfB2igDn67jw98NtX1HSo9Z1aS30LQHYKNQ1BtqtnpsQfMw9wMe9bX27wp8PtQePw9HYeNNYCjbqN3AwtLZuhCQn/AFhHZycdwK5++XX/ABfqH2vVrma6mIJVT0RfRVHCgegoA2bm/wDh74bkaLRtJvPE93GVK3uoymC3LD7wEK8sh7ZbNZeteItd8a3FvbWGlQxx20ZWOy0ezIG09SwXJb6mtfS/AsUUi/b3TjazlgTgHpj+Vd94CvZfA/ie3vdLtpLdCyidQMC5h7hv5j3FAHjl54P1nTtWsdP8QWVxo0l3jyX1CJ40IPpx+GB3NXpvBN3BcPbl908fEieWUKHPQg819E+LfiTdeIHNpfWOntphy6R3EAcqwPDgnlXHbHeuK8Q6vLq+rNezAzybREJXIEgbHUnvQBk/Cb4R6P4q1G5TxBq9zawRQmZBalQzhD8+SwOAAR0FYl14L0VdQuDbPdPYuS9qN+ZDF/CX4+9jBNdzod02k/bbuOJlupbZ7BUZsNGJMbmz3BA4xzWdp9zBZJM5AdYxsHmIT2/p60AZGi+H/DqCWy1jSw1vdIYxdxSk3Fs+PklXkAgHG5TxivUfgP8ABfQtX8DyT+OdCin1AXsiwzCd1LwgKB91gMZ3Y715r4chbWPEFvaJ5kklxMtvGOMNk9TX03rXneDdDs7Czup3KqXMpxgMOOnYe1AHnfxN+EPw18K6ZHdHStTNxdP5MFvbXzKC2CS2WzgAD3+lc98Nvgd4K8WaXPJPqmtR36NloFmRfLXPH8Jz9a7f44ayl34P8PTSpIbl52dZAu1eEwWGexz2rB+C+u/YNbsVuGjiinZ43lcbflIyB+YHJoAxPGP7NukaecaZ4yFvKeVh1GINkf7yYP6V5nrHww8e+CJV1LS45rq2ifeuoaFOZkVlOdzBfmXHuK+iPFl/Zaz4qmMaybN2xiWG0EDhh7Y607RPDetabNHc6DcKUZiRLFJy3fBA4YfWgD5pHjTS/FE03/CwdJjurifP/E405FguUfGA7qo2uB1Ixk1ieL/Al3odgmr6ddwaz4blcRx6raf6veRnY6n5kYeh/Ovq/wAafDbwb430uS91sQ6F4ijBE17ZqELv6unRznqPve4r5r8zVvhh4ju7Rkg1XRrrMc8E0Z+y6jCDwSp5Vu4PVTQB5kQR1pK9D+IHg2yttGs/FfhKZrnwvfv5ZR23S6fP1NvL/wCyt3H4E+ekY60AJRRRQB9q/sU/8ks1X/sNS/8AoiCij9in/klmq/8AYal/9EQUUAH7a3/JLNK/7DUX/oieviqvtX9tb/klmlf9hqL/ANET18VUAFLSVv8Agfw1eeLvFOm6Hpw/0i9lEe7GRGvVnPsqgn8KAPS/gZ4cs9G0jVPiZ4nhRtL0VSNNhkOBdXn8GB3CnH4nP8Jqv4fvdS+JHxJk8ReJlFysZ3MgXES4/wBXCoPRR19+SetSfHbxXa3N9Z+DPDL7PC3hxfs0Sr0nnHDyE98HIB9Sx71t/DC1aPwfAyxyNHIzuRjbufOPxwKAN7WLcrG5tZMSHjfjBU+1U5hOtpFbXWFlUbo516OO+fepLuVsqSAcZyQew7YqGS9d8ERrt24A7g0AZZuTJbmINmRHy3GFIqvYSJJqayM22KM5C/dBPYVWmmJuZYQPm3ZCkdQferVgoTzI7YhyeWPBK0AJrUNxeXMkMSMsUhzhT1/GuR/s94fF9l9oYKOSO+celehRKzqNxXDjGV+8B6Vy/iq1ex1nTLxZmWEsYdx5C/4CgDQ3rDrUryo6AqAik9CadqEzxXcayMsYAzkdGHtTnKnUBA08bB4w4bOce1R+IoSkEbNhVjGcY52n1oAns2aVpHCsFHKgcnPqfapZQ91p8yxfL5mQzYyVHfHvWfoVwssWws2EO0DpnNajSCMr8o3L/D/X3oA8+1fwlc6Zax6jpk0hkifeGQ4dCOQwPYivXHhtf2gfhy0irHF8RtAh+bAA+2xf4H/x1vQNWRJN5kcwfyxGw4wcnFcXp82seA/FaeKPDAAFsctE/IZD95HA6qf060AeZTRPDK8cqMkiMVZWGCpHUEetR17P+0JoNte/2N8QdBgCaR4khElwqcrDdgfOv44P4q1eMUAFfavw0/5M2vP+wLq3/odxXxVX2r8NP+TNrz/sC6t/6HcUAfFVFFFABU1vBLczxw28byzSMESNFLM7E4AAHJJ9Kk0ywutTv7ey0+3kubu4cRRQxrlnYnAAFfQKwaR8AdGgkube11b4nXkZaNS2+LS0YYBPq3P484IHLAGNZeDfD3wnsrbV/iXAmr+I50E1j4bik+WP/buW6YzxjkcHhuccP458a+IPiLqwuddugtvF/wAe9nF8lvbr6Iv9Tkn16VWgtNT8X6xNqmtXlxcT3Mhae5k5dz7dvYAcAcCtZtBtLa2lVN6R7tpaRxj/APXQBi2miLuTepbcMsByceoNTy6JDLPK6JvWNQWVP4R71q2hX7KbmRpoYpG8qOTGOnYL159afbIZZLkyx7YTwYVOOf7xNAGPoNpbW+v3MAhFyqx71APyA+5rsURnWYyujzCP5hn5QvoB61zekJKmr30kSAxTARKyYAz7V6FdabDp/hhnB82cMJHz+7ZD/snvQBzzGD7MFgTZLt+cADp7ntXFa3am91e3+yxoxK4CRAnJHc10l3KqRMZBtDjLY5/Bj3rKtL4XOuSqjkLFCT8vy4x6UAJpsbW8a7YwJ0Yhi3BPt9K0rO583MQAZt3yorYC1LcRQyWyu5YvsDEgfofWq4tmYGaNgsSkDaeufagDRs9QPnxQkM7KCFIGBn3qQW4ZJJEeINjG0tghvb2rPULDKTvdZARujX0+vpVpGTLu8IPnnamBwD6YoAZqWjpK8aqwCOAJC4yob0A71Wv/AAdp1ygisfOtrgDl926HP+0DyM+ord06GRpVkZzNOowyFv8AVj2HStdZEeOMLGZ9wIZnUAKAP1oA5fwf8Q7nQ4pPCPxCtJNc8JN+6ezlYNJaekkD9RgdACB6Yql8VPhqPDdtb+IPDF5/bXgy+ObXUI+TET/yzl/usOmSBnpgHirGlWOm6xC7fZkZLmVgZn+bgfwqf4aveFfEd38M9SlguLd9V8DawTFeWE+GEi9CR2EgHcY3AYPYgA8epK9L+L/w+g8MvZ674ZuRqPg3VvnsLtTuMZ6mGT0YYOM8nB7ggeaUAFfVX7DH/M7f9uP/ALcV8q19VfsMf8zt/wBuP/txQB4B8WP+Sp+Mv+w1e/8Ao965Sur+LH/JU/GX/Yavf/R71ylABSgZpVBYgAZNer+G/Bdl4Ls7TxP8T7KVbaQFtO0Jhtnv3HQyDrHEMjOeTxwR1AMLwj8O59V0KfxFr+o2+geG4WC/a7tW33Lf3bdAMyH6cfkag17xXc6vFDougWx0rQ1+WKwhc/vDjBeVurE4yc5A7Vo65qniT4n6ss9zsttMtW8q3giUpZ2CkDCRqO+AOnJrv/hT8O7lNYeXQ9R0XVJgv72y1G0eOUx9GaEnI3Dr1+tAHGeHfA8EBhuNUnYLncFjUhn+noPeu3ayWbC6dBHa+Y21fmwvuCfUetdFfWGnWWpzW2p6mI8SbZ2jQSSIfXA4PHTFVfECeH90K+HZNTkgYkzG+QKWOMZTHY0AQ63oXiHQbmEazagWd0mIZEZZIyFGcZUn64Nc5qN+b7UPLtHkVFQfKcg59q6SfVrk+FTpYEkllBdi9hkmO0plSjIB6c5x05rktAYnWbgOmVR8jB4Az2oAjk02+lxbyLIrq3A3ZIJ7mn/2G+nrvneeOXZlkP3uvbv+NdDLfO16JrZisgbcWPLe34VX8U3U+p3V1qEr5llKlsHjpzn24oAhS8VU/cgrHkOHxklh7mmaykc0VxLFIR5i+Yu1Rjdj5hn0qjDeECCPy2II5B4Byegq3JKgtxiEhQSwX+6enFAHO+Hrp4r9LmNiJoXR1CnGWBzuz+Feu+MvHU2s6rDMW8yPYN0a8pEcfdU9/U15j4OsFv0eTIa4RmKjO3cM8jFad1atB+7CqqMCSvOB7j/GgDR8deI7jU9N060ErTQ2u4KzkEAtzkenpS+FLgPd20+QtqhCybxyD6rnriuX1BsKIlj3BTgnrwe1Otr8WURihLlh0DD5U/CgDutSv7a3vbrZMssTudjtnDDPXj+Va2nePtT0+xMVpdN5e1owgHyqO+PQ15sjvdSK88qqH5UdifTFaWkTK16EmG2McKFPG7/CgDudIvNQ1F90gK5OQ7ktuJ/ixW34h8KaJr+lzWfiWC/giaPdAYE+cSHgSLnsDyexqXS7yx8MXMUjiOebbvEUowqgjqfWtGx8VzaxqEl3dqxjAKl9mFUHptBoA+ZPB+tTfD7xTqeieKbV7nQrsGz1mwxkSx/wyp23rkMp/Udayfit4IbwbrUP2Of7doGoxi70u/HIngPIBOPvrkAjjscDNfQP7QPw5GofD+LxPp9uHv8ASxvmkRQGntG5O71MZOcn+HPtXnHwoubPx14UvPhjr1z5M8rm90G8kORBOBzD7KwycD1bvigDwyir2t6Xd6Lq15pupQNBeWkrQzRt1VlOD+HvVGgD7V/Yp/5JZqv/AGGpf/REFFH7FP8AySzVf+w1L/6IgooAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgAr2r4XFvBPwr8S+OifL1S+P9iaQxxlWbmWQfQDg/wCya8Vr6B+IOnLHqPw5+Hq5+z6XpyXV4gHW4my75A+n5MaAKXwr8H2K6J/aWs2qz3NzkxLPnEcfZsdyx5rqI4UtFMazN9kdsp1xGO/HpW221bdPNMao3GE/hxwB7CsG51e38/bNIphhBUBeMn696ALVzbwuW8nlXOBg8kevsK5O7gmWWVIDm33YY9cf/XrSiRZJRLY6n5RYENE67gaS/YRWHlxyKqJkvz8pb296AOanmigeMzM+0btpzkqau+HZHdZpZ9iqCDvHBNY9wd9vLPMzbWOFOKraHfrFdBZDnLAjJoA9B87Mv2iTAUDBCjGPqK5HxjqcEep2CSLG6hzI3OUPoCK7i1igv4Ht+A23eNvJb2zXK6x4cstUniiaMps5KKcHI60ASafYJHA9xsV5rggOW48v0x7VLq9v9nsJFwJOxOfmx2b/AOtVtYILZUgtyVcLuY5J4HYetZPibUYYkTOGkK9M8j8KAMzT2beY4zknqEHJ/wAKuRXgSRBl94BDZP3RWLZSNlJTuWXooXjPpWxZWPmIs8hHJ5Qtkj3oA04WjlRXhIEI524wc+lXXW0axkmkTYACrpjdkEdarCK3jjMqRsdx4HYn2q3b3NoXSO4kWMyDiMjBHtQBU+CjL4y8KeKfhhqU2xp0a+0jzOPKuEOSB7Hgkem6vCbqCS2uJYJ0KTROUdD1VgcEfnXoninVDoPjfSdd0uU/arSRJWaM7Sdh6Ej1Xg1e/aP0m0h8bQeIdHVRpHiS1TUoCvTew/eD67uT/vUAeT19q/DT/kza8/7Aurf+h3FfFVfavw0/5M2vP+wLq3/odxQB8VU5VLEAAmkFexfBLw/p2labqPxG8Ww+ZomiMBZ2zD/j9vD9xRnghTg/XnoDQB0Xh60tPgb4Qi8QavbpN8Q9XhP9mWMq/wDIPhPBlkHYn35/hGPnrxC/utQ1rVLm+vpZ76+uHMs0rnc8h7811l3LqvjvxTe63r0pe5uX3uSfliU/djUdlA4A9K2dM8P26akzxyqIbUfvCgCsxPp2oAl0trebT7Z7J0NuiqwIOSh7qR2Oai1SIyRwsx2WwlZpNw5k9AorS1WziskjmgAgkRgJPkwrqezAfzqjqVusdzLJMB5ZHCq2UUEcEHtQBWtoVmIlmAiUofLAPEY9/Q0yTEyEMvlMQEjbpv8Adj6060ec2cqTOuzGAXXA+me9Pm8ye7EuNoiQKigdPf3oAl0q1hh1KGOPjsInHU+ufWvS/GVi0mgWqyqqyfZ8u6MOnbOeprkPBOnjUtZgnkZhDA/zyxnkP9K1/H3iJrhvsC5AV9sa7ckn1I7UAcIzGZWWSWONkAURhcE47nPesu6tWi1bTby2Ea3Eqss3oR0ye2a1oli+2BrpPP3ks2F5+gNYt9fxW+uWyzq6RlTtLdAD0HFAGzbp5tqzFiyouSx6HngVpWtushPkQElsbc/dB9qzLa/32mUVfJT5Nyg8H6UljMbe/SWRmbawIbccA+ooAfrFtPaXBKurIW+Y44z6Gk89tv3SXBHyrjk10ev20l1F9qKMy+XnaSPnP97FczboUYSoFj+XA3dQaANa1lJkj2qsMh+8xx+hrF8V6zdR2i2OmA+dcEw7gnzlT12+mavxOkKq7usnoqjAZj9ag8pTq8EscAQWMTM7IcmRj3J9vagCxpVp/Z+n21hbo6+WmZmBz5jnqfYCma9p39uLFZh5BaQvnzEHyg9zg9a0rSAsiyIY9zofM5x17gVatnjSBGRchSf3p5U+3Pf3oAyvAWtW3hfU77wP43b7T4L1ggSOwI+zOeEuY/7pBAz9M84weK+J3gm+8B+K7nSL0+dCAJbW6C4W5hP3XX+R9CDXReK7O48QQRw2EXmizDtHlcMAeWQt39q6rwrN/wALa+Gc3hC+zJ4w8OxNc6NK5+a4gGA9ufUgAAf8B9DQB4LX1V+wx/zO3/bj/wC3FfLMsbRuVdSrA4KkYIPoa+pv2GP+Z2/7cf8A24oA8A+LH/JU/GX/AGGr3/0e9csoLEAZJPpXU/Fj/kqfjL/sM3v/AKPevXPgr4H0vwf4YPxR+IMf+hwAPpNiwBaeQ/ckx3JP3Qf948AGgCDwl4V034Q+HofGnj+2iufEU6h9D0R2yyvj/WyjtjKn/Z/3sAcNdQ+IfiFr0mr+JLq5nmnPXHCr2SNeiqOwH1rRvE8X/FfxLe+LLjSr3UrSCdIpksovNFsnVYkTOWAHXHrk9a92n8DWF/b2c/hG9SO5NuFNpeSeUTJ0YA9nHQigDmdS1HS7nQPD2mWWnx6Z/ZBkgltonxEyvtImBPJYlTuzzk9+tUvDutrZ6/BdW8jWyQPIkbLz8zIV4B4GQcZqPxH4a17RAIb+1u7PA4lmj82Mn2kXI/XNcW9tqEF0UmMxDdsfK59aAOhaUCeWIsWiK7VWYZOB0JqC7uxFaKxIUgYY+o7E4rM8+9kVjOH/ANkY6/8A16qSak9ugdgC2c5wNo9setAHWaMrz6WvlqyvHuifDHDAnII/+vXM6mqw6i00EuN4/eFeCOcc1l6V4kn0u9LQRuy4IAV8de/oc+9O1jXJNYlMkVotu2CGDH5mHfOOKAL+kajLca6yKVG9CqBjwv0rd1a3LJAFCKpLDOea4eyYW8kMoZVIORu9O9dDfeI4TaLFGskpwcAjp7+lAFfUZlQrtboRjuEPfj1qld6s8kJtbZ8Kx+dh3H1rKl3TlpZGJIPXvSxqnnLkshHtxQB738GvDsV/LBb3MYZ3UyboeAgGMMT616Be/DO3ku5pL263KGaRsjau09vx9PWj4HaY9lbLI6lfMtUZV9M4Nb/xU10WGlfYo2O6cESkcbV9Ce1AHz/4yi0+2M8NnFGPLXCtjG4Dpn3rz6MMz4wBzuxW34i1A3N0YYQREDgbjx9apwxxocryOjD1+lAE1s3kSsZD8zD5Sp6f4U3z1aOO3T92+/72MZHp61FeXEYbKjeVA+5xUWis0uqxytjIJPPOaAPQ/DHg671ANcyTyyFBvHmMSHH90Zr1fwzYQyafOrwrHaRIGkkuFOxQOp6fe9B3rzzTvGP2KCFZbhlXIIiIyrY/pV3VPiHNq0628Uu627RITycdT9KAO+1XXL678N69Z6csMNu2lT/Y3kTzN7qh5bPXI7dveviWbTtV8NnQtSybd7qFNQ0+4jYMRtcgHPZlZTx9PWvsLRZLk6XH5xh2KwMZkJzlu2O+at/E/wCFNl43+H1hbQQwaTrGnIz2TDhFZvvRN/ssce4PPqCAfPvxNsH+Jfge3+JWmwJ/alsBZeILWH5irIMLcAdQpXGfQY9Ca8MYYNez/A3xbL4A+IU+k6/D5Wl6k/8AZuqW8/SJgSoY/Qkg/wCyxrlvjb4GfwF4/v8ASoo5Rpznz7F353wt0Ge+05U/SgD6W/Yp/wCSWar/ANhqX/0RBRR+xT/ySzVf+w1L/wCiIKKAD9tb/klmlf8AYai/9ET18VV9q/trf8ks0r/sNRf+iJ6+KqAO1+DXh3/hKfif4e0p13QPdLLOD0MUfzuPxCkfjXXDxWuo/HXWdfmMkltPczxI8YL7Ih8iH6YApfgZ/wAU94S8feNZYxusdP8A7Ps3b/nvOcce4GPwatT4M6NFF4RutSkXEtxOYRkYLxqOcH6mgDq9W1a0heKMyx+VGg3Y+YsMd8etctc+LNCe7t7JYZJfNJBkWMIuDxjnkY9a666ls7fcpt9yuoU7UBDAeprI1PTNN1W1eYxxblI8sqAroR3BoAyNV0FImd4doXPD54I7AGsr7HLbEgPKUIyhJz9c1vi6Wxt3j1TdJEq4+0ZwWb1Pt9KmUw3duZEWOZdm5XUELj196AOUjtpLqRbfehckkJng8d65jVrabTrvEySRM3K7h1Fdtaoia9aLuVBNKqyMegGe1YvxW1q6k8Y3trcxK+lwkJakJgrHjqD6mgCz4U8Sw2tqLa6UrKzfLKH7f0+tS6D4jgvPF9550vl2qQbIC7beR94+9cDKrLh0O+HorimFyu5sbWYfeoA9J8R+KEsbwmykhkkZdrFecL6fWuFubxryVmG4knAHtWcokcBew5Jrrvh3FpFzq00F0Zpr0QNLGyj90m0ZO7ueO9ACWUE9vbyF1+c4Yk9hWpY6vDFblJExIDjI7f8A1qTTojqd9NPcODGAenT2q7FY2l1G0ll5e8HaQq4b3zQBYg1mB18kxkTuc7s8Cp5ja3qWplh8yVScFh096p2tr9kjcLFumU5IPb2zU9nDduW5jTzMEqD932oAx/GnhOK8ikmsV8ueNNwUHPmD39Kn1Nx4l/ZqsZpCWvvCuqG2PHSCbkZ/4FgfhW9qt9GmhyQsoFz91WHHH19KxPgnH/bek/EjwruYnUNKa6gQc5lgbcv6mgDxevtX4af8mbXn/YF1b/0O4r4rr7U+Gn/Jm15/2BdW/wDQ7igD498N6Pda/r2n6Tp6bru9nSCMdgWOMn2HWvZvi7e2Y1nTvAmiFj4e8IxiN1zzdXh+8xHc5JHsd/rWL8A1t9AHiPx7qCqYPD9mUtAQDvvJspGAD+OfTOa47w2janeStcu8tzPKZJZOS4c87j685oA9O0vTrS20WQyOPtPls7PGvJY/3s/lVDw1HPBaulzb7VlO8S4yAe2RUspkTSGt7ydlbgMYxkyIOhA659atXsZNvGyOFjjQFmY4L+gFAEWoq8xu7NbhCxUJk5INYkkqalZkBHEinyZocFfmXoc96eZriC8NxdnJfjBH+r9BV+FkuUb51UK252UcZ/2jQBnW6slkMHekXEiSqcnPYCtTRbSGbUI8ph2XBVTnav0Pes9rhlE4AWQA7g+7GR7Vv+B5YZr5JJXWObcAoI4IoA9At7WDwr4UnuLgIWdWCbVCsQeh+teNRR/a55bp5GkeViVMhzzXqHjzVEudMmgWItInyxtu+WQfSvLrZVSMxxn9/g4jbkZ/pQA6WTMAmZGZiCnmJ2/4D3rn4pVu/EMO5ABGm0Z5C4749a30aKaZPuldvzuucK3oBWIxEWuwTRlJGkyo29vqKANaW3t4GN7DvDMNu09X99tQX4WRo1jkjTam9toIOfQ1LfTMLaNl24jbG3uff6VXea0kiVYmdmLfOScE/QelAHoPhR4b7w9HmJ5HQlSx6Hj+Y9K5O+0901ExuMqWKqGbDn3IrofAMhgsSjvGn73KrtLDB7kdjVHxcWS5W4bJkiYjPGW9DQBjCONHyzhmQeWATjb9RTl/dII7fK+W259wJDA98VPcTLdW6vJsHyfKgH7x29DVexmeaIySGVJIvlKN1U+hoAmklkDyRspAA3ZY4Dj2PatOS3FxpqbZQq7NzITnafTNZTEyybLePdMRyc8VrWFrBbgJdOZLtl8w8gKMegoAs2KLHbCFEZOB82Pl/wDr1y3il5vA/jrRvFHhvdC74uljH3Q68SIT6MM8ehrWttahTVLuzZGmbb5kaoSePr2qHxNpr3Wj3d1qcrNcPF5kSAErHjsooAr/ALQvh+0TV9O8Y6DEV0HxRAL2PA4inIzIh9Dk5x67vSvTP2GP+Z2/7cf/AG4rifBiyeMf2ffFnhyZ/NvvDcyatYoRlhEc+YB7Abz9Wrt/2Gevjb/tx/8AbigDkfCXw8Tx9+0R4x/tJcaFpusXlzfEnAcee+2PPbcQc/7IarnjHUr/AOOfxVsvDnhvEHh3Ti0duUH7uOFcCS4KjjnhUH0Hc10XjPxHH4O+GPjtbFvK1XxF4r1O28xeGESykSMD7KMfV6u/DKJvhh4DsGgt4R4m1xEvLmSUA+RAf9VFj6cn0JPXigD2qTRbLwP8P/7O8NW/2a1s04Kn5v8AakY8ZY9Sa8Z1XULO8sIzA6lTtZolGW3g/wCs+p71sJ8T9YE8sZeC+hClZYpo1KNntgYPtiuO1SGwlZn0tXthIC8sG7Kqx5wn+z6CgCtL4kvI47rTnv5ZtMmYhrd5WKH6KSccjORVXUY3kgCoH3Z8xfL/AK1k6kYktIpJl8p1yGyvPsP/AK1c1/wkN7aJLEMSRdM7iCPTmgDrvPU2B+0hXdf4wcE+qkd65HUr+C4d449q7Txt6VmXWsXdwgUExqxPTrz2qGNiHdwAp7dv1oAmTCgs5UKBjA96c5EaKejZ4A61TLsGU7cjP5GnNy25QWA5Ge9AE88q7twDqTznqM+/tVOW63fKF7dKWQsq5yWGOg/wqJsu3OAfYdaAGSzO74wyqDgDHStCxt5TcRiQgE8KcEkfSqW90+UFfk6e341YtLkrcRsA3UZwckgdhQB9gfBF5DAsfkssCRZQsTwT12nv756VwXxj1fzNSuo5WXMpwQhIB2nGcdjXo/wq1C2i+H09xfTqkLhpOG+4gUenevEtemtfFmuLbKX+0yMyrPnHzH7rN+FAHAzsMttZnwcA5zxTo4jPuUsQAu7avStvxv4H13wPepFq8O61k5gu4hujkOOQSOh9j+GaxILgOsbMRlfegAMSwqd7ZYDgkVLp7+UiyNhfbv8A5NTyqbiNQGAPZcdarmMhtkjMqjqOuTQBdkaa9fLlsk7ge+a77wFo0DxvNFGZZB94Y3Nu747157E8cQZ5CCM8AHnHrXonwx8W2Oj6zFcTOoVWwDjaWUjBGT3oA9o0m2/sKCCa7jQ30wDRRuMeTGOrN/teg7fnWbc+JpBZzNdNM9wHJVGwVj7Bvfjt0rlde8cprOpTHSnd5ixWQRjcqL0VQ3Qn1xVPWbpdOil/tYETPGQYpD9zjgn/AA60Acb+0F4EGqaFH450uJPtEcaJq8US/KynhZl9xwrfgexNZnjBpPiR+zxp3iGQpJrnhSf7FeuR88sB2gNnvwYz9Qxr234bLFq3g3VbK9tpPJvIJIMP3RlI/WvEf2Vb2KHxprvhLU9j2es2Ulu0UnIeSIkYx0OUZ/yoA9Q/YrGPhbqo/wCo1L/6IgorT/ZQ0qTQvB/ijSpyDJZeI7m3Yg5zsihH9KKAMz9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr468P6Vca5run6VZANc3twlvGCcDczAD+dAHr3i8Hwv+zx4O0IKBda/dyaxcAD5ti4Ef5gofwrpPB2ganoPhyCyv75JFZBMtqqH/R2bnBPc1J8UDDq3x+0rRLdVk03w3aQW8cQGRlV34I+pUY9q6a71KT5y+JpWJZi/YnqR7UAcF4jm1/T9StJ7SCK70wsDNEifNjvn/61aBKORJaiNEccqe3tzWi1/KHlYxhieOR09xisuWVpAHt4184D5QemPU+9AEOq2FtqUJjuwfLQZYK2Mj0q4j+ZbRxxQxx2sMexfQCodPu3+YzxOsuclSAVb3pmtSwQR8sDcSfdKcgE0AYESxwazDMX2K7HKk/dPbBrY1OxtdTVRPGJmbqWGAfxrCvY3i2vMQSuNoIwSK2LK9+0WcYkU+azYUDpQB5vrumS+Hb+TdEz6e0m10PQj610l1oHh6zuL+4vL+ZNOtbWK4QRDLTtIPljQnv6ntW34siiv9DvjOV3rE37sD7pHQ1xGqWkl/ovheNGYPeqUZ2P904zj0AoAz9M06+8QyiK1jW1st2Mk8fie5ruLHSbLw/pdytkS1xLGUkuG6n2X0FakNpBZWNrZWzZt4j8nGCfVjWf4hki+cxM+xRhFxk8/wBaAG+FlSe1njmHzLjaiDn60+PQoozK264COxJZCQwPvUenp5CQzYZP4HB4Ofeuge6UWe9iCnRypzt+tAGNBr0Fl5lrfyrHdIBtOzh19veqzeIGcFNPtZZ2AJHykD61n6jrFlJeW8ctoywpJxNIvB+nqK6e1u0dgbWIB2+UDHH1FAHE+IdUu7i2AkjaKQnBO37o78etM+Cmvjwz8V/D9+8hjtzc/Zpj0zHJ8hz+efwro/Ed61lE/mWbtOQcMy7vqa8rvnZ7g3KKE3NuUqMAEelAG78WfD58L/EfxBpO0rHBdu0WRj923zJ/46wr6n+Gn/Jm15/2BdW/9DuK8H/aFjGo3HhLxUspm/tzRoWlfH/LaMbH/pXvHw0/5M2vP+wLq3/odxQB4jqcLaH+zf4esAii68T6xJeHuTFEAgHtztP41VsPAtrb29veSm4hlOWWWObDYHGSD0rU+JGY/BfwYtWJEYsJJyBzyzoc/pW6G22m1ohLujUKZOoBPWgDzvx1bahZW0cIke4t4cSR3IGGRvqK6TSmuLvSbSXUALqJ4gzOflMh+gq5qkqxWN8s0byxtGwQ9WJ9MelYFot1pljZ3Vtie2MYzbqeQfUfSgDQvNrG4hWRACwI3ck+1crq0N3atOBujxjIRjhgf51vz65p4Hkp+9vHBARV6uemfTFMiguHtAl4oaUqd+D+gFAHJRXMqsNkoLDlRnO2uy8NTNBztKhlyHH65rn/AOw7gN9oVVyRxnnb9R2rQ0pXURJLJ5YjblS2P8igDrdZuBdkybiAAAioMAgDqPeuRvdSt4lZYWfaeSCozx1ya0tdu4rXQ7vU1mAMZEUaL1dm9M9q5Oy1SC9tkiddrbv3mBywoA19Hu47iRVMQDOx27m+Uj+lRajsa+sMbUkRzwwxn/dxT7cW7gM5WMp1Krw69voaqaxqEEN7ayTHIziIZHA9TQBevI1eVnYD5wSADVHSrPyZma4wSeQ6jOPQVavLkfZtu6PLKcHt+FYd/rgt7YRWnyS4GMcgH1oA9K0GTYhI2OmNu0KQQfQ0ni1YRGPJcglQ6p0O70Fc78LbmTUrDUraeR2uI5o5kk6swOQyk+nStzxXeBHW1KfPHls4+YegoA41r5rVlblXLZbeMgVestTti8rmL97KcNyWI9+etZq2lxeM3mgKpP3yOPrWrb6NcLbSrtLtGRhsAFh9fSgDZ04QAtDHIPMRfvNyD9KvWtvbxSFbXYXRg2X9D15PWucis7mJ2YLwnO5TyR7VvWTrLEkxQuFAWVgMbB2zmgB+qCGx1az1ERbWbMEnA2MD7+tbF2C2j3KiRNpPlxKx+b5q53xfdwXFsvkuFIlBEYHBx6Vqae32tVeTCqEXHfDehPrQBF8DVj0n45po9yxWLVLCaxmRl4JaPdgj6pXdfsXWb6dqnxCspCDJbTWkLEdMq1wD/KvLvCUpj/aS0LymIC6lFHknnkYI/U17l+zlDHb/ABQ+MUUKFI11SIBT2/eXNAHifipdR8V/FmTwzbRw3HkeI9R+zQTHbGxe6LuHIBIBEeCcHivefiv4f1GO7fWGswYLiKPzxHh1tyFAK54JwQADjnPavFNGvJdN/aC8UahbhvtFpf6tNEQm/Y3mSDcR3ABOa7BPGesTaTc28mp3WoJMAZFaQTbj1BA7D6UAcy8yW6SyEM53fwjjB71mtrIt1wCG2nHJxlfQelRahq9qsEibDFvzxgg9ece1cldyG4kdjIwUnPPcUAdJrnij7fbRxMeV+UHaM4HQE9xXNSOgJZk3M3JHrVNjiI4BB9h1qMTMWU46cAUAX8BS0cYBXqDSgMzh5SSn8qoFizck7QeQO1X1c4ZO56nHT2FAEk0Ucu1k+UY4YjBNQMu1FXaxTsf6CnrLtbgHIH3SOPwqxFCZ1+YOV5OF5x70AZ53jcF4Cj5sgk//AKqVIJThj8ik9f734f1reWziQr5qYUDhgeWPsaYAuw+YFZRwCOv0oAwmVA28gpkbWB9femWwf7Qi9M9NoyQParl2IQjEE7zwfpVOBNt7Egzt3hvl9aAPeL27ttO+GtvFHIwuGQjcQNme2Ox/HvXlOg31xb34nQmQoeYn43jPIre8X3jW+h21lGJI2kwTwAHHXJA4rlEYhkCHByCMDOPfmgD7xurHT/F/g8W13EWsdQtlOD95Ny5BB7MPX1FfF/jfwdrXgjU5bbW7STyvMK294BmK4GeCG6AkdVPIr6k+B2qwS+CtNtDdGR3DvAsjln2g/MuT1wT+RFdj4t8P2finw5faPqK5t7qMruxkxt/C49wcEfSgD4PttSaILuILnk59PSujDxXYiaFshlDY29fY+9cl4r0660DX9Q0e+AS8s5TFIAOuOjD2YYI+tT+FNUkiuGVsujDHTjigDubbSvIthOq/NISYy3X3yKvWWhR3UyJdbEicgMAMsSfT3p+k3KzsQJ1QMBtZui47e9dDp3jK80RXNvDbNMVCrJLErMPdfQ0ATSCz8O6SEs08q5jceUijCxgdznqxq14E8MXvjXXXvdQBa3gcOzSklST3P95sVyqzy63qJt+SxYNjJ+bnn8a9IvPEcHhDQf7I0rMs87DzpkJwWIA8tO+AOC31/AA9M0yHS9PYW9q7TQwzeWRxtjcgcdOT29q+Mdevh4N/aHvr+1SK0hsNeL7OiLEz/N9AVY/nX038Objz4r+W8RZJHCnaTnAHXp0I9etfKvx83f8AC4PGCSLtLXQxxjjy1wfxFAH2l4Ciji1zx2IfuNriycdy1haMT+ZNFcZ+y7rtz4k8G63qd8QbmTVFjcgYz5dlaxg/iEFFAGJ+2t/ySzSv+w1F/wCiJ6+f/wBmTRINa+L2mfbEL2tjHLeydguxTtJPbDFTX0B+2t/ySzSv+w1F/wCiJ64H9nhbGx+B3xD1ZTDZ6mElt/t8p27UMS7EDYOPmPQdSR7UAeefD3WrSz+IWq3U923lXLTCGeVizMxkO0lj3I7mvX7yJJFd2JdG++Cc7TXkPw98Hwan4amv78OY53MSRgYwFH3s/WvS4IRDY2sCs0vlIELnhuB3oAHiZXiQvtQHAKjpnoTVK/tY7eZt0pCKceYrcFv8KsahDdCHFm8Syrztl5Vvb1rBi1iK71aOx1K1ksbsDcI2+ZX90Pf6UAX71pGt4/KcbgfnTGMrVC+aO41CGBukYyQD92twFZPMkVQzKCqg8NXKxsGu55ZJWKAg/McYPofUUAN1XMim3cKY85Vz0OPWs/RZXjnjNzIeOfK79evvWjqDiOOSSRllhcEbfQ+gFY2mK3mIEaJWBAQk5KH3NAHSeJtkPhfUpZcJczKIYgTgsWPX8qztRsorCx8IKfLlFnN9nfsBvGefxrZu5tLeWCOe2n1K6tYy2B9xZWGAT64rGtXg1+1ksIpmiuxIrNB1dZEP3gPSgDUuJfs8jLKR5S7txIyU9PwrlLVmvtTLxdFYngdT64rqvH1qYLZJIbhZPMQMwH8PqD71ynh91jud8yk7lwADjFAGzeSYtN8+4ncCp/ib8K1bCSN9PclRu9cY21k+WZWKTNyF3AE9fQZqxbyyzRuHQrxtPr7EUAVm0NNXImn3G1g+VIxxlifvGtpLRLQrFbHAhG7rn8abGjW9mEid5PlzICefel8557Z1jjEQxwcZoAk1TU7F73yLqaGKUIrnPBCkeleN+IFjS7njgYGDcWQgYzzXcaroNobiN5rh5byZgGmc9B6D0FXdX8JWUunD7PABIqkDJw2exoATxSj6t+zT4RvyBnSNVuLBsDs43j+Qr3H4af8AJm15/wBgbVv/AEO4rwbwpfW0/wABvHWgX11FFeWl5bX1tDI2Gc7grhR3OBXvPw1/5M3vP+wNq3/odxQB5P8AEuNk8JfBOfh2bTzHkjj/AJZ4H4ZqUWskOmSst02QNoU8857e1V/jAX/4Uv8ACC8j+SSO3lRU9SAmD/47+tKlwbqwguWDrJIgYrKoDBu4+lAGXfXDNptxDbyebfFMeZ02DuDUul4TT7SPlH2bclckevNK7RbI4XVIZCTllGB+JqGa9jBmRPmjGIyCduD6570AV20ZJbye6d1SQnavlgYx6+1RPfSWUbSSxSARA4m/hI77veprvUYYocSb8qccLnP0qvqiyalAYSDFatgu8jcn0FAFWx1uDULlktGkSEqV3MNruT6dqcSkU5aSNmYLtAPAb3PrUktvFbOvlwrkLjywvIA9+wp5JlthLJglQQyp0A9APWgDmfGFxLNa26vJvTOQF4GfpXNWxdZN8YJC8kA44rr7qzF5E6gpbouSC/UD6etTxSabptnDFDp63aKpkO9Pmkkxxvb+6PQUAc9a3U7zNs3eb3UdMUy5LTSebMwdk45HQelMurj7DE1vauvnzDdcSp2zzsHoB3rM3tgjJ560Aa8qybIFi3MXbapJ4GaratY/YbgwySM1wPvKVwPwPcU/Rbx45RA4Lwk7gO6MO4rpriSHULZRdwRzlAV3PlWXPcEfyoAd4HZtMhaYrsE+FZmJVlI7jHUVtajNLc3CgsyzFuCn/LQHvk1lWafZkRZZHlggXbEQ3+r/AA71bAMl2kmQsTLnB6Z9T6UAXZGECSwyMkBRghJYK3Pds9avadfRyKY4pFnhRcSeYd2WHcY7Vz+s6XBNYz/apVa46/Lnd+feq/hrT2t7JZQJHt5SRtEuH49BQB1FzeJvgilugGn5iVjhh9D2WppbSbzndSwj2jcuTuJ9QK5O68Pw390JfOuQ27YMNlQv165+lb2lySWts9reXE0qR/IjE5JXsuaAOjaFJkCXSISD8oOMt71LczRWtk9w2BaxqCQoAU89/wDGucvtWheXyzHcldpOyNCzKcdjXB+J77V5gYLwTx2YAJTuw7bv8KAOp+Fs7an+0FoNxcFSZNTD5Q5HAJXH5Cvff2bJPO+JfxhkDFw2qRcnv+9uq+c/gEQvxn8JkcD7XgZ90avoz9m3P/CzPjBuTYf7Ui+X0/eXNAHj/ipL7wt8Tz4ktdTm0tL/AMQ6rB9thhExgCXJVsxnhxhwSp6iuh1bW5NVeKNNK0jTnhLJv0uDyUuMnPmevPXH8Occ1d+K2jLqfwh8U6lGuZ9I8Z6hIWBxtR52Rvr95DXM2fimzv8AwlocWk6esd9bReXf3M7FmllHGFGcBcc+pz7ZIBnXNmL6OUTszDPyBeMY64qnbeFmvIZWDErF8zSSOI1QehrVdJ/tiuq/LIvzgMFVT3P0qrqV9aWsMlpbp+8UEs4lLeYTyCe2PpQBgapZ2sCuElJMfIwMA1z03ytwfrz1rSe11PV5WdcyZONg64+lUpLC4WVYSA7MMg56fhQBXjcqcb+vrzmtNbczREpjPYdCavR+HkNibiQ5cEAgHB/Cq0Yezm8qUHYfu57/AFoAiS1ckt8+B97I6V0FuiJEqldwZcnB6+9VnlVCSpOGXBYHH4YpYJ1WVRIrZJ4HXPp9KALc4iVd0RPynIBBHOOeKzrjfIHdOBnOR14q7LJvfewZWb5SOgJ9qp3QLEMAchcFV/z0oAyLtz5hES7seootiouoTuPzHA2jGTUstncJDJceXILYnYrlSAW/ug9yPSobBZEuEeQgKG4DHigDY8W3hlNlGzEukfzY6L6YqlC65C53HHTPSql9cedcuQxZEAUYpbHd5hXd8x4GBk0AexfCe7vfI1SSC9e2tNLs3vVJcqQWIXC46EnFel/D/wCM0h1g6P418mHcheHUEG1T/suo6H3H5V5j8MdWh8LeGNavAYrjU9Sh+xJbs3ywR5O6SXPTr8q9TiuP1AnULpI7cDyrYYLu3K++e5oA734x6paeOPEST22jxQvbp5K3TOMz85GcdR6D3rlbLQhbyLbPbOZ35dR2Pp9BU2nZ0zaJQwdQRllP7s9pAvYioJtQ1k3ZitLmeSYjO9NxZwe5bHIPrQBdksZLFJJHhkjiYYiVgRv9WAPb3rLu74PJGEDLtG0ZOdvtWppPhPxHrdzGJbiO2RwYy01ykanH+8SfyrSu/AF7pVuz399o5LHCeVeLLLn3A60AZmh6o2nq4iG12+8w6kVsaczalfi6mJdSm2MbtuB/ez2rKSxeMlFhOF+8WXGD+PWtiwlWDSnCKfNDDYpHB+nvQB7P4C+zaTpF3c3EkPmH+DO4gdAT6+wr5u/am8qb4rRywFHefTbdpXVcb3+YZI7HGBj6V65oXhbxHdWdrfSTyQW4w8MMrD5pM9An8RPbtXnf7WFlFH4v0e+t7a5Rltkhup2j/dmT7ypu7uF5I9MUAen/ALGf/JMtX/7DUv8A6IgoqT9jsAfDrWtvT+25SP8AvxBRQBW/bV/5JZpX/Yai/wDRE9cD4SC6R+yPqU0libi31W8mSfacMuSESQZ4+VkXNd/+2n/yS7Sc/wDQai/9ET1wni3VP7B/Zh8CaSbW3kj1diZJJPvRDeZNyejHOM9gTQAeFrD7N4R0u1juGBVPnCcAk8n61YlSBZkVZWT0Zmzx9KdaXKPZWzyxskflgphcZGOtc5f3EesXpttNlDqi/vZsZRPYepoA2r69tYpkg86M3chCqiMCxHrj0rP1eG2kuIbO4mXz3J8qQkBtw9Kr2ei2On7bmGMNPjJnkbLH3rA8Xs4vtMv7dHneGUfutuSV7kCgDq4Dc28RhuY97A484chh2/Gucu0/0+RANoY4244z6101nqEGopG0DBoehB6qfSse+t5f7Ql5LLjYMngHtQBzWt3OxVtiSY8klh1qxoNkos1u3j+RmyDnjimX+h30qtKYvkRirODniuhsvLWxWNl/0ZRwMZwP8aAKsjfZpUkjO8XBwEVfu+9YGm2n/FQ6ldsZEuBNsV0OOvXn+ldQ+EZpijbVztC8tj6VgaGzub5Tt8suGY+n/wBegDQ1Uyy2qxMieVG2Djrn3rnYnK3qb3+YHB2jFdRaxwzWpWNn83dubj+Htj1rk9di8jVHcEeU+QXPagDf3os2Si+XnJI5C1e0kM0UhKkqG5LHk/SsiCVJrFTFlo9ucZ4JFaOl/LCxZjhhnpxQA3xBrcOkWLFlDvKpRIVPzMfUn0q9olwG0+GcyfMYl4HRvWotZt4IomnlRZSyEBWHI44ArjtA12RJV0yaNVJcqrs3C5oA7p4oZml86FURRhS3ANXrFN1vtjUgtjCHksKybpnO5VmMoTGN3T8K0tPcY2sCJDwD0x70AUfAvg3TdW8R/EKzubdbiaPRJbuyL9Y5Mg5HvnivXPhp/wAmbXn/AGBtW/8AQ7ivNfg7LPP8ebqB0GLrTLmDbu/hCZ/HkV6X8NgV/Y4vVPUaNqw/8fuKAPJPinIo+BnwgeQKka+cWGcnAK8/1/GrEcitHIC3+u/jboF/hNUPjQ7j4QfCGzQ7g9jLJt7kkR4/nWZoNpc6fpkEF9K88rLg7znYOyj1AoAcHjnuZEIdhG2C4Hysw9PaiWaNpWaZUVweQOdx9c9KnkidZ2OQ67dny/KFPrVO4sp0iLSsWD4IPTOPagCtLHmZ5JGWOIDgtyD/ALvelFzbkCFFkfB3bT0I9c+tSLYu6GZmEkh4BUcL9KpPBNbI0px5IYfLIB1oAtAyzWx8yQHywWyepHoaqNcsMeVIrFhlXHUH6Ut3LsXcCsj58whjgfT6VStWJleSRcowyg/woA0JSlxcRw7FbKb3dV+Zv8ari1WaKMscEscqh5Hpn0pLcliMlPlzwWIaruM28qyIiFQCETqx9SaAOR8R2IihjmUhhuKkqMD8feuf5rvtej3eH55gqvboQASMMrH09a451aRYUBZY9m8Z6Z7kUAbfh3T1WNp5l3Ky46/MPwrcELxrDHHHieV8Ig4yvrVbSJd+kxT7yW5Xb0zj+dX1COIWWSUyqvPHI56D0oArKG8qR23gK3lnIwMjt9atRo88c0abiigSts4bPofUVXMZiluQHYxkjDk5/Gq4uGguUljb5BwDn73+9QBso0cmDGv7xgAS4JC+1Q6TB9neWGc7YGJbf3z6D2q9BcxyWgDAKZm3AISentTYnNoHmkJdHyCJBnj0AoAVWcbtgZWQfOVB247HParUNrNJsMsiyRsQSoP5HNZEa6vdl1sbZIYSucM3UU9YNWaRRLdxRKq4dgmMUAdPbqbPzgSXJO1yPvD0xVS70qC+gmt7xmBKcFRyM9Dnv9Ks6V4N1jULNr0XxtdNJyb+7cQ23/AWPLH/AGUDE1tTw6VY20MNnd32ozA7nvZlEET9tscR+bHfcxz7UAeWfBYNZ/GXwqjclNTSLOOuTt/rX0x+z3H5XxX+MiYAxqkXT/rpc186+BLY2Xx+0S3kZcxavGdwHB+bNfSfwKXb8W/i9lSrNeWbsCpXlhOTwecZJxmgDzzxJI0Pw3+Lls+p22b3xPdmGz3AyKVnyeM5G7accfwe9eTeA/FQ03w1r+gtHGGvpILu3uGGTFJE3I/4Epx/+uuku9btF8d/FXwxqbRxQ6vqd29pcuB+5u4p5GjyeyvkoT7ivLLWzuby6jhtIJHuJJlhSJPveYxwq/UnigD0a/vFmgWN5hhTuO75Rkj1rMVLSRPMmuY5Z92EjSQYx65659q9csfg94U8B6Bb658VfEbreMpKWVu3yiT+4oGWlYcZxgfhzXFeJPjHaywnTNK0O0utIiIEQ1mCIyMn91ljAwP+BZ96AGaDo2ptqccFhayyXTnCxRMC+Sv93OTx19qz7sql2YCBA0chjkkcYPBwRg/pUtj468G3f2dtU+H0VheREGLUPD1+9rJGf7yqcgn6k1l+NPFNi2qGXTp9cuxOoMra9BEl1wMDEiH5x7kZoAtajIDdSiB2W2J+TeeQKbeW8D6XbTI5eWQk4bsBxwfXvWfY38F+saw3EXmsMNDIQhB9OeCPfNdtqfhy/s/A8WpahpMluFuAqzo2UeJh14ypwR1yKAONgjVgoIZueeatx2xeUTFQVUjI/wBn19jUflkxJsUxv1Vj1IrZ0wqgBZX8rdl9o749D2oAqjTmMwcEyxbiEJHGfTPSt6G1hgsHjm0iBbmSNfJvAxDKBks2e+7pj2rL8RJrNrp6eKNI1azit7aaKGOynIMkjk/K0aEbZMHr3HuK6+88ReIdV0eKHxtLaC5TauEgWP5s5AOzg/hQBixQXVzYCxddscnzlEkDMwPU46DOO3NdFo/wY1bxFoaaiuraZp9qzsPLnhOVGepI/DvVXw5Fby+IbN9WzHp8bhp225bbnkY64/pXo/jD4kNqcTWOj6Rbf2b5ir5l4m8Sop7RDoPQE59hQB5jffs+6/De4m17w/Hpu7Et7JMy7CBkjYR1x2zWfrcHhXwxcRw+D7z+2RHGxn1NkVkL/wByPHXHUnJAyK9C+JXjS1XwZo8dvZQ2muatcx3V9HEg27ITgbuuNwC4HUDr7+ULai7uXMmBEZPOMYGA7MefoKAMsvd6nIqR4SzU/KqnhyedxPetvRLyDRLiG/W2864tpRKkUqZVmXozevPatK6OmTW0CaPa3fm2Ydr7UJMLHIScLDFH1Kr/AHuKwZLYq4EjHlgQmefpigB+r+Kbm61e51BNL8mKaRpWCgyEuTliWbrk/h2rMn1vUHso7WGWWC1V3lWEMdqM/wB7aB0Ht0FbSwtLMFMm/nAHt6VNLb2nlucrndt8uMYIx3+lAHMRi9b5mdCGXAQrjI7fWtC1s72aREhcRyyAYVTjFakenXJmW5BXsAABjHoPwqRLWaJoZ40xiQsw64X29aANy11HW7CwSz1S2N1YREsFOS8b4wT65+taXhi707Ub6GdDyg3LG42gtnj/APVW9bTtdfYprkZLFVOTknj/ADzT/iNaaPomvwR2hMcixIX3HcvmH5scDsMGgDvvCPjKwS8+wXy+W7D5CclcjjjP3evStT4veFIPGnhQ6K3k+dLKJYg2A2QCNynsRuBJ9OO9cr4Y0Gy8T2rtDdASCRZhMBncMfMB6YOOa7vTY9Ys7m3t9QninXeUS4RRu2YUhWB5JOG5HTvmgDzL9j63ltPh9r1tcY86DXZonwcjcsMAP6iiug/Z/ZGh8fmNAif8JbfYUdB8kVFAHL/tpf8AJLtK/wCwzF/6Inrzb4r2yf8ACk/g+svJK4PzcbWRSf6V6R+2p/yS3Sv+wzF/6Inrz74s7ZPgv8H5giqAFG0HI/1a9/woA6LW7W2msUjBdLaSNQUXjaMYrEl0i1tba3jsdsYj+VPKXGB7+p+tb2pTN9ntpInHm+UGYEcdOmKwTcSWlyZMb4pVBIUcKfWgBskKwssTnD5GcDPHqap3kQhLCSMcD5XB5A9RVpbtXckuMq23p1zVebT7bzZN0z4zuQqeR9fagDmrxJtPu4r7T93lkhbiDGAyn+If7Vat7PFIbaeFthxjOM7/AHPoasFGurQlip8ptoQ/d47+9U7qQIPJl2GQDOQOB6UAbV54otLjR3t7SEfaXTy+F6t61y9u8sVo0UxPmj5mUnp7VY0+2YQhoThi/wA7e/bj0p2pxNBa3F08bkKuwPtypOeTmgCDVriGy0ySRpfLds4X+LOODmud+Ht01xFe28h+ZyGJJ/WuZ8Xa3JqeoEKdsMfCgdDxVPQNUl0rVIrhW+X7rj1FAHrsQaCMrsGU4Ur0+pNZV9YR6pqsEM0i7CCXCcEY7VeOqWl9DJLAjNHIijZnoR3qN4oZFAyBIOhXg80ANn01LGaWxt2LEHcjHgYx3qW0HkIJGdVZl5B46dT9Kow+ZBPKLiVpFXjBPUU+8iF/bS2q7lUjBOMHb3APpQBWi1N9YuzLGrJBExCA8hz/AHsd6oReHrWGVpsyvcZLKFOMk+talrFGbQW0YUbQVBTjGOwq9bxpFEoYszAffByfxoAraTbGEksZFbBO1vmxWvp4Ik3ghpAORuODTW+eQKDhdmGxyD+PrUrWhmtmV8xlhtUL1B9aAOi+FRtn+OegCLBni0+7aYj3XgH8zXa/D3/kz7Uf+wRq/wD6Mua8e/ZshuU+MWopdpI1xDp10pdj9w4HJP6fjXrvw2/5M4vcnJ/sbVv/AEO4oA8c+MnmR+HfhDZxwvNJDoiT7Ixktu2Hj/vmoHkWC0VwULOAY/MzuTPqK3fHkif278KZWYzQv4WijUq235tjjj35FZAiil02JZZUaMBQBjB/EmgCtbzGSN5WCb/uk5GBj0FRX3nTSOYrpGiXGwmPIHsaW2jtLcy+WkZDEh2x/nNTzXVrbLx5I+YFQmcN/hQBjTNqsC7lKqyfeUL8uPXFTXpP2KPcVQygZB5GfUVLd3nnySFI44S543N6VXmcXPmSSgedlVKAZBPrjtQBFBpE16shjBVQRjce3qag1BPsri3OAijgdQffNdTYM9rHLEygx8Ntf7xP+FYmp2DXcxCsUBO/a/f3oAy4tyRlwu0EZZmPJ9MVdacGCNt5M4GeByR6N7VzGuyTwXxjhdxCB8pKnn1xTYrt/JVBOxUeg5J9M0AXvETXF2gt4IgAcFVVuG+lQWeoWdjBa291azi6ttyvBJHkOT/KuhsoFEMIZYwWOSGGcj69quPZI+q6dISuxY2klcj5mI6DPpQBi6DDJa2ZS6t2EbyeYiseefbtWnFgtLHG22RjwwG3A9vWnbWuFuJgSN52kDgY+hqG6lRrbzdojmA2hmbG3Ht2oAzbuT53YuxwduScBvamW7F7wFh91flBHyD8azodR3ytFcINobhxyyn27EV0Ojaf9o1N428xAMFQnzg/X0oAtaOHiu1dgRjnn09QK2HSNpwwClcFhkZ3ew9DW1HbWsluIZ4SGUbS2eX+tc/eJJa3pSNmcKeO2z6UATRoV3oPN8vG4qG2bPx7/SruiXrabK1x9ms764eMqhvozIsR7PsyFc+gbI74qFGMpAJR4mHCk8g0+O2W8lZZZPkEW9SwPGD1AoAZqk1xfTC/1jULu9v8HE88u4Qj0RBhUH+yoFUYvEdnGjJc3G9VK7gwKEjPYGtgRkWrmOIZ4+Z+risjxHFbzaXNK+SI41CHAznPQH0oA5Twrqtze/GHSNUtoke4k1eKSNHbAxvGAT9K+r/gs4f4w/F5g/mA3Ngd2AM/JN2H+fWvk34Z2H274s+G7ON5FV9Uhy0ZwwUMCcH6A19V/AuXzvi98Yj8uEv7WIBRgAL56gY+goA+R/is234qeMv+wze/+j3qbwh4hGmajDd+SBNAI3VkJBkkjkDqxPY8YzUHxY/5Kn4y/wCwze/+j3rnLV8N1oA+h/hx4M1r46eJZ/EPi+7mh8O2UjRRxxfLvJO4wxegGcs/JOce4+mtE+HXg7RLQW2m+GtKjiHd7dZGP1ZssfxNc/8As4Lbx/Brw7HboEdI385cYPmF2JJ+uc16XQB478TPgJ4Y8UWU8+hWsOh63gtHNbJtikb+7JGOMH1ABHXnpXinwu129s73UPB/jHXrPTBZymM2ms6cNQjdxwUQHG3pknOCCMV9m14H8RdGutK+P3hm+8O6pHo13r6Ml3POqlJvKCjYuQfmKkfLxk45oAqXX7P+k+Iby31OKXQlsZY2dxpcEkUc5/h2fvGCD3GfpXjHjb4c+N/hjfT3mmQ38ekqSwurWXz4QvTEgwOP95cV9zWdpBZxlLaJIlY7iEUKCe5wOMmvjT9qDxDLqPjmUw6iDBaqLWC3ilfKAcu7AYAJJxg9loA4fSvHlgu9dZ8K2V4WUq0ljcSWjk9mwNyfgFANeweAvhs/jHRYdW0vUnsNMlys8eo27pcQY7KeFkUjowx+eRXEfBHwl4c+JFw2ia+Ly11SGNpYLuwAQyLnkS8EHHY8dcZr1Pxnonh/wra2fhe1W/8AFV1GcsmsX8k8FoTyuIVIUsey4GB160AZ3ivwX4J8O29rb6LAmsanMu+TU55zKsa54Eag7ASe4HAHU5rFljMkyxEEEf3+AxPoasCC0066OWRSOZII4yqoT0AUcL9KtJewLqBubi1S4hTCtFI20NnqM9vwoAy9iy3TQwyyybhl5OAF28EHHQe/etB3t9OsS889u8hOIow53DP8T/3V9O5q74p8SrqmpyTaZpZsomjWJY4nXA2A44AHHNclJpdxLmW55jbnO3CK3fJ9frQBRYT6vrT3Ls7SEEI5XHy+gFbT3kNnYxJEYpI2Jcng/XPpVnQNA1CeaJbC3lmldN7MnWNB/EfQD1qjNpyWfkxT2g+3Ru6zQZBYn+Fl9fXBoA6fwvpOnw6ff674kWD+zpoXt7O3JIa4l7vkchV456GuZENv5j4iYjOVRkLKTnru+naiW5hcqZblmIGAMErkHkf7IpTrFvL5cMJQPuwSTzjucUAWbDUp7SR4rKKOBZD8xWMMR68mkezjUDyVhXzG3SSlSR759jVc3dugMjbRbISVJIAc+vPp6VZRv7SVXaQi14Y8Abx7YoA3byz0xtAsvJe9guVYtI7xDycei9yfesyy0WTV7WFrUNOd5B3ERttHO7Bxx71Z1LUV8u0t3DMqjENunQc9h3z61et444ohe+JZWcgKEsY5BGxTsWlYYCjuBzQAzUrxYrOGzZPL8g7XYH5iOpPFS+HWbxR4widVaeBcZIAIOABgD1A6mqmbTynu9IMQswjMLR5ch8HkKzdSScBe9dD4D1qIeFr3VPClslyJmWDbAMyWpySwZRyoJGAcdqANLT2/4Rz4i6lp2lr5NtkEgHcEz3x685xXZ+KNbs/CegT+ItTut1hp0bN9nf8A1jTHARVbqCxONp45yeBXklhqS+H7v+0vE+oxae8j7w9yNu3n+6CXIH0ya43xL4l1L46/EHR/CehmWLw5by+a8m0I0irxJdMvbAJCKf7wzyeAD1n9ki+l1PwP4k1C5CrPd+Ibi4kC9AzxQsQPxNFL+yXBDa+CvE1vbOz28PiK5ijZurKsUIBPvgCigDP/AG1f+SWaV/2GYv8A0RPXnXxKkaf9m34Xz+WxEdwqGQDhcK6gH64/SvRf21f+SWaV/wBhqL/0RPXBaRjWP2Mr6KFxJNpd2WYZyUxOH/D5Xz9KAOk2LLo9nKuXVowpYcgccY96ybq3lDRqXKKFy3GSKm8CX9xqPgXSLmKKfaCyEsAASOCc+npUs1wk969rErGRBmQng89vegDlrnQ7iISvbSCSLP3c8+1U/wDSIk/eI6srYIB7+/rXZNbneqR/KxHy7utZ9/uGBIo8wElyRQBzA1Ao3ltt80ksAopweBjvvpjDEFMsrIu4gDtjuTUd5A51BWj2AFDyPvH3qle71gtx8qklserE0AVPDni2G91C7NzbCPTUyYE3YYP/AAk+v0rIj1nVNY1OWNpfKtbfc0ig/Lntx3NYv9gXX2j944t4Fcs8h7c+nerOoTW3yx6fGyxADc38Ujf3jQBntHbtKZbhTISSTt4yaikt7WYqY1ZD3B6GrtlZm6dxLIF2jJyO1Jc2KoWNufMjUAsc9KANXwjdTwSvA8Q8sKfmjXPHqa6/yZb0QzWyCUY4ERwT7GvPbW9m06RvL3LGy7XQngg9Qamh1S5jDWfnvDA4JTHTH1oA7C5tZVdZ5HL22SB0OAPf2qxEUmt/KRyo3fe9R71y/hK6nj0q9tHkaRJZAV3HgEdfzrZsFRoJQZNsh+4OhGKAL8bATiK2X5BneV6mnyaUJmDvcSKFH+rX5Rz61JFeRpES4XIGBgjIPep49hj3K26NSNxP3seo9qAHWUEccD7lYkDACn7x+taECFoQoz5hwcdR16VTsZmS3dJRkyElWHUDtV/TYi7FJCSRz+HXFAF34U2a23jTx3MVYFfDMz8Hk5Pr+Fdz8NP+TNrz/sC6t/6HcVyfheT7FJ8UtRJOLfwykYYc4Lo5A/QV1nw0/wCTNrz/ALAurf8AodxQB418R38z4cfB/wAQIRujtpbF9vQeU4A6d8bqltY4WtbyJkQKD3PT04qGKNNc/ZQkKqHn8P65uOByscgH8zJ+lcv4T1+3m04Wd85+1riOMZwZPRs+3SgDTudOhkuIyYpIw68FzkE+g9Kml8ORPvRHMThM/e4B9M9627ZBMjOoimCkIjjPHrmnlHAZnyOcjcQUFAHHWyqo8uVdyJy64++Px6VrWdqyGe7KBoowWQhh37Ad8VI+mmV1uXkAV3KkKc/kT0FSSQizQY3PGeQoOQvsaAHW8/lwxiRw+VBcnk4PSrDWe53eM7VPCyDkfSq0saII53h8uMHMm3nZ6Y74q3D/AKhAJFMMeZMo24E+hoAwtVsBLcpNcYKAeXtQZ2msa50qOxRpFYFozvKMOmfXtXd3emLJIFhLxeaof5eDuPevK9Su7+e5vrIzZUTYbHHmYPGaAO6MazCEmJo02AgdjnsBUtxbu4y6qQi4Qgnj2HvWjYQrcQWkjgu7IqmQ9iB0FWrAxyl5oQ27eYtrEbeO+DzmgDDWySFg5WQFwEPALk+p9K4zxRcSLqM6Bgw27DjkMK9P8sM4iHLMdy568emeteP67ORe3GMkGQ5zx3oA1/CuhnUp4xKCkKDeSOu2vQ9N0+PT4pZLSMruTdgDLN9apeB7Ex6GSzbVmQSbyMgL9PSune3eOCUzgO6oDGIhjK+o70AUoXFzPArMw2D96g6tkdPaufEV3Pp9z/aaqlxb3RWJm43R9gO5rfvozBDHK7sFlYDH94n1pGhmknSNI0dUVg5Y5H5+tAHG6iLi2RZrYtsL4OOmfTmr+neJkW6VLuB7b935ROwlSPoeRWxaQSJchp4xIyjG2QdB6j3qxdRWpn2X6xNLMP3MjkbXHt7j0oAZkqspjZmilTAlXnI7YFUbzSxqUMNsZVjsw3JP8WOSfrWtY6O0YghtZQmW2hWPHvz2pmst/Z2lXVyCq/ZbWZ8ZxkkbRg/U0Acx+zbZjUvjpoz7d8UDXFwT2AWNsE/iRXsP7It82p+Kviffu25rm8t5ic5zue5P9a8z/ZphXSrLx34tuQVh0rRnijk9JZASAPf5MfjXb/sMf8zt/wBuP/txQB8//Fj/AJKn4y/7DV7/AOj3rlkOGFdT8WP+Sp+Mv+w1e/8Ao965WgD7M/ZG8Qx6rpF/a3F7Gt5boiJZ+YNzRr/y02+mTjNfQ9fmh4M1+/8ADWvWeraReNZ31u2UlxlfQqw7qRwRX1Z4W/aX0lj9l8baTd6PeqBmW3Uzwv8A7Qx8wB7cN9aAPoOvGfiNqFtqvx6+HWgRyQ+fp5uNSn3kHAKYRQP7xKkj8DXPeNv2nNDtLKWLwjp95qF6w2xzXMfkwqT0OD8zfTA+tefeGpviZp1zea3qWoaT4aGtsJ7jUNangguJxjA2hg0iKBwAFAA6UAfYk88VvbvPcSJDCg3M8jBQo9yelfCH7QN/4cvvG91J4csYkZnLXFxHMzrKx6kg8Bs+nHSup1rXh4jvLXw6fiPDJYKDLeXs8bizibOBHCrfPcSEknLEKO2K767/AGZPDUunlNP1zUpNTWPd/pEqFWJHGVVcqM/WgDyj4M6tf6Lo+r39nrMthFAyRJpVkENxfTEHa0jMDtiGeSOvQYNblreXEEZ1WYzR3CufOOT8pLZJbPXPqK4rVvD2p+AdZjsvFulfZZoyVs77B2XCg/3l4bqPcZ5ruvCl9oBnhutc8Y6Fp1ttLRJC7TyNnhg6AfL9CaAOli0XVdV0e51G2t0t9GiImd5JMNK3fY3UtjtVXSYpY7xwEjFp0zMmVKnvjua6bxaHttTTRtJvpk0XyY5bVk5hkUrncoHDr/tDp0rnG1S20O38+6uI1UZ+Zxy59cUAdf4Y0mx8QzLZXExtrlomQzbAdx7bPQj3rjPiu2mfDa9trTV71dZlnj82OySMo7KDjMhzgAkEZ68GudtPirZ2Wqwx2Gjm9uSR9mW6n8uPzs5Duf7oPOK1bi0066s7q51fWtI8SeINR/0m8u3k27YlBJt7dzxkdkAGcUAfQPwputI1jwta6zpctpczXcYE8kAH7sj/AJY+oCZxg/XvXkvxysn07UL5pLONrm83TrcpJ96IcEMvXI4Gelcz+znreieD/iDrFjq2pNYwalBF/ZwllxBJlicMcYD9ACcdx1xX0r408Maf4p0eSz1BVRyP3NwAN8L9iD/Md6APiC51iSYmFS4THyBm+769KqR3l0GWFAN56SEZOP613XxA+Evifw5e3FwbJb3Td2Vu7QZUDtuX7y+np71wjxTWsv72PYynnPXPvQBdjs7mcxXAgZ5QDhHyQx9atfb9YtJhNbIsMkn3TncI8dcDtTtO1u3iidJ3YZwVPZSP8aiudYiun3wxl1HLgcbT2GKAOp8Kza3fXVzI89rbzyLgXMsPmyD12KcKorcUaBasqX9/JcahMS63NxJvaEDsQeEB54ArzvRpxeXipd3slvabgJI4n2M/tu7fzr07Rk8PWq280bWQV23CG3Us7H3d8kkc9PWgC9o2vW1xLY3em6Y1re2zBrSUxt/pe0/cUuNgd+QD6mp/HulWnimwS21SGfSdemimvhffLH/Y4YbktGKYMpcjGD0zkc8HetE0m2YKbC8uY7oloNOubpPL8rOfMkbBKgHkAc1ZHieTR9F1C+0yystN0uwaSaSSAec5wM7N78HceSQOBigD4o2szl5gxmJw2/JYHpjnnPavrf4caInwR+DuseLtftwNevIlcQEfNFniKHP1O5v/ALGvKv2a/C6eN/ipJqmpqXttOY6nKpXIkmZ8opOMDBO7B67frWj+174+j1zxTB4Y0y4kaz0kt9qAOEe4PbHfYOM+pYUAep/sYyvP8M9ZmlO6STXJnY+pMMBNFM/Yp/5JZqv/AGGpf/REFFAB+2t/ySzSv+w1F/6Inrzb9l6b+3/BnxA8EsAz3tk1xbjP8RUxn9fLr0n9tb/klmlf9hqL/wBET185/s7a42g/GHw7N54hhuZvscxJ4ZZBtAP/AALafqBQB6/8ILyPUfANtZsuZrINbTRdCjgnG761papNLApVECuF+Un5gv1qnp2hJ4S/aE8VWKIix6hbm+tMsQqpIcsQO5U7h+Fdfq+nQ2yHyz5kjfKSf+WgIoA4SWyvblFLXDb/AG5P4elYmrx39opjfkqevVh9a7qziWWxd0/dsxOMcEYrA1kbYX2jzAxPLdT6k0AcbbRs05nZnc4IJHQGnXcJl07cQCQeAOualMiW8ybnby89fU+9PlkV1PzAjGV9qAOL1eZyixIThc9aq6Vopv2y83kRseCere9dfZaBI0nmFC4H3sjrVq3sIZ70QTqIkXkBeg9qAI7Tw/p8Nm0KRiWWWJk8xjnnHUe9ct4C0I6vZ3vmsF2v5YbPOVHavR1EcPlbVXy2wmGHPT2rF+H1vFH4Yb92VlN5OWkPAA6CgDg/EGlz6fckMDJGeBJjPPvVKw8prmAXKloVO4gcE/SvQ9ZW7SExSiL7JI21ivLEVyWraI9tumgVxD1HcigDSSOIX0stjbiOJlBwWzk+1WbriJpBhSo5zwoqj4deWQb0yNoyAR0/xq7q2Ft1iAIV33c9c+9AGfYw3FwztF8sYbJHXIrYQiGXahbd3Xsa1EsUFmsbqY3cDG09R60s1mYYRgOWI5Yj5hQAkWFjjEhJDHCn1PpXRafA2VLrg4wwXt2rEgsZShidizKRJGw9fer2s3y6Not9cTMRPHGfkB7kdfzoAvXN+NP+CHxL1uNV/wCJtqEelwMO6JtQ/oXruvhp/wAmbXn/AGBtW/8AQ7ivKfi4snhr9nzwB4emLJealNJqlyjfeyQW5/7+j8q9W+Gn/Jm15/2BdW/9DuKAPG/2fb+xm8HfEfQNWNzLb3mmrNHbWsLSysyB/mUAHkEofTjmvGLeZoXSVPvqQwPoRXqX7LOsNpXxl0mIf6q/jls5ATjgoWH/AI8i1x/xM0UeH/H3iPSo/wDVWt9KkYxjCFiV/QigD1Hw9m50OzlDjNxHvYnjBPt/WrFxaeefKzkI2AV/jP06AVr+ELPTrfwrp08sysslshQ/ey2OgxT4rfzmeVVbagKnHyeZn+dAGBd2ga5toJG2xwA7hvBVz7j1pbqzysKNHsZzjMPPHq1aEVi0mqCQhGwPLAJwHb0rVkkSzlBaPDBfmQ4Kj8qAOZe2Nu6BCrr/AKvBbl/XPoKSG1tbcCa2jC5zuAOA9P8AEWo29rZXN3H+/t0IZtwxIp/urXKQ3+peIUVbG1a0iBJzMdqoPUHuaALfinxHKVltdHIlvboCEY+9EO5FecWNlLJeCORGV4324wcE55ya9PbR4dF01zbTefdz/uvNmABLHrj2qmljFthEMYQx8l1P3j3AFAGzZ6jIlq37uIxkCNUHAAHeohqEReWeOZ1dxtCbRwfbvWEG3o37l2hBwFZsEN64FKyzqd0ciu3UGMc/THagDUvdSZoFijcx3JOTIRkqPauB12zmuN8kMe7yyWYAdR3NdCBvkEYaX5pMMMfMPXn+lXrS1hcSi8jd4Wyp25DbPXHtQBD8O/EYt4LfSNT2BefssrdHB6xN6e1entl7LCO7SRp+7fG1lX+7714/aaVbGe60q5dpFjffE4XazxnowzWymsal4aktTqsbXunj5Yizchfp6/WgDubeF31qWFVwlrEHDsuSWPf61Y8kRPKwct8oCQhfnLHqSaPDeuaL4hZW024WWfvbO22fA6kr3A9s1ra3NZWmmT3bzJbJaq0i5yiu/pk8k+1AGK2ntIqSIxeQNjc44H496JLMTWosZreN4VJAOMFT1LLnoa6bwxPHr3h6x1Owg+0xM2XEaZSHH3s+hrTW2sJrjEzmSNGOAv3hn684oA4WwskgtkS6nneCPLBnX5z6dOtec/FLxGxRtFt4WCOVMs7KV3qDkKoPQZ5Ne6+KZtN8P6E+r6igi05pRDARGXFzjn5AOeOeenFfL3jTWz4g1ppoC7QLlYdy4Y5PpQB6VG6+Gf2WZslo7zxTq2Fz1eCLGT9Nyf8Aj1d1+wz18bf9uP8A7cV5r+0NKmlN4R8GRbx/wj2kxrcK3a4lAd/02/nXpP7DH/M7f9uP/txQB4B8WP8AkqfjL/sNXv8A6PeuVAya6r4sf8lT8Zf9hq9/9HvXLxqWYBRlicAe9AG7DoN3/wAI6mszbYbGWY28DP8A8tnAywH09TVuyvNOvIBbajDJA6KPJnt8l0x1Qg9VPX1B6V7T4u8Cx2fwj03w+BdT66lyk9rbx5dYsJ++MmOEVieM85A968m8MeHrnxDes2hCM6lC3z6dJL5TyHOMRE9ST/CeaAKmi2+oDVI20K2vLi8kfy7VzFuZnP8AcXGS38q94+Hf7O2pa5OmtfEe5njlkkDvaO/mTSj/AG3ydv0yfwrpvhz4q8F+DfDOn+KNUsL6yuNUnksJ5fszSpp8sXytG2MmMuRuIAyxz2HGlb/Edvi94jn8I+DzqGl6OkTSalqxAjnaHO3ZADnaXJxubkDPGaAPN/if8W/+EW11vC3w4W0tvDumx/ZpfKiR1mkzlwGIJKjO088kHmrPwf8AjIuiaV9gltNPklvbsQ2skknk/ZWY8CZsFjCCeGAJHI9K9Ou/gN8M47R9Pj0e5+17NwlhuZWmXtuyTtH4jHtXifiT4G694Qv7i8guYb7RIP3txewyrHcW0I+b5kP3W4zlSenagD6I8RXPh7xx8NtVTxZBAFs5JILqK3uEL291EOkMjbRv6FScZ3YPBIr4stLmW01SSax0yd9MkDIsWo2vmrJGeAzYHDY5yvQ9K9luPEWmL8ItQ8eNa2cvi6e//sq11GaNX850wVuWgOUE3lggsBnjPQ4rwGXXNYk1M6jLqV69+X3md5SzFs+/8qAPQPDPh7xRdpAPCFwqNPOY7fSpbgbpMgsZYQ3/ACzAzufIx3q7eeAviKG1Wa7d45LGRFcSSgI8zDiKEkYlfacnHA9c0fs6Near8USsGoahaarPazOl3AVZIiBuJljYYkQnjaMHOCCO32H4f8Pw6d4XtrLyDO6M0rfaG3l3diXJ3Z27tzcDoDgUAfnfLb397LKZFmnmjGXBG5gucZ496l8PXS6fqkL3EW63WQNJGfl6Hnnseo45r6ZXw/q998T9d1nRLi60ZtLglj/tyaySK0tkCnMcVuR+8AGfmbJ/i9K8B8WSXuv3Z1nXtSh+3ahuuHCQhYyQAFbavAZgBnj60Aa/xV8SaLqthpWmaBZiO0tI3JaXDP5jHJ2v94x47N35r6X+FutL46+Gui2uk+JILnWNNERu4ZotskeFKhXHU4PRxw231zXxADnHBOa6Xwn4h1bQNdtNT8LSPaalaqchOfMX+JWH8Snup/DmgD7m1lbVbH7IsV6yWcIguLiGQooY4whU/fBPJxnFeH/EH4e6jeTJfXc8UUMikROQEYkcndjr/OvUPhV8Q9G+JGimODybbWIz593psxLssmeXQE5aIn05XP0rvNSsZsHy/JCAEgPDvVcdzjrx09e9AHyjY/DjcrPcSYt0ZciCJn356gHv9a6TUfBVjp1hbR20R+yuc+aiHG3HI3HknNev/wBgIb2S4iMkVlFnc9yzQxIOuUHoaPGOlrFo4Cq08s7IC6YxsHO2PPTPUkelAHjg8LWFvFbyfZhbRo2Xlm5Ea+oHdjS/8IrZwXonivJoreUM0bIMEKOnA5BNejDTIToc7QXNxHK7+XHDPHuLsf4Vc8YPt0qjbac2oWUtmYDcXCcyNAGkkAH8A6DOffPuKAORttAhsZi16janG4w0RlIUgfw7l5Pv69K8++NviAy3cPhbSo3ilLhru0gOEjdiNluoyfmHBb3IHY103xM+I1h4YjfSfDUsV3r0b7jcRvvg0x8YIQ9JJuvPKoemSDXI/s2+D38YfE22ursu9lpLDULl2yxkkDfu1J9S3zHPUKaAPpTwxZWnwb+BrXGqRqlzaWpuLvyQN0lw/AUHudxVcn09K+CLy5nvbua6u5XmuJnaSSRzlnYnJJPck19g/tp+IxZ+D9I0CKTEuoXJnlUHrHGOAfYsyn/gNfHFAH2r+xT/AMks1X/sNS/+iIKKP2Kf+SWar/2Gpf8A0RBRQAftrf8AJLNK/wCw1F/6Inr4ut5pLeeKeByksTB0deqsDkEV9o/trf8AJLNK/wCw1F/6Inr4qoA+sviTqh8U/DbwT8VLCNXvtMdYNTVM8oTtkBA7Bx09HrtiYtQ0yLUbVmaCaMOhj7pjOfpXkH7KGv2+ojX/AIe63IG07Wbd3t435Ak24kC+5XDf8Aqz4FvNb8O61rPwx1twJ7UP9gunOGROuE9Q6kEfjQB3OjxSDRxLcqiHLODnOQTxgdq5vxNP5VtdOCdw4XHfPau8vdPMejQusKO8cSgAPwBjq/vXnepW8kpkllYSKnzKoGRmgDltOtPtsjyyqERPuqDgE1NqFuICN4PIwAOB9a2tDs2klBZdqL1B6nNN8T25jhhZlBw5APc0ANtEkSytFRM7uXfdjjt+NVNTt28wNCwEv3gzHk+1XGE8emxRRyBHcjax9O4qS3nVo2LQ7QoI3dcmgCK3j8+FtylPk2sFPIHcg9qzvBkKweGkic+YEll5PBCZ4+proYYrdo4xhjkEnB68VgeHmP8AwjSRyruKySAMOpG7v70ARySxjzLm9dVtYRuX0Y+rf4VAbqK+ZpY4XWCZQDIRhWz2ArP1qCW+1O1s2bZE7CSWMcgIOhPrmtq9+VgY2yF6DsvpQBhx7bF3W3jVkJwF7r7ZqE/8TC4ZBguB0681dtI2lnmib5mdtxPUfhVW7h/su/iuQBtkO1gKAJrK4uLdo4dWDCBX+SUHofrXQQtIrxF5VZX5LDnaPw61VmlaK2HmRebEV5IG7Hv71Fp5spCJbK6MTNwAGwT9AaAN+2BDq7Pv54J+8RWd4i01fE+oeH/DdqzC+1a8Cv6rADl2I9AAa1rcpb6flzunzkkDHHrUnwquINIi8b/FnVEMkFjEbPTd/HmycKcexYov4tQBwX7VevJqnxPfTLSXfZaJbR2Majorgbn/AByQD/u17h8NP+TNrz/sC6t/6HcV8Z6jeT6jqFze3khkubmVppXPVnY5J/M19mfDT/kza8/7Aurf+h3FAHx74Z1efQPEOm6vaEieyuI7hMHGSrA4/HGPxr2H9qnT4f8AhNbDxNpriXTfEenxzpIo+UsoCnB/3dh/GvPPA82hWlvdy6zp6X9zM6W8KzsyQwKfvyEjq3QAdOte0x6RN4y/Zy1nTERZbzwretcWIU72+z43bc9/kZ+n90UAeH+HfGGp6Fbtb25Sa3P3Y5eie4x0NF34w1STUJbuyuLixaVPLkSKYlWz356VzlJQB13hfxpJolvHby2z3MAkMrbpzkt6j0rdXx7Lqs0cIsWUmXcMSgYB6Z45rzUCp7W4MEiMCSoOTjj9aAPXtEsm1yVm1JMXMMpWaOM5wP4Wz6V09pbW9tI8LfvY3BKsy7VVh7d65TwfryT2VpFCfLn5icmP7wPv3NdL4jvINL8J3rx3it5Ee6IJ98yE8Ek9cUAYGq3ca6zloUnS2TekLvjDfh0qu2oC8uRvtIrdyMo9sp/UH+dYPgyC7vLK5uIWiebdukZ5VRpM9cE960kv7Bbh2kv7aGaNsBGbdJjuoxxmgC7cWgE0koMhYj5wg3D/ABqubN7sG48xl46Eld2PT3rtdD0631uVpNKYtFDFu86TA57jirU+iwx2oK3AeRlMrEqfyoA4JY5YooFYIGZ+CvH0yfWn3dxPDeFbLb5wGWaQfNnvx3FdXrOl20ENhNdeW0YQyyKoO1PTdjvXC+LNZ05wGtrky3gGUlzkp7HHagCn4t8ST3MegtLb20d1YyMpvI12u6k52MPQVanuZtWtGhXaWlkDyuEAGB0FcXczDVZ1a8u44sjqqlsY9QK19Kll0qD7UbmOUy8BR1PtjtQBl6lbNFqM72zeTJAd/mBipB7bcd6z9R1O/wBTcPqV7c3bDoZpS+Pzq/rl67nylfoxdsHOSfU1i0AXtO1fUNNBWxvrqCNjuZIpWRWPqQDXR23xM8X2zI8GsyLMhBSYopdcdACR0rjqKANbxF4k1vxLfC817VLy/uFyFaaQnYD1CjooPoMV0Hw4trfSNY0jxX4gtRL4fs75DLGxG+bHdF/i2nBI9q4vLMFTj29q9Y8e+KvD2u/DfwXoOlpJaXeiwypPE3zK8rqPmDjqCQW7dcUAc58Z7zTNd8eavr+gX7X2m38wlDyRmN42IGUKnnAxwfSvbP2GP+Z2/wC3H/24rynVdE8M6f8ABKx1ddRtZPEmpSrCtnC2XiVHbezjOQcAdgORjNerfsMf8zt/24/+3FAHgHxY/wCSp+Mv+w1e/wDo96rfD2yXUfHHh+0c4Wa/hQ8Z43jtVn4sf8lT8Zf9hq9/9HvTPhjfnS/iB4fvVkEZhvI23k4wM0Afdd3a2Vho3inV764ayna3bz54W+6FyQyqejE/0rwb4OeB7+PWbbxZeXdube5c3U8Tru+zwq25XnPZmxkAc9zXrOu2Vz49ubDSbd5IbF4XvJpCAAp3YXco+9nH1rqPEd1o/wAPvB0TXCiQBxEoyqtNK4wWweCe+McAUAeSaL8QPC1p418TaP4lvV0nSNRle6ijU+fA8shy8hkKko56jAAHY9K6jTfEHw/+G3hLWde8KXL6r9rf/WIxl3yKuEiMmAFUZ/iOfmPWvln4gyxXOoy6jME829lkdVAAWNQcDA65756VmweL9WPgk+FkeRtN+0G5KA4Uk/3h359aAPoeX9pDS/D/AIfltrLQtUn8Ss5a5F+6LGZCMly6E5HTChRwAOK+fbLXfFOteK9R1nT5rm41a8LSXrQrmN42IVhIv3fL5C4PHSqmjXvh+S9t7jxLZ6tdJGoE8drcIgmIPHzMpKjGAcc+hFdRefE5otZ1G/0HSLXSxOqQ29pbqFhiiQgpuAA3sCueeMnPpQB79+1JoTWHwh0y30qCytdM0+7ilu4YVCYypRSqgcjc3Pf6818kTKI3KoFYkDBHP4+1evfEL453PjvwPJomuaMtlfLNFPDd2sp8vcuc7o255BPc9favFmf92F6EE5wKANLS9QuLC5gfTriSzuYn3rcwOVcN2IIr9Dfhn4kbxb4E0fW5YjFPdQgyoRwHUlWx7Egkexr87dItJ7zUbW2trWa6mmlVEt4VJeXJ+6oHev0g8G6Pa+H/AArpel2CTx21tAqIlwQZFHXDEcZye1AFb4jRSzeAvEEdvE80rWMoWNCAW+U9M/yr4H8O+H7vXdK8S647hbHRrQTTMVPzs7bURR2J5Ptiv0B8Z3tlp3hLWbvVX8uxitJWmb/Z2nOPftXxv8FpZtf8OeM/CFsYYF1KGO7BmuFi+WNv9XlhjnjJHTBoA8jtYw0cjhsSqMxjux9BXp/wu01tT8K6vbi1SZ7uVS0+0eejIDgIcjA5+hqLS/h3ZN4d1u61Bb977T4VlNvChBEZB/fgH7yg/Kcdua88t9QvIVQWd1NE8WSNrYIFAHSeMbP/AIRbVNPvtInmsr5fmE9vOVZHHUjByrevavVvh/8AtM6hYiO38b2B1ONAFF9ZAJPj/bQ4V/w2/jXhfhq48zxRYTX2rvpiGYCTUfJM5t1OctsHLfQV678O/hn4a+K2pavHoK3+gW2mRJF9oVmuorqQkgS/PtK7gNxTtkYIoA920P41fDjUYju1+0gkYAGK8tpIdozyDkbc/Q1uy+M/BN1cC8XxL4cZfKMayNqUWF9F2np7mvhnxf4eTwx4j1jRby4eSfT5WgWVFGyVwRjjqoIOf0rnUjDE7VX5evtQB9p+IPir4B8MRFl8QLq5KES6bp0YuBKx7iQ4VQPqDXhPjz41ax4gsp9I8NW3/CO6FJkyRwylricd98vZT/dXHcEmvJOmFGAo9sVLBHJLIkcSPJJIwVERSzMxOAAO5J7UAWtI0+61XUrTTtLt2nvLmQQwRIMl2J/l3J7Cv0F+E3gi38A+C7LR42Sa6C77q4VcebKeT74GcDPYVxH7O/wkj8E6Umta5CreJbyPlWGfscZ/5Zr/ALR/iP4dOvbfF7xpD4C8BalrTlftSp5Nmh/jnYEIPoOWPspoA+Q/2rPFI8RfFa6tIHVrTSIxZIV7v96Tn2Ylf+A141U13cTXd1Nc3MjSzzOZJHY5LMTkk/UmoaAPtX9in/klmq/9hqX/ANEQUUfsU/8AJLNV/wCw1L/6IgooAP21v+SWaV/2Gov/AERPXxVX2r+2t/ySzSv+w1F/6Inr4qoAv6Fqt3oes2WqabKYryzmWaJx2ZTkfh6j0r6h+MccPjbwPoHxb8Hrt1HT1UX0aHLIgPzBsd0Yn/gLZ6V8n17R+zR8RovCfiObQdc2P4d1siGYSY2RSH5Q5zxtIO1vbB7UAfQfhbWrLxT4Ts9XsCJLe7Ty5UXloJR95SO/rXNa7Z/Z2ljMa46JJjAY/SsOKCX4G/EG60a+kkfwT4gbzbWYj5YXz90nsVyB7jBr0TWLaG+tYzE4cNyu3kYx1B/rQB51pULR2szRkmYODvP15GKTW4C6SMUyjHAGOARWpFZyRLPZsNk+47SB19Kl1NC1lDuXbIeCvfNAHNXsKSW9tcSBmmtmDIQeCO4NVLsyw3CCzj8wS/MsYONp71qyxqZRKgBWHG5CcD8arXECPJ5sDZcElPRfY0ARSXEtvbPJJbMGRGYcAk8dq5vwF5v9iu11k5ZmCg8nJ6V1d88sVhLJIg3rG2IwM4OOoFU9CtBp/hqweJclo90nGSxJ/SgDL0uxeC9uZrp3k+0fc3DGwD+GptT8u2tpGdTuAHbite8i3W8USgBpTlCT0Nc9dCf7JLDcEs6T4cjnf9PagCDTAWt5WUBzIR8yHBFVdXBvNHkkUFDHJj5uuB3FbmmwhNsakHOdpA5Hsapa1AI9MngHUnnPPPoKAEsr1mijRxxtBAHQe9WJba2vAxkh8vbjaQev+FVrCzYWsbvkPs24zjA9ven6lq1ppGnySTlFQqCCerH0HvQBQv7nU9a1uy8HaIA2qahIsRnQ/ciPUn0wMkn0FX/2k/EFno9ro/wz8NPt0rQ41N2yn/XTkZAbHUjJJ/2m9q3fD8qfCnwVefELWYlHi7xAhh0axlTmCI/xsOvTBPttH8VfN97czXt3PdXUjS3E7tJJIxyXZjkk+5JoAgr7V+Gn/Jm15/2BdW/9DuK+Kq+1fhp/yZtef9gXVv8A0O4oA+T9I05r3wprl1Gu42DRStjJIViVzj096+2vgppscfhMTeUUtb7TbZjE6CPHyMGAPcf7VfEnhfxC2jad4gsypaHVbE2rY7MGVlP5ivp3xF4hfw8vw7tGd00rWPCz6c43jaHaOPDnt8uc/jQB8oazaNYate2jwtAYZnTynOSgBOBnv9e9VK6j4j+Hr/w14mlstRkS4JRWjukfctwmOHB/TFYEVhcTWM15HGWt4SFdvQnpQBAFBTOctnG3FSCHagLnDMeBW14e04i7uXmWN5LRRI9u7bWcdwM9wKbqmmQqtzeW8hFqfnhBPzEH/wCvQBDo013aXCvZzBQpyN3b3Fa+o3eo6+2nW96iQQTSmN51PMrD+8D0rmLSdY5F84MYu4Xqa7h4pr3wxIbZYpbFCsslyFH7nHYnsaANK6tLbTtHltrQ/Z4xH+8SRhsdx/tHnP0rz3VIoYhE0W1TjJ2Hd+OabcXF3qDbfNlmhXkKen5VSI6g0AfRfgfRzo9pY2do6zwSQibLvnbuHLYH8qfqcl0PFWnJbSOwjiaNg8eA6H27fWuC8N+JibHTftWTbW6CJmVtp2jt7mu81G5jl1/RZ9OlknjdTw3ylVHT5vT2oAl8RWE89hJbXWoW8FrPhI4olII9yR96vA9e04aPqb2cpyUJ3FeNw7H/AOtXu2vWr6laPcWwQTohmWNCdykd/SvAdbmludTmkmkMrs3MhOc0ARx/Z9hCgk9iTg/jVUAqcqSOe3Wtmy8OXt/FJ9gUzzxgM0C8sV9RVGC33xyQSIyS5+8w+5jsaAKZbcSSck9aKt31yZLe3i3o3l54WMIB+Pf61o61o4sZIoow4m8hZZoZCCYmPTDD7wI5FAGH2opWwO5J78d6SgDtfhR4HvPHWv3dpZkKlnaSXcjEZ+6PlUDuSxArE8OaLceIvE+n6RAyQz384gDy8KjE8lvTFe1/shJc2GqeJNd8t3sLa3SGby0DOxZsgKOvauc+JPjLSY/GfiG80/QJLC8uCyvBc4YJcYx5yEfdYg5I9aAPI9WtzZald2rSJK0EzxGRPuuVJGR7HGa+nf2GP+Z2/wC3H/24r5WPWvqn9hj/AJnb/tx/9uKAPAPix/yVPxl/2Gr3/wBHvWL4fdU1zT3csFW4jZivXAYZxW18WP8AkqfjL/sNXv8A6PeuYgkMUySL95GDD6igD9GfBtjaQaDbX0Ls6wyNJCEl3skbdVPcjnO09DXh37XerPLrWiWSSjy44DLBtY/fZsMf++QMfjW98PvifpcWhebqd0yztGJGkDbc8cCM+vUEHk14R8TPG8Pjf4iQX9xPcDS7cLArRwBXEanJwhJ5OT1PNAHnE7F5GLOzHJwWogmMD7lVW7bWGQa1/E0UEl89zZRCK0kJMRYbWdc8Hb2rDoA0/DOlS654h03SoHVJb24S3VmIABZgM88d69C8f+FfBHgae4sbbxRd6/r1s+xoYLURwxkdVaQMcMD6Z6YNeWwyvDKkkLtHKpyrKcEH1FauhW8DvLJdxvKqjOFfbz9aALcOm3Esf2sFIs/MgmbJkPoM1mX9nJazESKysecMpU4+hqS/1S5mmZXcLGRtWNW3BF9M/wBa2LDUItYEsOpR3MjIfMh+yxqzrxhhz2x69KAPQf2V0RvijaNLaXM7CJ/JngPFuxU5MgI+6RkdiDivuAkAEk4Ar5c+EPjD4V+D5FubHW7uymeEI1ndW0mUc4375VBV8kfLngV6Jrnxt8NaXBrryXgbVLSFWtLFJUnW53DKFChwSTjcCcqBQBW+LOg6p47+IOiaBb6hLB4bs41utWXG2LLNhIyf4pGHRTwo+bByK+efjv8ADZ/hf4ms5NKuZpNGv9zWrO2ZImXG6Nj3AyCD3B56Vyt34o8S3+my3V3rDvCl62oGMy7d122P3pH8RGAB6AcV6t481x/jHodrLJcR2n9i+HpNUutzcG4VgrgKPXjGSMA0AVda+MMOufCzS9PuTPbeJbWYLPc28YjhlhAZQC2cncpGR0yOa8b0tba68RRJ9he/ikkAFskpieQf3A4BwT2ODz2qnZzpJBFHOm+OJt5TO0v6DPtXV2UN5r0Gh6Z4VuLmS9hucRQyyJG1qxII+cY3Lu5DH7uO1AGrr+jeC4bSO+8OX2t6HqUed1tqhSVd2OUBUAg9QQwq38P/AIx694H0yPS9Gs9Et7EFjNstmaWRiP8AWs275mHGB0wAMYr0fxx8I/Ds/htntfGVnceLrm4d2lvb1Y472Tblo0XpuzwGHc4Pt88pp72paOWB3uMECPH3MdS3+FAH1Z8K9C8C/Ejw4viTXYbHWPFUSldWmuY2Q53cM8IIUfIAAwGOD6EV4D8YfFekatrDaX4N0qw0vw1ZSMITbQqr3bZwZWbrg/wjPTnvV7RviJdeH/Bz6Zo5s7aaa3a3kaKANcShzzumPKj0VfrmvLpFIchgBjjA6D2oARR6nA9a+rf2Z/g21mbPxn4phZLnHmabYuP9WCOJnH94j7o7deuMeP8A7PvgeDxx8RLW01GIyaXZxm8u1xxIqkBUJ9GYjPsDX2F8YPG8Hw88B3usGNXuRi3s4TwHmYHaD7AAsfZTQB03iDW9M8O6TPqeuXsNlYQjLzTNgD2Hck9gMk9q+D/j58VJ/iT4jUWgkg0CxLLZwtwXJ6yuP7x7DsOPUni/F3jDxB4vvjd+I9Vur+TJKrI/yR5/uIPlUfQCsCgAooooA+1f2Kf+SWar/wBhqX/0RBRR+xT/AMks1X/sNS/+iIKKAD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qoAKKKKAPpL4R+N9O+JHhV/hp8RZ181kC6RqT43q4GEXJ/jHYn7wyp5xmz4a1bW/hLrf/CH/ABCDf2PI5bTdUA3Rqc4yG/unup5WvmUHBBHBFfRPgP406N4h8Mx+Dfi3ZC801lEMWqAZeIAYVmGMhh/fXn1B5oA9ufT4byaO5EkMvmAbJ4yCkg9Qe9Y1zB/pgyN6QoyiNuDyevvXBa14G8efDq1GofDjU28S+EpV82ODAmaJOudo+8P9pPyFcr4f+NskeoXH/CU6awYsF/0ZceX6gq3NAHez6dcC9mbnyyMsoGQaWHTbVrZ2uFk3Bdy7OgOeBSaB8U/CF/cMj6nHbqzYxcRlN2ffGBitnUfFfhi00q7u4NXspIFUuFiYMzD2XrmgDC1S3fT/AA3qV5ICVhtneRmbnGPX3qTSUttW8M2N7aFljktUJBXayn6dxXhnj74hal4kMllGrWWllt3kA/NJ6Fz/AEruv2etfuJ4rvRZ5kZIf30auMsF7gH09qAOquYgkYkcorIMISMc1iuHkmRY0zGPvFv55r1DWdNs7hYwkARnwU5zu9c1y+tW1np8U095LDB5YLNvIA29sCgDIe2a3ibageVlxGuPXvn2rKk06UrEkpL4fcxPc+ua5q++J1vDrIMFrJd2cSlNu7ZvPrnsPaqx8cap4h1CLTfC+i3E15LwkQ/eOW9cD096ANDXvE+m6ZJcW0kj+ch4XGc/Q1ueEPCKHST8SvieGt/D1niSw03GHu3z8gI/uk4+vXpWloHw/wDDnw3LeJvjRf2tzrBHn2mjROJWc56so++c8f3Rjknt458UPiLrPxC1s3eqSeVZREraWMZxFbp2AHdsYy3f2GAACv8AEzx1qnxA8TzaxqxCDHl29sh+S3iB4RfzyT3J/CuSoooAK+1fhp/yZtef9gXVv/Q7iviqvtX4af8AJm15/wBgXVv/AEO4oA+LVORXq/xJ8U2niL4T/Dy1R86npkc9tOB0VflCH8QorydTzU6N+6kX+8P1FAHufxo0618SfCXwR470qFVkigXStRAAXDoMAkf7yvz6MtW/DLeEb3wJ4bjtytm8Epnv3ODvmXohz93nBGetbPgJrfxV8M/GPgXSxEDd2EWr6VA772L4HmxjvkSRj6b68D0Wx1HURcW2ixyTXbjbLp6KWkkABJZV74weByKAOs+Isui3niFbqOeOecoZLqWJsEP2BxweKz3s4te0Se/S38qKxthHFbw/Kz/7ZJ6isrwJqP8AZfiPTmks4Ly1muUjuLaZRiZdwypJ6V7D8U9c0PSfiJd6lp9gi6XqVj9hKrHsQSKACQB0xx2oA+ecYPPWt3wraSapeRWE7XX9l+ZvuEg6se3tntntTNXitWuS9lvniQjzSoyB+PYV638DbzT7iYpNZYgicRJIqbvmborEfzoA8ev7aaDWX0+6ZbVo5NhBbiL0ye/FU2jEczq0gcDI3Y619HfGj4L3F7aT+J9GKW1xEcX9pOdqqoHEit6+or52uIXs3aCUAuQd2OeO1ADIbqSDCocqG3AHnFd5D4nLaNaqkrgFygL/AK5PavOQCeByatR3BhRQpB7nPSgDvm+IM8unPpF1HgxbkhaFsI2e7Hqa4khWa43bWUfNIAOAc+tNttNur12NpH5rKN22Mgtt9QvU4p0M4Fp9lXaXkm2tx1HrQBY0LV5tD1OHUdPl/wBIBKtCM/d+tM1LU5b9pLjyvLDOxaUKfmJ7E9K95+GX7OUmpzwal4qvgmjALKiWzAm5Xrgt/APU/ljrUX7RVw1oumW+l6daQeH7ImIQWm3aQOFDY7e55oA+d3fcw3jJAwR611nhLwrf+KJrfT7RWjvJHCRzTowjT0DMAce3FYFvHJ9ne+iEYVJAdxOSh7cV9HfA/wAR6Z4D+G0/jbxNfXD3eoXklpa268mcADqPY5OeMAe9AHmPxT+E+veBbPTtT1GJpbK5HlzzLgiGbn5TjoD1BNee6Zpd9qupQ6fplrLdXk8giiiiXJdj0FfZ/hHxldfEjwz4gt9e0Wyv9JMJlti8f3/m43oeynByOeK4f4WeAYte+JGow6lKl1pOiKsRggkMCl2GQw2YJxj1oA0fhno1v8KfBepW8ry6x4t1vNs9hY4cWsiI2Eds/LjdksfwzjNfKer3lxd3UjXbM0+4+YSc5fua90/aF8byP4p1Wx0mQRx6dItgksRwQQvzDcOWIORz6V8+uSzknqeTQA2vqr9hj/mdv+3H/wBuK+Va+qv2GP8Amdv+3H/24oA8A+LH/JU/GX/Yavf/AEe9cqK6r4sf8lT8Zf8AYavf/R71ylAGnZ3kv2RrVZGGDujA9e4qtvYDvnOST61XRmR1ZCQwOQR2r1nwD4FsfiRpV22jXcVn4itIzJPYPkRzoP8Alop/hPtyM+maAPNBcF4yrkc8ncMioHCg4XJ9ya6Pxh4R1Pwlqi2er2txbSMA0RliKrMPVD0NY62ebR5pXCFWwEVCSx9z2oA0dC02XVdJ1COz0uW6uLdRK9wjhFgj9Wz1596oJaOYZId0AZwJF3jDMB2Unp9O9ehfBjQ7698XNY6fLYBrmIbTckl05/1kQ+6zr6NxzWh8VvBNjot9PeXeu26XrOVaznPnXGVONzlAFBb0FAHEaD4I1jUWgkksp4rWX7jBNzSH0Cjk1m3ME+h69Na+ZslhkaNzE/TsRkfkRX0l+z/pOh6ZoF7431TUrQWlguRPJdEvBJ02yIv3RyAF5Jz9K8F8eQ6jPr02tahbxiLVp5Li2u7aLy7a4UNhjEPr1zznrzQAumNMDc20EQ8uVeFIxkDnBFZt0kMdqZdioeiFVwS3qMVaguzHbxqq7vNfbJg847AH3pZbJSF+0BsqSIxnAK96AO1+CHh7T9Wi8RXWr6RLrV5Hp5msNNEyxLKCSHmLMeNmBgj1OATivN9P1WfTrHUY7afnUYfs0u3IzHuBIP1IFbnhzXrjwvqF5ciJJIr+2e3UbtqqSCOccgDOcd65GBFLDcflXJb3A7UAdX4A0q11TT/FjX9vE8NnpL3UdxJIE8iZXUJj13ZK7epzxWh4EXw7/wAJtZ3muwG30iOVVZPM3BWAyCWYY2E8EEHg1ymkyYtdQ2uUfYCBxgjPfPXFTanBGukWMkMu+R8/aFK4IPYn1GKAOv8AG0viCTxib2400Ja6b+8srNv9ItLa1DZUIRgNHzweCa5DXdVfVNQnvXt4bczHcY4AVTJ9M9B7VseH9c8RjR5dChuLmTRgrTtZvJsjhJ/j56ew756VzF7dG7kEhPyj5QCMHFACwzmKQtgEgfUL9PeiaUzy78nnjBOcCoMghsAKx7DoKFzsbHXFAH2n+yDocdh8OLnVWjZbnU7t2LEEZjj+RMe2dxyPWuE/be1otd+GtDQ8Ikl7IM+pCL/6C/517Teawfh58FLG/wBG0mXVBYadAI7a3JwcquXJAJ2jJYkCvhz4leOdW+IXiRtZ1sQpMIxDFFApCRICSFGST1JOSe9AHKUUUUAFFFFAH2r+xT/ySzVf+w1L/wCiIKKP2Kf+SWar/wBhqX/0RBRQAftrf8ks0r/sNRf+iJ6+Kq+9f2oPB2veN/AOn6b4Ysft17Fqcdw8fnRxYjEUqk5dgOrLxnPNfL//AAz58T/+hZ/8n7X/AOOUAeVUV6r/AMM+fE//AKFn/wAn7X/45R/wz58T/wDoWf8Ayftf/jlAHlVKDivVP+GfPif/ANCz/wCT9r/8co/4Z8+J/wD0LP8A5P2v/wAcoAxPh58UvFXgJimg6iRZs257OdfMhY/Q/dPupBr23T/Hvws+LHkxfEPSotG14phr5GMUbHPAEgOe/wDGMe9eW/8ADPnxP/6Fn/yftf8A45S/8M+/E/8A6Fn/AMn7X/45QB6Rq37NtvqCzXPgPxdY6hAFLLDPtk+g8xCR+JArynxF8HvHnhxDNe+HLpogMmWzInA/74JNdL4a+EPxn8Magt9oGkz2N0v8cWoWvPsR5mD+NexeHdd/aC06JY9U8IabqqqMb5Lu2ikPuSkoH6UAfH95DPbORdwzQy9CsqFTn8a+hvCvwp0qy/f6V4yki1gaXBcCCPyt3mzKW2kE5ZcDAUfMa9cXWPHOozbvEPwcs7nB4YapZyEf99n+tQ3GjrbxiPT/AIImRRL9oBlvbCNlk9QRKxHtz+VAHz18RPEniXw5q8Wi2mqXz272scy+bAokVnHzAYyQM5xnmuV0Xwl418dX+2z07VL6RiFaaZWWNf8AeZuAK+wW1vxfFcJJbfB8ZA5c6tYq4I6YIJrlPFmt/HvUgY/D/g+y0SDBGVvbWeT82kwPyoA4zw/+zfb6TYNqfxI8R22n2EHzPFauFGPeVun0ANUfEHxn8LeBtOn0T4O6NDFL9x9YnjyW9Sob5nPu2B7VzniX4SfGvxPdtc6/p15qEpOf3+qWzBfovm4H4AVjf8M+fE//AKFn/wAn7X/45QB55r+t6l4g1SbUtavJr2+mOXmmbLHHQewHoOKzq9U/4Z8+J/8A0LP/AJP2v/xyj/hnz4n/APQs/wDk/a//ABygDyqivVf+GfPif/0LP/k/a/8Axyj/AIZ8+J//AELP/k/a/wDxygDyqvtX4af8mbXn/YF1b/0O4r5//wCGfPif/wBCz/5P2v8A8cr6g8D+Dtd0z9mi58KX1j5Wvvpmo262vnRtmSVpjGN4YrzvXnOBnnFAHwVUkbYYc4r1H/hnz4n/APQs/wDk/a//ABylH7PvxPH/ADLP/k/a/wDx2gC98No7nRL7SPF2mB7q00eUXd3HAdzpbt8kxIHIUAnPal/aH0R/B3xYOs6BK9ta6mF1WxubdsBXJy5Rh/tfN9GFd78Pfhh4t8I3uh6vD4S1UanGz2ur2gvLGS1vbR+GKkzgq+P4SCpIBytXfHfw68V+IvhxZ+HYPCerm80W+k/si4nu7ID7E3SKUi4JDKMDgEHy16ZOADzDXND1HxPpms+L7O1ht9a0w295fpaKFDBxkXCJ05xubHuayvG3irxXq/h61g8SzW17ayzi4t74Rp5ivt5XcMEDHUGvdfg94S8Y+FZbv/hJ/Bmo3kd1p/8AZ8y215ZNvQH5fvXC/wAJIrRufA9zP4K1DSn+H+pvqUhb7PcN/Z+xACfL4+1ZBxgE89+tAHzM/i2ePwTf6NaWMa2+qTxT3kpXo8R4CY6A981d0rxnq3hzV9W1HQ4Bo1/K0Ui20EYMUSAfew2cg/1zXq+n+B/ic1jLa6x4CsZwIfLgmgns45Iz6EiXDA/TNce3wW+Kqast7beHZI2QbE3X9q+Exjbgy9PagDJ1D46eO76O4SbVVjimUqYooUEeDwQQQcgj1rze4vHuWDSqhbttGOPSvco/gj4vlcXsvg2e11GJ1kWKO5s5rafHVXRp1IB74zXc6b4f8d6beWN5o/wi0LRNSWX/AEm8tLi1l3Q91SJpgAT67qAPle6ZXhRoI3it2JxGSSAw64Y9aqV9UeK9G+NXifQtX0jUfDkAsLyUtHBGbECJc8BW83KngZPJ968p/wCGf/idj/kWT/4H2v8A8doA860ie7s7xbzT/NW4t/3iyxAkxEfxcdK0PEVhr6smra5pl7bi7UTLcSWpiSTPRgcAc16n4J+FHxf8HeIbfV9H8PBJ48q6veWrpKh6oymXkGvVhf8Ax2uNUv2v/DFvJpVyCkdms1l/o47MrGQ5I9GyKAPmKfx54svYrW1n8Qai1vbKI44RKURV6Y2jA/OrM+uX66Fa2+qo80IuDcQNgAOB2b+8te9J8OPEHibXW1Hx34EuraPYBJbaI9iPtcg6SzSNcqc+qqAD61xvjz4SfEbxR4hS7h8HGxsIY1t4YE1C1O2JenHm4B9v1oA8OvZJbi4luZoliNwTIFRdidf4R6Vpa1Jem30q3umm8iGAfZ1b7uCckgfXvXuuvfCnxfd+HILSDwNJdawIlQ6jc3VnH5Kr0jjjWcrtx/Eea5N/gR8RJ5rQ3Hh25MYK+aovLQ7ADyE/ff4UAewfCwWfgz4QjxLNN5Oo3UUkUaqdys3IUjPbjJHSr3wUvbfQPBPifVvs8X2iztjdz3TOQLhyjPyvZeAKwviN4U8feJ7uys7LwpewaDZ28cEEbz2SsuMbiUFwVOcf3q15fD3iuP4aeKfD9v4P1eTUNVUQwySXNisSRhVUZxcEggbjgAjOOaAPI/jB4HXQJrPUmhv77RtaSO7uZyQDa30w3HD4wynrgj8a8Rv7c2t7PATkxOU59jX35rEurXHgKfQl+HmsalIbJbZVv59PWKZ1QKrPi5YjkA8AkY4r5Sf9n74oMxZvDRLHkk6ha8/+RaAPKK+qv2GP+Z2/7cf/AG4ryr/hnz4n/wDQs/8Ak/a//HK+gP2Uvh94n8Cf8JR/wlemfYPtv2XyP9Iil37PO3fcZsY3r1x1oA+Vfix/yVPxl/2Gr3/0e9cpXuvxC+BvxF1fx94l1LT/AA951leanc3EEn222XfG8rMpwZARkEcEA1z/APwz58T/APoWf/J+1/8AjlAHlVa3hfX9S8Ma7aavoly1tfWz7kdeh9VI7qRwR3Brv/8Ahnz4n/8AQs/+T9r/APHKP+GfPif/ANCz/wCT9r/8coA9o0T4j+GPi54fOneJbGyj1UxCNrKWTYjEHJaFvvD1wDkY6kVwHjb4BawjC48ETzarp7Qef9nuCEmQ8/J2DE4JHQkfrzC/s/8AxQVgy+GiGByCNQtcj/yLXoGieG/j7pcew6U90AoRWm1C2LooGMAiXpj1oA8Z0jwl4uuZrb+zNN1Bmldo4SqMAzr95c9mHcHpXsPwz+BmravqSal8SheyaZDL5K2cMpkkkbPJYj7sY7lTk+3Wux0i1+LsMQW/8ISB9yu0ltqNquWU5zjzep6H1Fek6JrXi60m33vgvXJVk5eNbmwIj46R/wCkjjPYigDR0L4beEdIt5oLPTYPsk+VFu/MYXrjafvEEZ3HLD1r5j/ansdXsfG9s01klv4Zitli0t7ZMQkE7pNxHAkLk56ZG3619RS+ItWmjdZ/AHiCTqFBn0/oe2ftVZFr59tdNPB4D8VwpLzNaLfWD27k+sbXRX8gKAPhvTFNy3lW8ck8gGStvGZD9flBrtNH8CeLtTMEsHhnV3iZtqs1u6YGP9rHHvX2JZaze2IYWnw816EMefLfTU/ldCrB8UazuGPAfiMjvm40/j/yaoA+VZPhDfxPBL48n03wvoSXHlyXFzcqrP8AKTiFRncx98YANeI6hbizv7q2V/MWGRow+MbwDwfxHNfYvxi0zx14x1rRLjRfBt9HZ6fDcbor+awYNLIAoYL57A4UHk8jPFeEXPwE+JsszuPC5AY5x9vteP8AyLQBxHhS6sbSLVjfWiXM0toyWZc/LFNuBDkdGwueD61WaGRxLdWL3DrEgMrbSxXsWPGFXJwM16f4d+A/j2LVLVdc8L3baUZP9IFpf2fnBCMEpulxu6deK6CD4XfEPS/A+reH9G8GzeZq8ire3dxqVrl4Y5N8Sqol4PXdzg/rQB4iupztYwWUrbbFZfMYIBvdvVj1bHb0rOuQgkbYQQWzjGOP6V6vf/Aj4kzXO6HwuyxqAq/6bajP4ebx9Mmq8nwD+Jrn/kV8euL+15/8i0AeV7qlj5yCeoxmvTP+FAfE3/oWD/4H2v8A8dpy/AL4mqf+RYP/AIH2v/x2gD61+AficeKvhdo90yFJrVPsMw7FogFyPqMGuZ+MHwF0Hxnb3GoaJFFpPiDBZZIVCw3DekijjJ/vDn1zXJ/s/wDh34ifDm91KHWfCV7c6ReIrbLa8s3kWZeARunUAEE5/Cva/wDhKNX/AOhE8Sf9/wDTv/kqgD849a0u90TVbrTdVtpLW+tnMcsMgwVYf5696o19g/tAfD7VfiOttqWieC9bsvEEAEReefT1iniz0crck5XnBwfT0I8T/wCGfPif/wBCz/5P2v8A8coA8qor1X/hnz4n/wDQs/8Ak/a//HKP+GfPif8A9Cz/AOT9r/8AHKAPoD9in/klmq/9hqX/ANEQUV0H7L/g7XvBHgHUNN8T2P2G9l1OS4SPzo5cxmKJQcoxHVW4zniigD1+iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A) and coronal (B) fluid-attenuated inversion recovery brain MRI scans show bilateral symmetric hyperintense signal changes involving the corticospinal tracts. (C) Sagittal T2-weighted MRI shows the hyperintense signal along the corticospinal tract from the cortical area extending into the internal capsule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sehgal R, Sharma S, Sankhyan N, et al. Selective corticospinal tract involvement in late-onset Krabbe disease. Neurology 2011; 77:e20. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16726=[""].join("\n");
var outline_f16_21_16726=null;
var title_f16_21_16727="Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas";
var content_f16_21_16727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Michael Allon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Ivan D Maya, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16727/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/21/16727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis requires access to blood vessels capable of providing rapid extracorporeal blood flow. These requirements are currently best met by both primary arteriovenous (AV) fistulas and synthetic grafts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of the treatment of venous stenosis and thrombotic complications of hemodialysis AV grafts is presented in this topic review. Issues surrounding clinical monitoring and surveillance of AV grafts to prevent thrombosis are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying stenosis of the vascular access circuit is an important predictor of graft or fistula thrombosis. Therefore, angioplasty of a stenotic lesion has been advocated as the treatment of choice to prevent graft or fistula thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    failure of the vascular access.",
"   </p>",
"   <p>",
"    In general, preemptive angioplasty of the stenotic lesion in grafts is not a permanent treatment due to its short primary and secondary patency (defined as time to next radiologic or surgical intervention and time to complete failure of the access, respectively). Even after an excellent technical success (visual inspection at time of the angioplasty), which is close to 100 percent, the low rates of access patency at three, six and twelve months are discouraging [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In fistulas, the treatment can be divided into two arms. One is the use of angioplasty as a form of treatment to salvage immature fistulas, and the second is the angioplasty of a stenotic lesion on a matured fistula.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a stenotic lesion at the juxta-arterial anastomosis is causing the fistula not to mature, then sequential balloon angioplasties can help bring the fistula to maturation. If the cause of the failure to mature is a long segment of diseased vein close to the arterial anastomosis, the chances for maturation are very slim and these patients will benefit from a surgical repair.",
"     </li>",
"     <li>",
"      The development of stenosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombosis is low once the fistula has matured. However, once the fistula develops a stenotic lesion its primary patency after angioplasty ranges from 35 to 70 percent at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/4,6,8\">",
"       4,6,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described elsewhere within UpToDate, greater than 90 percent of thrombosed grafts have a stenotic lesion. Most grafts requiring angioplasty have only one stenotic site, but up to 30 percent can have two or more stenotic sites. More than 60 percent are located at the venous anastomosis and about 20 percent in the venous outlet for a total of 80 percent. The other stenotic lesions are: arterial anastomosis (1.5 to 2 percent), intragraft (11 percent) and central venous stenosis (7 to 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, these findings suggest that an anatomic abnormality is required for graft thrombosis. Given this, correcting the stenosis may decrease the risk of thrombosis and improve graft patency. However, several well-designed studies have found that such correction does NOT decrease the frequency of graft thrombosis or improve graft survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, the treatment of venous stenosis of grafts is important clinically because it provides reduced vascular morbidity (via elective versus emergent repairs), preserves future access sites, and decreases the requirement of catheter placement, thereby obviating the adverse risks associated with catheter use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since it is safe, effective, and easily performed, we recommend angioplasty for the initial management of venous stenosis affecting dialysis access grafts. Surgery as the initial procedure is less desirable because, although the lesion is eliminated, new lesions frequently emerge over time and potential venous access sites are lost.",
"   </p>",
"   <p>",
"    In agreement with the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, we define a clinically significant stenosis in a graft as a greater than 50 percent narrowing of the diameter and the presence of abnormal physical findings, decreasing intragraft blood flow (less than 600",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    or elevated static pressure within the graft [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Percutaneous angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, preemptive percutaneous angioplasty, even if not clearly associated with decreased thrombosis and access failure rates, provides reduced vascular morbidity (via elective versus emergent repairs) and preserves future access sites. The strategy of preemptive angioplasty also decreases the requirement of catheter placement, thereby obviating the adverse risks associated with catheter use.",
"   </p>",
"   <p>",
"    A detailed discussion of the use of modality in this setting for hemodialysis AV grafts can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18010?source=see_link\">",
"     \"Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of stents is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11944?source=see_link\">",
"     \"Use of stents for venous stenosis associated with dialysis vascular access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Surgical revision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major advantage of surgery for venous stenosis is the elimination of the lesion. However, new lesions frequently emerge over time.",
"   </p>",
"   <p>",
"    The major disadvantage is the loss of potential venous access sites. Even a patch angioplasty, for example, results in the loss of a small portion of vein. Since venous stenosis is a recurrent problem, this may result in a progressive loss of venous anatomy available for access creation. Additional adverse effects include postoperative pain, the occasional need for a temporary access following the operation, and the inaccessibility of central veins to the surgeon.",
"   </p>",
"   <p>",
"    Thus, lesions unsuitable for percutaneous transluminal angioplasty can be referred for surgical revision. As an example, tight stenoses associated with a previous thrombosis respond poorly to angioplasty and require surgical correction. One study found that clotted grafts with unsuccessful percutaneous thrombectomy almost always (92 percent of cases) have a stenotic lesion at a location other than the venous anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, following an unsuccessful percutaneous graft thrombectomy, successful salvage by surgical revision was feasible in only 8 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional techniques are being evaluated for the treatment of vascular stenosis in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding the management of stenoses of hemodialysis AV fistulas are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12376?source=see_link&amp;anchor=H15#H15\">",
"     \"Early and late hemodialysis arteriovenous fistula failure\", section on 'Late AVF failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT OF THROMBOSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     AV grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once thromboses have developed, the therapeutic options include percutaneous or surgical thrombectomy, thrombolytic agents, and mechanical dissolution. If these modalities are successful, a fistulogram can then be performed and detected stenoses treated with angioplasty or surgical revision [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/10,12-18\">",
"     10,12-18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment of thromboses'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no optimal approach to the treatment of a thrombosed graft. The approach varies largely based upon local practice and expertise.",
"   </p>",
"   <p>",
"    Although not adequately studied, it appears that surgical repair is comparable to endovascular interventions. This was shown in a 2009 meta-analysis of eight randomized studies, in which similar results with both techniques were reported with studies published after 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/19\">",
"     19",
"    </a>",
"    ]. The primary patency of grafts after thrombectomy and angioplasty ranges from 30 to 60 percent at three months and 10 to 40 percent at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/6,20\">",
"     6,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that, with thromboses of grafts and associated stenosis, each institution should determine whether percutaneous thrombectomy with angioplasty or surgical thrombectomy with graft revision is preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/10\">",
"     10",
"    </a>",
"    ]. The guidelines do not recommend any one approach to the removal of thromboses in patients with fistulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Percutaneous thrombectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosed grafts can be treated by mechanical thrombectomy in conjunction with angioplasty of the underlying stenotic lesion. Overall, primary patency after percutaneous thrombectomy is slightly better for grafts than fistulas (at six months, it is 25 to 40 percent for grafts versus 20 to 40 percent for fistulas) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/6,21\">",
"     6,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary patency is much worse after thrombectomy than after elective angioplasty of a patent graft. In a number of series, primary graft patency after thrombectomy and angioplasty was 37 to 63 percent at three months and 11 to 39 percent after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/5,22-29\">",
"     5,22-29",
"    </a>",
"    ]. A large observational study comparing more than 300 graft thrombectomies to more than 300 elective angioplasties performed at one large medical center observed a primary patency at six months of 19 percent after thrombectomy versus 51 percent after elective angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Surgical thrombectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical thrombectomy, using a Fogarty embolectomy catheter, requires a small incision in the hemodialysis fistula. Clot is then removed by expansion of the catheter. This outpatient procedure is quick, has a very low complication rate, and is initially successful in 90 percent of cases. However, failure to correct the underlying outflow stenosis leads to rapid rethrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts to treat fistula thrombosis with thrombolytic agents, such as urokinase and streptokinase, originally yielded disappointing results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/30\">",
"     30",
"    </a>",
"    ]. However, subsequent dosing adjustments and technical advances have improved the success rate and reduced the incidence of bleeding in patients in whom there is no contraindication to thrombolytic therapy (such as a bleeding disorder, a recent bleeding episode, or severe hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. As an example, use of the pulse spray technique, which combines thrombolytic therapy with mechanical clot disruption, rapidly established access patency in over 90 percent of cases with minimal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/29\">",
"     29",
"    </a>",
"    ]. Fifty percent of these fistulas remained patent at one year.",
"   </p>",
"   <p>",
"    Although not performed in all centers, the most common thrombolytic agent used is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Alteplase is delivered into the entire portion of the thrombosed access by a four French catheter. The operator has to wait at least 15 to 30 minutes before proceeding to perform a mechanical thrombectomy including an angioplasty of the stenotic lesion. One must be careful since the thrombolytic agent can be inadvertently delivered directly into the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mechanical disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators have reported on the mechanical disruption of the clot in the graft without use of any lytic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/23,24,34\">",
"     23,24,34",
"    </a>",
"    ]. One study, for example, found a similar rate of success in opening thrombosed grafts with mechanical clot disruption, surgical thrombectomy, and pharmacomechanical clot disruption using urokinase; however, the grafts treated with mechanical thrombectomy had a considerably greater long-term patency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/24\">",
"     24",
"    </a>",
"    ]. Another study found that the Amplatz thrombectomy device and pulse spray pharmacomechanical thrombolysis were similarly successful in recanalizing thrombosed grafts, resulting in comparable primary patency rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major concern with these techniques is the possibility of developing clinically significant pulmonary emboli. In a review of over 650 cases, only one clinically apparent pulmonary embolus was documented (the symptoms of which resolved within 24 hours) and two patients developed transient chest pain of undetermined etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/23\">",
"     23",
"    </a>",
"    ]. A second well-designed study compared ventilation-perfusion scintigraphy before and after thrombolysis in 13 patients with clotted access grafts, of whom nine underwent mechanical thrombolysis alone and the remainder had pharmacomechanical thrombolysis with urokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/36\">",
"     36",
"    </a>",
"    ]. No patient had radiographic evidence of pulmonary embolism.",
"   </p>",
"   <p>",
"    To reduce the possibility of large pulmonary emboli, a device has been developed that consists of a high-speed rotating cam tip that pulverizes the clot into tiny particles (as mentioned previously).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     K/DOQI goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated by the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, reasonable outcome goals for each institution after treatment of graft thrombectomy include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16727/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A success rate of 85 percent, as defined by the ability to use the graft at least once post-procedure",
"     </li>",
"     <li>",
"      Primary patency of 40 percent at three months after percutaneous thrombectomy",
"     </li>",
"     <li>",
"      Primary patency of 50 and 40 percent at 6 and 12 months after surgical thrombectomy, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     AV fistulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues surrounding the management of thrombectomy of hemodialysis AV fistulas are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12376?source=see_link\">",
"     \"Early and late hemodialysis arteriovenous fistula failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF DIALYSIS CATHETER THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cuffed tunneled dialysis catheters are an alternative to native AV fistulas and grafts for hemodialysis vascular access. A discussion of the treatment of dialysis catheter thrombosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with stenosis of hemodialysis access grafts, we recommend percutaneous angioplasty rather than surgery as the initial procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Lesions unsuitable for percutaneous transluminal angioplasty can be referred for surgical revision. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Percutaneous angioplasty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgical revision'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18010?source=see_link\">",
"       \"Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Issues surrounding the management of stenoses of hemodialysis AV fistulas are discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fistulas'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12376?source=see_link&amp;anchor=H15#H15\">",
"       \"Early and late hemodialysis arteriovenous fistula failure\", section on 'Late AVF failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Once thromboses of an AV graft have developed, the therapeutic options include percutaneous or surgical thrombectomy, thrombolytic agents, and mechanical dissolution. If these modalities are successful, a fistulogram can then be performed and detected stenoses treated with angioplasty or surgical revision. There is no optimal approach to the treatment of a thrombosed graft. The approach varies largely based upon local practice and expertise. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment of thromboses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Issues surrounding the management of thrombectomy of hemodialysis AV fistulas are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12376?source=see_link\">",
"       \"Early and late hemodialysis arteriovenous fistula failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A discussion of the treatment of dialysis catheter thrombosis is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=see_link\">",
"       \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/1\">",
"      Moist LM, Churchill DN, House AA, et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 2003; 14:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/2\">",
"      Schwab SJ, Oliver MJ, Suhocki P, McCann R. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 2001; 59:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/3\">",
"      Murray BM, Rajczak S, Ali B, et al. Assessment of access blood flow after preemptive angioplasty. Am J Kidney Dis 2001; 37:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/4\">",
"      Maya ID, Oser R, Saddekni S, et al. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis 2004; 44:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/5\">",
"      Lilly RZ, Carlton D, Barker J, et al. Predictors of arteriovenous graft patency after radiologic intervention in hemodialysis patients. Am J Kidney Dis 2001; 37:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/6\">",
"      Zaleski GX, Funaki B, Kenney S, et al. Angioplasty and bolus urokinase infusion for the restoration of function in thrombosed Brescia-Cimino dialysis fistulas. J Vasc Interv Radiol 1999; 10:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/7\">",
"      Maya ID, Saddekni S, Allon M. Treatment of refractory central vein stenosis in hemodialysis patients with stents. Semin Dial 2007; 20:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/8\">",
"      McCarley P, Wingard RL, Shyr Y, et al. Vascular access blood flow monitoring reduces access morbidity and costs. Kidney Int 2001; 60:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/9\">",
"      White JJ, Bander SJ, Schwab SJ, et al. Is percutaneous transluminal angioplasty an effective intervention for arteriovenous graft stenosis? Semin Dial 2005; 18:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/10\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/11\">",
"      Maya ID, Smith T, Young CJ, Allon M. Is surgical salvage of arteriovenous grafts feasible after unsuccessful percutaneous mechanical thrombectomy? Semin Dial 2008; 21:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/12\">",
"      Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol 1992; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/13\">",
"      Windus DW. Permanent vascular access: a nephrologist's view. Am J Kidney Dis 1993; 21:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/14\">",
"      Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney Int 1998; 54:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/15\">",
"      Hurt AV, Batello-Cruz M, Skipper BJ, et al. Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. Am J Surg 1983; 146:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/16\">",
"      Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis. Kidney Int 1999; 55:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/17\">",
"      Palder SB, Kirkman RL, Whittemore AD, et al. Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985; 202:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/18\">",
"      Lipari G, Tessitore N, Poli A, et al. Outcomes of surgical revision of stenosed and thrombosed forearm arteriovenous fistulae for haemodialysis. Nephrol Dial Transplant 2007; 22:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/19\">",
"      Tordoir JH, Bode AS, Peppelenbosch N, et al. Surgical or endovascular repair of thrombosed dialysis vascular access: is there any evidence? J Vasc Surg 2009; 50:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/20\">",
"      Beathard GA, Welch BR, Maidment HJ. Mechanical thrombolysis for the treatment of thrombosed hemodialysis access grafts. Radiology 1996; 200:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/21\">",
"      Jain G, Maya ID, Allon M. Outcomes of percutaneous mechanical thrombectomy of arteriovenous fistulas in hemodialysis patients. Semin Dial 2008; 21:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/22\">",
"      Turmel-Rodrigues L, Pengloan J, Baudin S, et al. Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant 2000; 15:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/23\">",
"      Beathard GA. Mechanical versus pharmacomechanical thrombolysis for the treatment of thrombosed dialysis access grafts. Kidney Int 1994; 45:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/24\">",
"      Beathard GA. Thrombolysis versus surgery for the treatment of thrombosed dialysis access grafts. J Am Soc Nephrol 1995; 6:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/25\">",
"      Cohen MA, Kumpe DA, Durham JD, Zwerdlinger SC. Improved treatment of thrombosed hemodialysis access sites with thrombolysis and angioplasty. Kidney Int 1994; 46:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/26\">",
"      Sands JJ, Patel S, Plaviak DJ, Miranda CL. Pharmacomechanical thrombolysis with urokinase for treatment of thrombosed hemodialysis access grafts. A comparison with surgical thrombectomy. ASAIO J 1994; 40:M886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/27\">",
"      Trerotola SO, Lund GB, Scheel PJ Jr, et al. Thrombosed dialysis access grafts: percutaneous mechanical declotting without urokinase. Radiology 1994; 191:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/28\">",
"      Trerotola SO, Vesely TM, Lund GB, et al. Treatment of thrombosed hemodialysis access grafts: Arrow-Trerotola percutaneous thrombolytic device versus pulse-spray thrombolysis. Arrow-Trerotola Percutaneous Thrombolytic Device Clinical Trial. Radiology 1998; 206:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/29\">",
"      Valji K, Bookstein JJ, Roberts AC, Davis GB. Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialysis grafts: early and late clinical results. Radiology 1991; 178:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/30\">",
"      Young AT, Hunter DW, Castaneda-Zuniga WR, et al. Thrombosed synthetic hemodialysis access fistulas: failure of fibrinolytic therapy. Radiology 1985; 154:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/31\">",
"      Ahmed A, Shapiro WB, Porush JG. The use of tissue plasminogen activator to declot arteriovenous accesses in hemodialysis patients. Am J Kidney Dis 1993; 21:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/32\">",
"      Schon D, Mishler R. Salvage of occluded autologous arteriovenous fistulae. Am J Kidney Dis 2000; 36:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/33\">",
"      Cooper SG. Original report. Pulse-spray thrombolysis of thrombosed hemodialysis grafts with tissue plasminogen activator. AJR Am J Roentgenol 2003; 180:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/34\">",
"      Turmel-Rodrigues L, Pengloan J, Rodrigue H, et al. Treatment of failed native arteriovenous fistulae for hemodialysis by interventional radiology. Kidney Int 2000; 57:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/35\">",
"      Sofocleous CT, Cooper SG, Schur I, et al. Retrospective comparison of the Amplatz thrombectomy device with modified pulse-spray pharmacomechanical thrombolysis in the treatment of thrombosed hemodialysis access grafts. Radiology 1999; 213:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16727/abstract/36\">",
"      Petronis JD, Regan F, Briefel G, et al. Ventilation-perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts. Am J Kidney Dis 1999; 34:207.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1971 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16727=[""].join("\n");
var outline_f16_21_16727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Percutaneous angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Surgical revision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT OF THROMBOSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AV grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Percutaneous thrombectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Surgical thrombectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mechanical disruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - K/DOQI goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      AV fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF DIALYSIS CATHETER THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12376?source=related_link\">",
"      Early and late hemodialysis arteriovenous fistula failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18010?source=related_link\">",
"      Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11944?source=related_link\">",
"      Use of stents for venous stenosis associated with dialysis vascular access",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_21_16728="Pleural effusions following cardiac surgery";
var content_f16_21_16728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pleural effusions following cardiac surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16728/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16728/contributors\">",
"     John E Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16728/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16728/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16728/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16728/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/21/16728/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative pleural effusions are common in patients who undergo cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/1-13\">",
"     1-13",
"    </a>",
"    ]. Most of these effusions develop as a consequence of the surgical procedure itself (\"nonspecific pleural effusions\") and follow a generally benign course. Postoperative pleural effusions may also occur with postpericardiotomy syndrome (PPCS, also known as the postcardiac injury syndrome or Dressler's syndrome), or as the initial manifestation of a potentially serious complicating event, such as heart failure or pulmonary embolism (",
"    <a class=\"graphic graphic_table graphicRef55729 \" href=\"UTD.htm?2/1/2075\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The extent of the evaluation required for a postoperative pleural effusion depends upon the presence of associated cardiovascular symptoms and the volume, timing of onset, progression, and persistence of the pleural effusion. Effusions with the following characteristics almost invariably represent nonspecific pleural effusions, and require only observation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small to moderate in size",
"     </li>",
"     <li>",
"      Present within one to two days after surgery and not progressive",
"     </li>",
"     <li>",
"      Not associated with respiratory symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, symptomatic, large, or progressive pleural effusions require thoracentesis with pleural fluid analysis, and, in some instances, further evaluation with serum brain natriuretic peptide (BNP), echocardiography, helical chest CT, or other diagnostic studies. Postoperative pleural effusions can also be caused by hemothorax, pneumonia, pleural infections, central venous catheter erosion, mediastinitis, or chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONSPECIFIC PLEURAL EFFUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions of a generally benign nature occur after cardiac transplantation, coronary artery bypass grafting (CABG), and, less often, mitral and aortic valve replacement surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/2-13,16-18\">",
"     2-13,16-18",
"    </a>",
"    ]. These effusions can occur in the early (&le;30 days) or late (&gt;30 days) postoperative period.",
"   </p>",
"   <p>",
"    Small, usually left-sided, pleural effusions that typically encompass a radiographic area smaller than two intercostal spaces are common in the early postoperative course following CABG procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/2\">",
"     2",
"    </a>",
"    ]. Multiple studies have demonstrated a large range of reported incidence of these early nonspecific effusions. These variations reflect the different timing, methods, and frequency of postoperative imaging examinations used to detect pleural fluid in the individual studies. As an example, one study of 47 patients noted that 89 percent had pleural effusions when examined by thoracic ultrasound on the sixth postoperative day; only 60 percent of these patients had evidence of pleural fluid when evaluated with standard chest radiographs, which have a lower diagnostic sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to early nonspecific effusions, late effusions can be large, and 10 percent of the patients in one series had an effusion that occupied more than 25 percent of a hemithorax [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/19\">",
"     19",
"    </a>",
"    ]. In this study, 63 percent of patients had a pleural effusion at 30 days after a CABG, and 45 percent had an effusion after valve replacement surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several potential causative factors have been suggested for early and late nonspecific effusions, but their relative roles and importance have not been completely defined (",
"    <a class=\"graphic graphic_table graphicRef75443 \" href=\"UTD.htm?0/35/571\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Early nonspecific effusions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical cardiac cooling with ice is a potential pathogenetic factor for early effusions. In one retrospective study, pleural effusions occurred in 50 percent of patients who underwent topical cardiac cooling with ice but in only 14 and 18 percent of patients who received topical cold saline or no topical cardioplegia, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/5\">",
"       5",
"      </a>",
"      ]. Similar results were reported in a different study of 191 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/20\">",
"       20",
"      </a>",
"      ]. It is speculated that the degree of cooling associated with ice cardioplegia causes effusions by injuring pericardial and pleural membranes. Some authors have suggested that ice cardioplegia may cause pleural effusions due to left phrenic nerve injury, which causes left diaphragmatic paralysis and atelectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgical interruption of mediastinal lymphatic channels may interfere with drainage of pleural fluid.",
"     </li>",
"     <li>",
"      Pleurotomy causes pleural injury and contributes to the late onset of nonspecific post-cardiac surgery effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/11\">",
"       11",
"      </a>",
"      ]. Pleurotomy is frequently performed in patients undergoing placement of an internal mammary artery (IMA) coronary artery graft, and pleural effusions are more common after IMA-CABG operations than after procedures that use saphenous vein (SV) grafts alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3,6,17,18\">",
"       3,6,17,18",
"      </a>",
"      ]. Early effusions occur less commonly in patients undergoing IMA grafting if the parietal pleura is not incised [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/22\">",
"       22",
"      </a>",
"      ]. Pleural fluid is often hemorrhagic in appearance with high protein and LDH content after pleurotomy.",
"     </li>",
"     <li>",
"      Early effusions occur before the usual onset of postpericardiotomy syndrome (PPCS), which develops during the second or third postoperative week. Furthermore, the other defining clinical features of PPCS &ndash; fever, leukocytosis, elevated erythrocyte sedimentation rate, antimyocardial antibodies, and pulmonary infiltrates &ndash; are typically absent in patients with early nonspecific postoperative pleural effusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Late nonspecific effusions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominance of isolated left-sided effusions has led to suggestions that underlying pericarditis is an important causative factor. One study demonstrated that patients who had persistent pericardial effusions after cardiac surgery were also more likely to have late onset pleural effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/13\">",
"       13",
"      </a>",
"      ]. In another report of 47 patients undergoing elective CABG surgery, there was no correlation between pericardial and pleural effusions seven days after surgery but a relationship did exist after 14 and 30 days [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3\">",
"       3",
"      </a>",
"      ]. These observations led to the suggestion that the late onset of pleural fluid results from direct surgical trauma to intrathoracic tissue, while the late persistence of a pleural effusion depends upon the presence of pericarditis and drainage of pericardial fluid into the left chest.",
"     </li>",
"     <li>",
"      Even in the absence of pericarditis, the presence of elevated pleural fluid protein content, inflammatory cells and vascular endothelial growth factor support the role of pleural inflammation in late nonspecific effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/23\">",
"       23",
"      </a>",
"      ]. Some experts suggest that incomplete resolution of postpericardiotomy syndrome (PPCS) is the primary cause of lymphocyte-predominate pleural inflammation in the late postoperative period [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Postpericardiotomy syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Heart failure does not appear to be a contributing factor for late nonspecific pleural effusions. Although left ventricular dysfunction is the most common cause of symptomatic pleural effusions that first develop &gt;90 days post CABG, these effusions are transudates in contrast with the exudative nature of late onset nonspecific pleural effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/25\">",
"       25",
"      </a>",
"      ]. Also, a low left ventricular ejection fraction does not occur more commonly in patients with postoperative pleural effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Additional causes of late nonspecific effusions are constrictive pericarditis and a trapped lung due to surgical or immunologic pleural injury and the development of a visceral pleural peel [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=see_link\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of postoperative pleural effusions are small and are not associated with increased mortality or prolonged hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Only 7 percent of internal mammary artery (IMA) and 2 percent of saphenous vein (SV) CABG procedures have pleural effusions that encompass more than two intercostal spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/2\">",
"     2",
"    </a>",
"    ]. Large effusions that require decortication for control are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a postoperative pleural effusion have a greater decrease in pulmonary function test parameters than those without an effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the pleural effusion may be a marker for other factors that restrict ventilation rather than a direct cause of the restriction itself [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pleural fluid findings of nonspecific pleural effusions occurring after CABG have been described in three series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/16,26,27\">",
"     16,26,27",
"    </a>",
"    ]. Both early and late effusions are exudates. Early effusions tend to be bloody with a high eosinophil count and neutrophil predominance, while late effusions are typically yellow exudates with a lymphocytic predominance. Thoracoscopy for diagnosis is warranted only in patients whose pleural fluid characteristics differ from these expected indices. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=see_link\">",
"     \"An overview of medical thoracoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only symptomatic pleural effusions, predominately right-sided effusions in the absence of heart failure as an explanation, late onset effusions, or effusions larger than 25 percent of the hemithorax require thoracentesis for relief of symptoms or pursuit of alternate diagnoses. Chest ultrasonography can estimate the volume of fluid and guide thoracentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/28\">",
"     28",
"    </a>",
"    ]. Although most effusions resolve spontaneously, 73 percent of patients with an IMA CABG and 29 percent with an SV CABG have persistent ultrasonographic evidence of pleural effusion 30 days after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/3\">",
"     3",
"    </a>",
"    ], and effusions may take 2 to 20 months to clear completely [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/29\">",
"     29",
"    </a>",
"    ]. The large majority of these effusions are small and asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=see_link\">",
"     \"Thoracic ultrasound: Indications, advantages, and technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large, non-bloody effusions that persist with symptoms may require serial thoracenteses and oral nonsteroidal anti-inflammatory agents (NSAIDs). A therapeutic trial of a glucocorticoid may be indicated in patients who fail these therapies, although this has not been tested in clinical trials. Glucocorticoids have not been shown to prevent long-term sequelae of nonspecific effusions, such as a trapped lung.",
"   </p>",
"   <p>",
"    Chest tube drainage or pleurodesis is rarely required; video assisted thoracoscopy with pleurodesis appears to be effective for treatment of the rare, persistent nonspecific effusions that do not resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The management of refractory nonmalignant pleural effusions is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POSTPERICARDIOTOMY SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpericardiotomy syndrome (PPCS, also known as post cardiac injury syndrome) is a general term that refers to the occurrence of fever and pleuropericardial disease days or months after cardiac injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/32\">",
"     32",
"    </a>",
"    ]. The syndrome is more specifically termed postmyocardial infarction syndrome when it develops after a myocardial infarction and postcardiotomy or postpericardiotomy syndrome after cardiac surgery or trauma. PPCS is also a rare complication of pulmonary embolism, traumatic hemopericardium, radiofrequency ablation for tachyarrhythmias, percutaneous coronary intervention, and implantation of pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link\">",
"     \"Pericardial complications of myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link\">",
"     \"Post-cardiac injury syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PPCS typically present one week or more after myocardial injury. In one report, for example, 65 percent of affected patients presented within three months and 100 percent within 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/38\">",
"     38",
"    </a>",
"    ]. Rarely, the disease onset is less than one week after myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PPCS is characterized by pericarditis with chest pain and a pericardial rub, fever, leukocytosis, an elevated erythrocyte sedimentation rate, and variable combinations of pulmonary infiltrates and pleural effusions. The chest pain may simulate myocardial ischemia or may be pleuritic in nature. A pleural rub may also be noted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardial effusions, usually small, can be demonstrated by echocardiography in 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/40\">",
"       40",
"      </a>",
"      ]. Tamponade has been reported in 0.1 to 6 percent of patients who have undergone open heart surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary infiltrates are nonspecific in appearance and often mimic the radiographic manifestations of heart failure, pulmonary embolism, or pneumonia.",
"     </li>",
"     <li>",
"      Pleural effusions are common, being noted in 62 percent in Dressler's original series and in 83 percent in a later report [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/32,40\">",
"       32,40",
"      </a>",
"      ]. The effusion is typically small and is unilateral in 60 percent of patients; unilateral effusions are usually left-sided [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/40\">",
"       40",
"      </a>",
"      ]. The effusion is hemorrhagic in 70 percent of cases and frankly bloody in 30 percent. The pleural fluid pH and glucose are normal, and the leukocyte differential reveals a predominance of polymorphonuclear leukocytes during the acute phase and mononuclear cells later in the course [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/40\">",
"       40",
"      </a>",
"      ]. A case report noted a predominance of lymphocytes in the pleural fluid of five patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/42\">",
"       42",
"      </a>",
"      ]. Some experts have speculated that persistent PPCS effusions may evolve from polymorphonuclear to lymphocyte-predominant effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients who have undergone a CABG procedure, an association has sometimes been noted between PPCS and early graft occlusion, which results in myocardial ischemia with anginal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/13,43\">",
"       13,43",
"      </a>",
"      ]. It has been suggested that PPCS-induced pericardial inflammation may predispose to occlusion of bypass grafts, although evidence for this is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations suggest that PPCS may be the consequence of an immunologic response to damaged cardiac tissue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relationship between PPCS and antibodies to cardiac tissue has been noted in prospective studies of pediatric survivors of intrapericardial surgery and of adults undergoing a CABG procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. In the latter report, a statistically significant correlation was found between the postoperative to preoperative ratios of actin and myosin antibodies and the clinical occurrence of PPCS [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/45\">",
"       45",
"      </a>",
"      ]. However, these \"anti-heart\" antibodies may be an epiphenomenon, rather than a causative factor [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The excellent response to glucocorticoid therapy and the occasional relapses reported after glucocorticoid withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prolonged latent period from cardiac injury to the clinical onset of PPCS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The putative pathogenetic sequence begins with myocardial injury that releases cardiac antigens and stimulates antibody formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/49\">",
"     49",
"    </a>",
"    ]. The immune complexes that are generated then deposit onto the pleura, lungs, and pericardium, eliciting an inflammatory response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9679216\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in preventing PPCS following cardiac surgery was examined in the COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS) trial. Significant decreases in the occurrence of pleuritic chest pain and pleural effusion were noted in addition to reductions in the other manifestations of PPCS. The details of the clinical trials and the use of colchicine for prevention of PPCS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link&amp;anchor=H6#H6\">",
"     \"Post-cardiac injury syndromes\", section on 'Prevention and treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PPCS is based upon the clinical recognition of the typical signs and symptoms of pericarditis and pleuritis in the late postoperative period after cardiac surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link&amp;anchor=H5#H5\">",
"     \"Post-cardiac injury syndromes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiographic detection of pericardial fluid supports but does not specifically confirm the diagnosis",
"     </li>",
"     <li>",
"      Thromboembolic disease as a cause of the pleural effusion is evaluated with a helical CT with contrast (CTPA)",
"     </li>",
"     <li>",
"      The finding on thoracentesis of an exudative pleural effusion with normal pH should exclude heart failure (which is associated with a transudative effusion) and complicated parapneumonic effusion due to bacterial pneumonia (which is associated with a low pH exudative effusion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients with PPCS respond well to the initiation of anti-inflammatory agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/50\">",
"     50",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    (650 mg every four to six hours) is preferred when the PPCS occurs after a myocardial infarction because of its combined antiinflammatory and antiplatelet properties. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is generally avoided in this setting because it may increase infarct size compared to control patients or those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/51\">",
"     51",
"    </a>",
"    ]. Ibuprofen (400 to 600 mg every six hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (375 to 500 mg every 12 hours) is commonly used in patients who cannot take aspirin.",
"   </p>",
"   <p>",
"    Glucocorticoids promptly improve the clinical manifestations of PPCS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/48\">",
"     48",
"    </a>",
"    ]. However, their use after myocardial infarction has been associated in some but not all studies with a greater incidence of ventricular aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. As a result, consideration of the use of glucocorticoids in post-MI PPCS is generally limited to patients who do not respond to or cannot tolerate nonsteroidal antiinflammatory agents.",
"   </p>",
"   <p>",
"    Cardiac tamponade can occur rarely in patients with PPCS regardless of the presence or absence of concomitant anticoagulation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/32,54\">",
"     32,54",
"    </a>",
"    ]. Most experts agree with continuing anticoagulants in the face of PPCS if the patient can be monitored for tamponade closely and if strong indications exist for anticoagulation therapy (prosthetic valves, large myocardial infarctions, and atrial fibrillation) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter erosion into the pleural space, infectious mediastinitis, and chylothorax are additional causes of effusions occurring after cardiac surgery and are reviewed here. Postoperative pleural effusions caused by heart failure, pulmonary embolism, hemothorax, and pneumonia are reviewed separately. Clinical, radiographic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    echocardiographic findings in association with pleural fluid analysis are usually sufficient to establish these diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=see_link&amp;anchor=H666174#H666174\">",
"     \"Overview of the management of postoperative pulmonary complications\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Catheter erosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erosion of a catheter through venous structures should be considered when pleural fluid accumulates in association with radiographic evidence of mediastinal widening (mediastinal hygroma) in patients with a central venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/14,55\">",
"     14,55",
"    </a>",
"    ]. Catheter erosion can occur any time after catheter placement. In a case series, the mean time to erosion after catheter insertion was 3.6 days [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/55\">",
"     55",
"    </a>",
"    ]. The diagnosis can be confirmed by demonstrating extravascular extravasation of contrast infused through the catheter or by the finding at thoracentesis of a pleural fluid-to-plasma glucose ratio greater than one in patients infused with glucose containing fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/14\">",
"     14",
"    </a>",
"    ]. An elevated pleural fluid triglyceride concentration or milky-appearing pleural fluid in the absence of an underlying chylothorax may be seen in patients infused with intravenous fat emulsions through the eroding catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infectious mediastinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious mediastinitis is a serious complication after cardiac surgery that requires prompt surgical interventions such as debridement and irrigation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/56\">",
"     56",
"    </a>",
"    ]. CT imaging of the chest reveals mediastinal fluid collections that are difficult to differentiate from aseptic, postoperative mediastinal hematomas. Infectious mediastinitis, however, more commonly produces bilateral pleural effusions with CT evidence of mediastinal soft tissue swelling compared to patients with mediastinal fluid collections that do not require drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylothoraces occur in less than 1 percent of patients undergoing cardiac surgery and result from surgical disruption of the thoracic duct or its intrathoracic lymphatic tributaries. Chylothorax is most often seen after surgical correction of congenital heart disorders that involve the regions of the aorta or pulmonary arteries near the thoracic duct; it rarely occurs after intrapericardial operations, such as coronary artery bypass surgery (CABG) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16728/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98463917\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural effusions are frequent following coronary artery bypass grafting (CABG), cardiac transplantation, and, less often mitral and aortic valve replacement surgery. Several potential causes of pleural effusions after cardiac surgery have been identified, including nonspecific effusions, heart failure, postpericardiotomy syndrome, pneumonia with parapneumonic effusion, pulmonary embolism, central line erosion into pleura, chylothorax, and hemothorax. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small, left-sided effusions are generally nonspecific and have a benign course with spontaneous resolution (",
"      <a class=\"graphic graphic_table graphicRef75443 \" href=\"UTD.htm?0/35/571\">",
"       table 2",
"      </a>",
"      ). Only symptomatic pleural effusions, predominately right-sided effusions in the absence of heart failure as an explanation, late onset effusions, or effusions larger than 25 percent of the hemithorax require thoracentesis for relief of symptoms or pursuit of alternate diagnoses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations and course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The postpericardiotomy syndrome (PPCS, also known as postcardiac injury syndrome or Dressler&rsquo;s syndrome) is a general term that refers to the occurrence of fever and pleuropericardial disease days or months after cardiac injury. It is characterized by pericarditis with chest pain, a pericardial rub, fever, leukocytosis, and variable combinations of pulmonary infiltrates and pleural effusions. A pleural rub may also be present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations and course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of PPCS is based upon the clinical recognition of the typical signs and symptoms of pericarditis and pleuritis in the late postoperative period after cardiac surgery. The initial treatment of PPCS is usually nonsteroidal anti-inflammatory agents and is discussed separately. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis and management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link&amp;anchor=H6#H6\">",
"       \"Post-cardiac injury syndromes\", section on 'Prevention and treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      decreases the incidence of PPCS when given as primary prevention after cardiac surgery. (See",
"      <a class=\"local\" href=\"#H9679216\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link&amp;anchor=H6#H6\">",
"       \"Post-cardiac injury syndromes\", section on 'Prevention and treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erosion of a central venous catheter through venous structures into the pleural space is suggested by the accumulation of pleural fluid in association with radiographic evidence of mediastinal widening (mediastinal hygroma). The diagnosis can be confirmed by demonstrating extravascular extravasation of contrast infused through the catheter or by the finding of a pleural fluid-to-plasma glucose ratio greater than one in patients infused with glucose containing fluids. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Catheter erosion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infectious mediastinitis commonly produces bilateral pleural effusions with computed tomography (CT) evidence of mediastinal soft tissue swelling compared to patients with mediastinal fluid collections that do not require drainage. The diagnosis and management of postoperative infectious mediastinitis is discussed separately. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Infectious mediastinitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chylothorax is a rare complication of cardiac surgery and results from surgical disruption of the thoracic duct or its intrathoracic lymphatic tributaries. The diagnosis and management of postoperative chylothorax is discussed separately. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Chylothorax'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"       \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/1\">",
"      Light RW. Pleural effusions after coronary artery bypass graft surgery. Curr Opin Pulm Med 2002; 8:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/2\">",
"      Peng MJ, Vargas FS, Cukier A, et al. Postoperative pleural changes after coronary revascularization. Comparison between saphenous vein and internal mammary artery grafting. Chest 1992; 101:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/3\">",
"      Vargas FS, Cukier A, Hueb W, et al. Relationship between pleural effusion and pericardial involvement after myocardial revascularization. Chest 1994; 105:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/4\">",
"      Vargas FS, Cukier A, Terra-Filho M, et al. Relationship between pleural changes after myocardial revascularization and pulmonary mechanics. Chest 1992; 102:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/5\">",
"      Allen BS, Buckberg GD, Rosenkranz ER, et al. Topical cardiac hypothermia in patients with coronary disease. An unnecessary adjunct to cardioplegic protection and cause of pulmonary morbidity. J Thorac Cardiovasc Surg 1992; 104:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/6\">",
"      Landymore RW, Howell F. Pulmonary complications following myocardial revascularization with the internal mammary artery graft. Eur J Cardiothorac Surg 1990; 4:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/7\">",
"      Kollef MH. Chronic pleural effusion following coronary artery revascularization with the internal mammary artery. Chest 1990; 97:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/8\">",
"      Bevelaqua F, Garritan S, Haas F, et al. Complications after cardiac operations in patients with severe pulmonary impairment. Ann Thorac Surg 1990; 50:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/9\">",
"      Florence SH, Hutton LC, McKenzie FN, Kostuk WJ. Cardiac transplantation: postoperative chest radiographs. Can Assoc Radiol J 1988; 39:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/10\">",
"      Shirazi KK, Amendola MA, Tisnado J, et al. Radiographic findings in the chest of patients following cardiac transplantation. Cardiovasc Intervent Radiol 1983; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/11\">",
"      Kollef MH, Peller T, Knodel A, Cragun WH. Delayed pleuropulmonary complications following coronary artery revascularization with the internal mammary artery. Chest 1988; 94:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/12\">",
"      Kollef MH. Symptomatic pleural effusion after coronary artery revascularization: unsuspected pleural injury from internal mammary artery resection. South Med J 1993; 86:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/13\">",
"      Ik&auml;heimo MJ, Huikuri HV, Airaksinen KE, et al. Pericardial effusion after cardiac surgery: incidence, relation to the type of surgery, antithrombotic therapy, and early coronary bypass graft patency. Am Heart J 1988; 116:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/14\">",
"      Duntley P, Siever J, Korwes ML, et al. Vascular erosion by central venous catheters. Clinical features and outcome. Chest 1992; 101:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/15\">",
"      Chaiyaroj S, Mullerworth MH, Tatoulis J. Surgery in the management of chylothorax after coronary artery bypass with left internal mammary artery. J Thorac Cardiovasc Surg 1993; 106:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/16\">",
"      Light RW, Rogers JT, Cheng D, Rodriguez RM. Large pleural effusions occurring after coronary artery bypass grafting. Cardiovascular Surgery Associates, PC. Ann Intern Med 1999; 130:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/17\">",
"      Hurlbut D, Myers ML, Lefcoe M, Goldbach M. Pleuropulmonary morbidity: internal thoracic artery versus saphenous vein graft. Ann Thorac Surg 1990; 50:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/18\">",
"      Jain U, Rao TL, Kumar P, et al. Radiographic pulmonary abnormalities after different types of cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/19\">",
"      Light RW, Rogers JT, Moyers JP, et al. Prevalence and clinical course of pleural effusions at 30 days after coronary artery and cardiac surgery. Am J Respir Crit Care Med 2002; 166:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/20\">",
"      Nikas DJ, Ramadan FM, Elefteriades JA. Topical hypothermia: ineffective and deleterious as adjunct to cardioplegia for myocardial protection. Ann Thorac Surg 1998; 65:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/21\">",
"      Vargas FS, Uezumi KK, Janete FB, et al. Acute pleuropulmonary complications detected by computed tomography following myocardial revascularization. Rev Hosp Clin Fac Med Sao Paulo 2002; 57:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/22\">",
"      Ali IM, Lau P, Kinley CE, Sanalla A. Opening the pleura during internal mammary artery harvesting: advantages and disadvantages. Can J Surg 1996; 39:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/23\">",
"      Kalomenidis I, Stathopoulos GT, Barnette R, et al. Vascular endothelial growth factor levels in post-CABG pleural effusions are associated with pleural inflammation and permeability. Respir Med 2007; 101:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/24\">",
"      Heidecker J, Sahn SA. The spectrum of pleural effusions after coronary artery bypass grafting surgery. Clin Chest Med 2006; 27:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/25\">",
"      Peng MC, Hou CJ, Li JY, et al. Prevalence of symptomatic large pleural effusions first diagnosed more than 30 days after coronary artery bypass graft surgery. Respirology 2007; 12:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/26\">",
"      Sadikot RT, Rogers JT, Cheng DS, et al. Pleural fluid characteristics of patients with symptomatic pleural effusion after coronary artery bypass graft surgery. Arch Intern Med 2000; 160:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/27\">",
"      Labidi M, Baillot R, Dionne B, et al. Pleural effusions following cardiac surgery: prevalence, risk factors, and clinical features. Chest 2009; 136:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/28\">",
"      Usta E, Mustafi M, Ziemer G. Ultrasound estimation of volume of postoperative pleural effusion in cardiac surgery patients. Interact Cardiovasc Thorac Surg 2010; 10:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/29\">",
"      Cohen M, Sahn SA. Resolution of pleural effusions. Chest 2001; 119:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/30\">",
"      Paull DE, Delahanty TJ, Weber FJ, Harostock MD. Thoracoscopic talc pleurodesis for recurrent, symptomatic pleural effusion following cardiac operations. Surg Laparosc Endosc Percutan Tech 2003; 13:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/31\">",
"      Lee YC, Vaz MA, Ely KA, et al. Symptomatic persistent post-coronary artery bypass graft pleural effusions requiring operative treatment : clinical and histologic features. Chest 2001; 119:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/32\">",
"      DRESSLER W. The post-myocardial-infarction syndrome: a report on forty-four cases. AMA Arch Intern Med 1959; 103:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/33\">",
"      Jerjes-Sanchez C, Ibarra-Perez C, Ramirez-Rivera A, et al. Dressler-like syndrome after pulmonary embolism and infarction. Chest 1987; 92:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/34\">",
"      Tabatznik, B, Isaac, JP. Postpericardiotomy syndrome following traumatic hemopericardium. Am J Cardiol 1961; 7:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/35\">",
"      Snow ME, Agatston AS, Kramer HC, Samet P. The postcardiotomy syndrome following transvenous pacemaker insertion. Pacing Clin Electrophysiol 1987; 10:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/36\">",
"      Gungor B, Ucer E, Erdinler IC. Uncommon presentation of postcardiac injury syndrome: acute pericarditis after percutaneous coronary intervention. Int J Cardiol 2008; 128:e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/37\">",
"      Zheng LR, Hu X, Xia S, Chen Y. Postcardiac injury syndrome following radiofrequency ablation of idiopathic left ventricular tachycardia. J Interv Card Electrophysiol 2007; 18:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/38\">",
"      Welin L, Vedin A, Wilhelmsson C. Characteristics, prevalence, and prognosis of postmyocardial infarction syndrome. Br Heart J 1983; 50:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/39\">",
"      Khan AH. Pericarditis of myocardial infarction: review of the literature with case presentation. Am Heart J 1975; 90:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/40\">",
"      Stelzner TJ, King TE Jr, Antony VB, Sahn SA. The pleuropulmonary manifestations of the postcardiac injury syndrome. Chest 1983; 84:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/41\">",
"      Ofori-Krakye SK, Tyberg TI, Geha AS, et al. Late cardiac tamponade after open heart surgery: incidence, role of anticoagulants in its pathogenesis and its relationship to the postpericardiotomy syndrome. Circulation 1981; 63:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/42\">",
"      Kim YK, Mohsenifar Z, Koerner SK. Lymphocytic pleural effusion in postpericardiotomy syndrome. Am Heart J 1988; 115:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/43\">",
"      Urschel HC Jr, Razzuk MA, Gardner M. Coronary artery bypass occlusion second to postcardiotomy syndrome. Ann Thorac Surg 1976; 22:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/44\">",
"      Engle MA, Zabriskie JB, Senterfit LB, Ebert PA. Postpericardiotomy syndrome. A new look at an old condition. Mod Concepts Cardiovasc Dis 1975; 44:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/45\">",
"      De Scheerder I, De Buyzere M, Robbrecht J, et al. Postoperative immunological response against contractile proteins after coronary bypass surgery. Br Heart J 1986; 56:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/46\">",
"      Kim S, Sahn SA. Postcardiac injury syndrome. An immunologic pleural fluid analysis. Chest 1996; 109:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/47\">",
"      Hoffman M, Fried M, Jabareen F, et al. Anti-heart antibodies in postpericardiotomy syndrome: cause or epiphenomenon? A prospective, longitudinal pilot study. Autoimmunity 2002; 35:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/48\">",
"      Khan AH. The postcardiac injury syndromes. Clin Cardiol 1992; 15:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/49\">",
"      Mehrzad R, Spodick DH. Pericardial involvement in diseases of the heart and other contiguous structures: part I: pericardial involvement in infarct pericarditis and pericardial involvement following myocardial infarction. Cardiology 2012; 121:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/50\">",
"      Indik JH, Alpert JS. Post-Myocardial Infarction Pericarditis. Curr Treat Options Cardiovasc Med 2000; 2:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/51\">",
"      Jugdutt BI, Basualdo CA. Myocardial infarct expansion during indomethacin or ibuprofen therapy for symptomatic post infarction pericarditis. Influence of other pharmacologic agents during early remodelling. Can J Cardiol 1989; 5:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/52\">",
"      Roberts R, DeMello V, Sobel BE. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976; 53:I204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/53\">",
"      Stubbs DF. Post-acute myocardial infarction symptomatic pericarditis (PAMISP): report on a large series and the effect of methylprednisolone therapy. J Int Med Res 1986; 14 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/54\">",
"      Lawrence MS, Wright R. Tamponade in Dressler's syndrome with immunological studies. Br Med J 1972; 1:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/55\">",
"      Walshe C, Phelan D, Bourke J, Buggy D. Vascular erosion by central venous catheters used for total parenteral nutrition. Intensive Care Med 2007; 33:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16728/abstract/56\">",
"      Misawa Y, Fuse K, Hasegawa T. Infectious mediastinitis after cardiac operations: computed tomographic findings. Ann Thorac Surg 1998; 65:622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6703 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2959C7380A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16728=[""].join("\n");
var outline_f16_21_16728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H98463917\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONSPECIFIC PLEURAL EFFUSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Early nonspecific effusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Late nonspecific effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations and course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POSTPERICARDIOTOMY SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9679216\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Catheter erosion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infectious mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98463917\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6703|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/1/2075\" title=\"table 1\">",
"      Postcardiac surgery pl effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/35/571\" title=\"table 2\">",
"      Causes of nonspecific pl effus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41414?source=related_link\">",
"      An overview of medical thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4072?source=related_link\">",
"      Diagnosis and management of pleural causes of unexpandable lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26408?source=related_link\">",
"      Thoracic ultrasound: Indications, advantages, and technique",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_21_16729="Overview of hip pain in childhood";
var content_f16_21_16729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hip pain in childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16729/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16729/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/21/16729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip pain is a relatively common complaint in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/1\">",
"     1",
"    </a>",
"    ]. The differential diagnosis is broad, ranging from the benign to the potentially devastating (",
"    <a class=\"graphic graphic_table graphicRef65257 \" href=\"UTD.htm?38/44/39628\">",
"     table 1",
"    </a>",
"    ). The clinical evaluation and common causes of acute hip pain in children are reviewed here. A discussion of radiographic imaging of the hip in children and adolescents is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25097?source=see_link\">",
"     \"Radiologic evaluation of the hip in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history in the child with hip pain should focus on distinguishing infection, sterile inflammation, orthopedic disease, and malignancy (",
"    <a class=\"graphic graphic_table graphicRef65257 \" href=\"UTD.htm?38/44/39628\">",
"     table 1",
"    </a>",
"    ). The age, gender, and body habitus of the child can help to focus the differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef66131 \" href=\"UTD.htm?22/9/22683\">",
"     table 2",
"    </a>",
"    ). Important aspects of the history include the onset, duration, severity, and location of the pain, associated systemic symptoms, past medical history, family history, and social history (",
"    <a class=\"graphic graphic_table graphicRef63566 \" href=\"UTD.htm?8/47/8955\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute onset of hip pain, particularly when it is severe, is associated with infectious processes (eg, septic arthritis, bacterial osteomyelitis), transient synovitis (TS), and major trauma. Hip pain of insidious onset is more likely to be caused by slipped capital femoral epiphysis (SCFE), Legg-Calv&eacute;-Perthes disease, or spondyloarthritis. A history of previous episodes of similar symptoms in the same or contralateral hip increases the likelihood of systemic arthritis (particularly juvenile psoriatic arthritis) or transient synovitis, which has a recurrence rate of up to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/2\">",
"     2",
"    </a>",
"    ]. Severe pain typically is caused by acute infections, malignancy, and trauma.",
"   </p>",
"   <p>",
"    The presence of pain at sites other than the hip can help to narrow the differential diagnosis. Conditions that affect the hip alone need not be considered if the patient has joint pain at other sites. However, children with hip pathology may present with complaints limited to the thigh or knee. Juvenile idiopathic arthritis (JIA, formerly juvenile rheumatoid arthritis) rarely presents with isolated hip involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of systemic symptoms increases the likelihood of infectious, inflammatory, or neoplastic etiologies and decreases the likelihood of mechanical or orthopedic conditions (",
"    <a class=\"graphic graphic_table graphicRef65257 \" href=\"UTD.htm?38/44/39628\">",
"     table 1",
"    </a>",
"    ). Fever &gt;38.5&ordm;C is associated with acute infections but also may be present in both acute and chronic inflammatory processes (eg, systemic-onset JIA, inflammatory bowel disease) and malignancy. Similarly, gastrointestinal symptoms, weight loss, fatigue, and weakness may indicate systemic disease that requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Additional history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent upper respiratory tract infection can suggest transient synovitis; however, recent viral infections also are common in children with traumatic arthropathy or septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The recent use of antibiotics can alter the presentation of septic arthritis or osteomyelitis. Avid sports participation, a fall, or other injury suggests traumatic hip pain. However, minor trauma occurs commonly in childhood, and initial symptoms of inflammatory or malignant disease often are attributed to an incidental injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performing a complete physical examination of the child who presents with hip pain is essential. Abnormalities of other joints, the skin, and other organs should be sought because such findings can help distinguish systemic from local disease. Performing a thorough musculoskeletal examination, looking for abnormalities in joints other than the hip, is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/5\">",
"     5",
"    </a>",
"    ]. The finding of abnormalities distant from the hip strongly influences the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hip examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hip examination begins with simultaneous observation of both hips; the hips should be uncovered. The examiner should look for asymmetry of the pelvis, thighs, and knees. The position in which the femur and pelvis are held should be noted; partial flexion and external rotation of the hip may be indicative of increased intraarticular pressure. Swelling, heat, and overlying erythema rarely are identifiable on physical examination, regardless of the severity of hip disease. However, atrophy of soft tissues may hint at the duration of the problem.",
"   </p>",
"   <p>",
"    Examination of the affected hip should be performed after the remainder of the musculoskeletal examination to optimize patient cooperation. The pelvis should be stabilized as much as possible during examination of range of motion, since pelvic motion can compensate for loss of mobility within the hip. Prone examination is particularly helpful in this regard. With the knees flexed to 90 degrees and both feet caused to \"fall outward,\" subtle asymmetry in internal rotation is readily appreciated (",
"    <a class=\"graphic graphic_figure graphicRef67713 \" href=\"UTD.htm?31/54/32608\">",
"     figure 1",
"    </a>",
"    ). Hip extension is also best evaluated prone.",
"   </p>",
"   <p>",
"    Severe symptoms do not always imply severe disease. As an example, TS can immobilize the hip with pain but is a benign and self-limited condition. On the other hand, the inability to bear weight is a sign of serious pathology until proven otherwise, and children who are unable to bear weight should not be sent home until a diagnosis is made and therapy instituted. Note that refusal to walk can arise from pathology outside the lower extremities; in particular, discitis may present in the young child as isolated refusal to bear weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=see_link&amp;anchor=H14#H14\">",
"     \"Back pain in children and adolescents: Overview of causes\", section on 'Discitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory evaluation of the child with hip pain is directed by the findings from the history and physical examination. When an acute severe process, such as septic arthritis, is suspected, a complete blood count with differential, acute phase reactants (eg, C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)), and blood culture are the most useful tests. In addition, these children usually require arthrocentesis to obtain synovial fluid for Gram stain, culture, and white blood cell (WBC) count with differential.",
"   </p>",
"   <p>",
"    Laboratory evaluation is less helpful in the child whose hip pain is chronic or insidious in onset. Nonetheless, measuring the CRP or ESR can be helpful in differentiating inflammatory from noninflammatory disease. Anemia, leukopenia, or thrombocytopenia may suggest an underlying chronic illness, including malignancy. HLA-B27 is associated with spondyloarthropathy, but the frequency of this marker in normal individuals and its absence in some patients with disease limit its usefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/6\">",
"     6",
"    </a>",
"    ]. Lyme serology is reasonable in the appropriate epidemiologic setting since Lyme arthritis can affect the hip. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of Lyme disease\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=see_link&amp;anchor=H18#H18\">",
"     \"Lyme disease: Clinical manifestations in children\", section on 'Arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic evaluation is necessary in all patients in whom septic arthritis, skeletal injury, or tumor remain in the differential diagnosis. The need for radiographs in children who present with mild hip pain and have a normal physical examination, normal laboratory values, and reliable follow-up is controversial. Some authors advocate following these children clinically without obtaining radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/7\">",
"     7",
"    </a>",
"    ], whereas others obtain radiographs in all children with hip pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial imaging study is typically a plain radiograph of the hips in AP and frog-leg views (the frog-leg is the true lateral for the femur) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/8\">",
"     8",
"    </a>",
"    ]. Plain radiographs can identify bony abnormalities, including some forms of trauma; tumors and other malignancies; advanced (but not early) Legg-Calv&eacute;-Perthes disease; SCFE; and processes causing changes in the joint space, though small effusions often are missed by this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is an excellent technique for identifying small joint effusions and should be used when plain radiographs are normal but the suspicion of septic arthritis or transient synovitis remains high [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Ultrasonography also may be used to guide aspiration of the hip when that procedure is deemed appropriate (eg, isolated unilateral hip effusion in a febrile child). Bilateral effusions suggest a systemic arthritic disorder or TS, because as many as one-quarter of patients with symptomatically unilateral TS have bilateral effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of three-phase bone scintigraphy may be of great value in diagnosing the child with hip pain. In the acute setting, a bone scan can be used to help differentiate septic arthritis or TS from osteomyelitis. In more chronic cases, a bone scan can identify avascular necrosis or Legg-Calv&eacute;-Perthes disease earlier in the course than can a plain radiograph.",
"   </p>",
"   <p>",
"    Bone scan also can help in the diagnosis of both early tumors and myelodysplastic disease. In one prospective study of 50 children with hip pain, a protocol of plain films followed, as needed, by ultrasound and three-phase bone scan successfully identified the diagnosis in 48 patients; the remaining two children went undiagnosed without reported complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) and computerized tomography (CT) are used most often to pursue a cause of hip pain when other modalities have not been helpful or to provide more detail of an abnormality already identified. MRI can identify marrow changes suggestive of osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/13\">",
"     13",
"    </a>",
"    ], early Legg-Calv&eacute;-Perthes disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/14\">",
"     14",
"    </a>",
"    ], and early SCFE. MRI with gadolinium contrast also can document the presence of synovitis and cartilage destruction. This additional detail makes contrast MRI generally preferable to bone scan, though this improved resolution must be balanced against considerations of availability, cost, need for sedation, and the ability of bone scan to detect multifocal disease. Imaging with gadolinium should be avoided, if possible, in patients with moderate or advanced renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, CT or MRI may identify an intraabdominal cause of hip pain, such as appendicitis or psoas abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22839?source=see_link\">",
"     \"Psoas abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic bacterial arthritis is \"the diagnosis not to miss\" in the evaluation of a child with hip pain, given the potential for rapid joint destruction and long-term morbidity that can accompany delay in diagnosis and treatment.",
"   </p>",
"   <p>",
"    The epidemiology of septic arthritis of the hip is not well defined. An early peak appears to occur in the first months of infancy, with an overall average age of three to six years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/4,15-17\">",
"     4,15-17",
"    </a>",
"    ]. Boys and girls are equally affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H2#H2\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with septic arthritis of the hip typically are febrile and ill-appearing, although occasionally the presentation is more subtle [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/15\">",
"     15",
"    </a>",
"    ]. Neonates and infants may present with irritability and pseudoparalysis of the affected limb, even without fever. Weight-bearing and motion of the affected hip are quite painful and strongly resisted in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/15\">",
"     15",
"    </a>",
"    ]. The presentation of septic arthritis may be altered by recent use of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H2#H2\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical and laboratory features predictive of septic arthritis of the hip include fever &gt;38.5&ordm;C within the week before presentation; refusal to bear weight; ESR &gt;40",
"    <span class=\"nowrap\">",
"     mm/h;",
"    </span>",
"    WBC &gt;12,000",
"    <span class=\"nowrap\">",
"     cells/mm3;",
"    </span>",
"    and CRP &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis is confirmed by ultrasound-guided aspiration of inflammatory hip fluid with identification of a causative organism by blood or synovial fluid culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H28#H28\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy consists of urgent and, in some cases, repeated drainage to avoid buildup of intraarticular pressure that may impede local blood flow, and administration of parenteral antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=see_link&amp;anchor=H2#H2\">",
"     \"Bacterial arthritis: Treatment and outcome in infants and children\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Septic arthritis of the sacroiliac joint also can present as pain in the region of the hip. Careful examination reveals that gentle hip motion is not painful, whereas maneuvers that torque the pelvis (eg, the FABERE test) (",
"    <a class=\"graphic graphic_figure graphicRef79475 \" href=\"UTD.htm?5/55/6015\">",
"     figure 2",
"    </a>",
"    ) reproduce the patient's symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis of the femur or pelvis can present with hip pain. The diagnosis of osteomyelitis, like that of septic arthritis, should be made as soon as possible, because delay in treatment increases the likelihood of a poor outcome. Similar to that of septic arthritis, the presentation of osteomyelitis may be altered by the recent use of antibiotics.",
"   </p>",
"   <p>",
"    The proximal femur is the most common site of osteomyelitis in children. Pelvic osteomyelitis, a rare condition, also typically presents with hip pain and limp. However, children with pelvic osteomyelitis often permit careful manipulation of the painful hip, a feature that distinguishes it from osteomyelitis of the proximal femur and septic arthritis of the hip. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17416?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=see_link\">",
"     \"Clinical features of hematogenous osteomyelitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of osteomyelitis may be strongly suggested by plain film, bone scan, or MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72897 \" href=\"UTD.htm?29/55/30581\">",
"     image 1",
"    </a>",
"    ). Bone scan has the advantage of detecting multifocal disease, which occurs in 7 percent of cases of pediatric osteomyelitis, usually in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/20\">",
"     20",
"    </a>",
"    ]. MRI is more sensitive and specific than is bone scan in the diagnosis of osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/21\">",
"     21",
"    </a>",
"    ]; however, these benefits must be weighed against cost, need for sedation, and the ability of bone scan to detect multifocal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transient synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient synovitis (TS) is a relatively common disorder characterized by pain and limitation of motion in the hip, arising without clear precipitant and resolving gradually with conservative therapy. Fever typically is absent but may occur. In one prospective study, the average annual incidence was 0.2 percent, with a cumulative lifetime risk of 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/22\">",
"     22",
"    </a>",
"    ]. TS typically presents in patients between the ages of three and eight years, with a mean age at presentation of six years and a male-to-female ratio of slightly more than 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. The prognosis usually is excellent. Recurrence rates from 4 to 15 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/2,25\">",
"     2,25",
"    </a>",
"    ]. Most children with recurrent TS have a benign course [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At clinical presentation, most children have had symptoms for less than a week, although 12 percent in the largest series had discomfort dating back at least one month [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/23\">",
"     23",
"    </a>",
"    ]. Fever typically is absent or low-grade, and children are nontoxic in appearance, although high fever and accompanying systemic symptoms can occur. Symptoms affect both hips in as many as 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/23\">",
"     23",
"    </a>",
"    ]. Even in symptomatically unilateral disease, ultrasound can detect bilateral effusions in 25 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the frequency of TS, its etiology remains obscure. Although posttraumatic or allergic mechanisms have been proposed, an infectious cause commonly is assumed, because between 32 and 50 percent of children presenting with TS have had a recent upper respiratory tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. In one small series of patients with TS, approximately one-half had elevated blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    synovial fluid interferon levels, and approximately one-half had elevated antibody titers to M. pneumoniae or a range of viruses (sometimes more than one), including parvovirus B19 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Synovial fluid viral cultures, performed in a subset of patients, remained negative. The significance of these findings is uncertain, because no control patients were tested. Traumatic arthropathy and septic arthritis also may be preceded by viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In fact, in the only published comparison with septic arthritis, the prevalence of preceding URI was no different between groups (32 percent in TS versus 29 percent in septic arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of TS may be early Perthes disease (idiopathic avascular necrosis) or a forme fruste of this disorder. One large series documented reduced femoral blood flow in 15 of 192 patients with TS, of whom four went on to develop overt Perthes disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/29\">",
"     29",
"    </a>",
"    ]. Note that a joint effusion under pressure (aseptic or septic) can reduce femoral blood flow as measured by bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/30\">",
"     30",
"    </a>",
"    ], so this finding is open to multiple interpretations.",
"   </p>",
"   <p>",
"    The management of TS is conservative, with the use of nonsteroidal antiinflammatory drugs (NSAIDs) and return to full activity as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/31\">",
"     31",
"    </a>",
"    ]. Hip infection must be excluded. Patients who are nontoxic with minimal fever and benign WBC and ESR often can be followed clinically. Patients with clinical or laboratory findings of concern should receive hip imaging as outlined above. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Radiographic evaluation'",
"    </a>",
"    above.) The prognosis usually is excellent, with full recovery to be expected. A small percentage (1 to 2 percent in most series) may go on to develop Perthes disease with avascular necrosis of the ipsilateral femoral head [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/22,23,32\">",
"     22,23,32",
"    </a>",
"    ]. Children with delayed bone age as measured by wrist films may be at higher risk for developing this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/33\">",
"     33",
"    </a>",
"    ]. TS has a recurrence rate of up to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Legg-Calv&eacute;-Perthes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legg-Calv&eacute;-Perthes disease (LCP) is a syndrome of idiopathic osteonecrosis (avascular necrosis) of the hip, described independently in 1910 by Legg, Calv&eacute;, and Perthes. It typically presents as hip pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limp of acute or insidious onset in children between the ages of 3 and 12 years, with peak incidence at five to seven years of age. It is bilateral in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/34\">",
"     34",
"    </a>",
"    ]. The male-to-female ratio is 4:1 or greater, and African-Americans are rarely affected [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/35\">",
"     35",
"    </a>",
"    ]. Avascular necrosis secondary to an underlying disease (such as renal failure, steroid use, or lupus) may present similarly. Children with HIV infection also appear to be at higher risk for LCP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of LCP remains undefined. Approximately 10 percent of cases are familial, and patients often lag behind their peers in bone age and height [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/34,37\">",
"     34,37",
"    </a>",
"    ]. Some reports have documented an unusually high frequency of factor V Leiden and other inherited coagulopathies among patients with LCP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/38-42\">",
"     38-42",
"    </a>",
"    ], suggesting thrombophilia as a contributor to avascular necrosis in a subset of patients. However, this finding has not been consistently reproduced, and the area remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Structural abnormalities of epiphyseal cartilage have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/46\">",
"     46",
"    </a>",
"    ]. LCP also has been associated with prenatal or secondhand smoke exposure (odds ratio of 5 in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], material deprivation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/50\">",
"     50",
"    </a>",
"    ], and birth weight less than 2.5 kg in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis of LCP demands a high index of suspicion, because initial radiographs often are normal. At this phase, bone scan shows decreased perfusion to the femoral head, and MRI reveals marrow changes highly suggestive of the diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63334 \" href=\"UTD.htm?34/51/35632\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Radiographs taken subsequently show fragmentation and then healing of the femoral head, often with residual deformity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52637 \" href=\"UTD.htm?10/43/10943\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Therapy for LCP is poorly defined, because no large controlled trials are available, and long-term consequences become evident only after decades of follow-up. Although almost all children do well in the short term, long-term outcome depends upon age at time of disease onset and degree of involvement of the femoral head [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Children who are younger than six to eight years have a better prognosis, perhaps because more time is permitted for femoral remodeling and because before eight years of age the acetabulum is plastic and can mold to the deformed femoral head, maintaining congruity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/34,57\">",
"     34,57",
"    </a>",
"    ]. Current treatment focuses on maintaining containment of the femoral head within the acetabulum, through the use of splints or occasionally surgery, although the data for these interventions are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients diagnosed with LCP should be made nonweight-bearing and referred to an experienced pediatric orthopedist for management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Slipped epiphysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In slipped capital femoral epiphysis (SCFE), the femoral epiphysis slips posteriorly, resulting in a limp and impaired internal rotation. The typical patient is an obese child in early adolescence who, if female, has not yet reached menarche and, if male, has not yet reached the fourth Tanner stage. The mean age of presentation is 12 years in girls and 13.5 years in boys, near the time of peak linear growth. The male-to-female ratio is approximately 1.5:1. SCFE is bilateral in 20 to 40 percent of cases. Patients may present with acute hip pain and inability to walk, often after minor trauma, but more commonly they come to attention after months of ill-defined hip or knee symptoms and limp with or without an acute exacerbation. The absence of pain, or pain localized to the knee or thigh instead of the hip, can lead clinicians to overlook the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], a delay that may be associated with increased slip severity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/60\">",
"     60",
"    </a>",
"    ]. Simultaneous external rotation and abduction of the hip during hip flexion is a useful, though variably present, finding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Systemic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic rheumatologic diseases can present as isolated hip pain. Of these, the most common are the spondyloarthropathies, particularly psoriatic arthritis, which can start as isolated or recurrent hip arthritis. The skin manifestations of psoriatic arthritis may be subtle, such as dryness behind the ears or nail pits (",
"    <a class=\"graphic graphic_picture graphicRef62855 \" href=\"UTD.htm?38/42/39599\">",
"     picture 1",
"    </a>",
"    ), and may emerge years after the onset of arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other types of JIA rarely present with isolated hip disease. Systemic JIA (Still's disease) commonly involves the hip, although usually in the setting of an obvious systemic inflammatory state with concurrent arthritis in other joints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other arthritic conditions that can potentially involve the hip include Kawasaki disease, Lyme disease, acute rheumatic fever, and poststreptococcal arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Osteoid osteoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoid osteoma is a relatively common benign tumor of bone that can present as a painful hip because the proximal femur is the most common site of occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/62\">",
"     62",
"    </a>",
"    ]. Although osteoid osteoma is seen in all age groups from toddlers to adults, most patients present in the teenage years. The pain is typically nocturnal and aching, and it responds briskly to NSAID therapy. The lesion may be visible as a lucency with surrounding cortical thickening on plain radiograph (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80598 \" href=\"UTD.htm?7/45/7890\">",
"     image 4",
"    </a>",
"    ) or computed tomography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58624 \" href=\"UTD.htm?33/6/33903\">",
"     image 5",
"    </a>",
"    ), or it may be apparent only on bone scan or MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Osteoid osteoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy presenting as arthritis occurs rarely but is well-reported. Leukemia, principally acute lymphoblastic leukemia, is the most common cancer to present as joint pain in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. These patients typically have severe, migratory musculoskeletal pain secondary to leukemic infiltration of bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other cancers that can mimic arthritis include neuroblastoma (especially in the very young child), lymphoma, Ewing sarcoma, and other soft-tissue sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Pigmented villonodular synovitis (PVNS), a benign but potentially destructive neoplasm of synovium, also can present in the hip.",
"   </p>",
"   <p>",
"    Hallmarks of tumors presenting as arthritis include pain at night, bone pain distant from the joint, and abnormal laboratory evaluation, particularly the CBC, which may show anemia, leukopenia, or a platelet count lower than would be expected based upon the elevation of ESR. Elevated blood levels of lactate dehydrogenase (LDH) or uric acid can suggest leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/65,67\">",
"     65,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Stress fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress fractures are rare in children, but they can occur in athletes engaged in endurance sports. The femur is the third most common site of stress fracture in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In young adults, pain commonly is experienced in the anterior thigh and typically can be reproduced by asking the patient to hop on the affected leg [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/70\">",
"     70",
"    </a>",
"    ]. Plain films usually are negative early in the course of the fracture. Bone scan or MRI are the tests of choice. A temporary change in activity pattern is important to avoid progression to a displaced fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Idiopathic chondrolysis of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic chondrolysis of the hip is a poorly defined condition in which the articular cartilage of the hip is injured by an undefined but presumably inflammatory process. An association with spondyloarthropathy has been postulated but not confirmed; other authors consider this condition an independent subform of juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic chondrolysis of the hip affects females more than males, usually in the second decade of life. African-Americans are affected more severely. While symptoms are commonly unilateral, disease in the contralateral hip is sometimes noted on physical examination or imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/71\">",
"     71",
"    </a>",
"    ]. MRI demonstrates cartilage loss and synovial hypertrophy. Biopsy reveals mild chronic inflammation and is helpful to exclude infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some patients recover, most go on to develop painful and disabling osteoarthritis of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16729/abstract/14,71,72\">",
"     14,71,72",
"    </a>",
"    ]. Administration of antiinflammatory therapy seems useful in some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of hip pain in childhood is broad, ranging from the benign to the potentially devastating (",
"      <a class=\"graphic graphic_table graphicRef65257 \" href=\"UTD.htm?38/44/39628\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The history in the child with hip pain should focus on distinguishing infection, sterile inflammation, orthopedic disease, and malignancy. The age, gender, and body habitus of the child can help to focus the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef66131 \" href=\"UTD.htm?22/9/22683\">",
"       table 2",
"      </a>",
"      ). Other important aspects of the history include the onset, duration, severity, and location of the pain; associated systemic symptoms; past medical history; family history; and social history (",
"      <a class=\"graphic graphic_table graphicRef63566 \" href=\"UTD.htm?8/47/8955\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is essential to perform a complete physical examination of the child who complains of hip pain. Abnormalities of other joints, the skin, and other organs can help to distinguish systemic from local disease and influence the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hip examination includes observation (for asymmetry and position of comfort), palpation (to localize the source of pain), and range of motion in the prone position. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hip examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory evaluation of the child with hip pain is directed by the findings from the history and physical examination. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic evaluation is necessary in patients in whom septic arthritis, skeletal injury, or tumor remain in the differential diagnosis after initial evaluation. The need for radiographs in children who present with mild hip pain and have a normal physical examination, normal laboratory values, and reliable follow-up is controversial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiographic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific causes of hip pain in children include infection (eg, septic arthritis, osteomyelitis), transient synovitis, Legg-Calv&eacute;-Perthes disease, slipped capital femoral epiphysis, systemic arthritis, osteoid osteoma, malignancy, stress fracture, and idiopathic chondrolysis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Specific causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/1\">",
"      Spahn G, Schiele R, Langlotz A, Jung R. Hip pain in adolescents: results of a cross-sectional study in German pupils and a review of the literature. Acta Paediatr 2005; 94:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/2\">",
"      Taylor GR, Clarke NM. Recurrent irritable hip in childhood. J Bone Joint Surg Br 1995; 77:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/3\">",
"      Kunnamo I. Infections and related risk factors of arthritis in children. A case-control study. Scand J Rheumatol 1987; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/4\">",
"      Taylor GR, Clarke NM. Management of irritable hip: a review of hospital admission policy. Arch Dis Child 1994; 71:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/5\">",
"      Goff I, Rowan A, Bateman BJ, Foster HE. Poor sensitivity of musculoskeletal history in children. Arch Dis Child 2012; 97:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/6\">",
"      Gran JT, Husby G. HLA-B27 and spondyloarthropathy: value for early diagnosis? J Med Genet 1995; 32:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/7\">",
"      Beach R. Minimally invasive approach to management of irritable hip in children. Lancet 2000; 355:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/8\">",
"      Gough-Palmer A, McHugh K. Investigating hip pain in a well child. BMJ 2007; 334:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/9\">",
"      Miralles M, Gonzalez G, Pulpeiro JR, et al. Sonography of the painful hip in children: 500 consecutive cases. AJR Am J Roentgenol 1989; 152:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/10\">",
"      Zawin JK, Hoffer FA, Rand FF, Teele RL. Joint effusion in children with an irritable hip: US diagnosis and aspiration. Radiology 1993; 187:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/11\">",
"      Alexander JE, Seibert JJ, Aronson J, et al. A protocol of plain radiographs, hip ultrasound, and triple phase bone scans in the evaluation of the painful pediatric hip. Clin Pediatr (Phila) 1988; 27:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/12\">",
"      Ehrendorfer S, LeQuesne G, Penta M, et al. Bilateral synovitis in symptomatic unilateral transient synovitis of the hip: an ultrasonographic study in 56 children. Acta Orthop Scand 1996; 67:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/13\">",
"      Jaramillo D, Treves ST, Kasser JR, et al. Osteomyelitis and septic arthritis in children: appropriate use of imaging to guide treatment. AJR Am J Roentgenol 1995; 165:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/14\">",
"      Bleck EE. Idiopathic chondrolysis of the hip. J Bone Joint Surg Am 1983; 65:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/15\">",
"      Kocher MS, Zurakowski D, Kasser JR. Differentiating between septic arthritis and transient synovitis of the hip in children: an evidence-based clinical prediction algorithm. J Bone Joint Surg Am 1999; 81:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/16\">",
"      Bennett OM, Namnyak SS. Acute septic arthritis of the hip joint in infancy and childhood. Clin Orthop Relat Res 1992; :123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/17\">",
"      Betz RR, Cooperman DR, Wopperer JM, et al. Late sequelae of septic arthritis of the hip in infancy and childhood. J Pediatr Orthop 1990; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/18\">",
"      Kocher MS, Mandiga R, Zurakowski D, et al. Validation of a clinical prediction rule for the differentiation between septic arthritis and transient synovitis of the hip in children. J Bone Joint Surg Am 2004; 86-A:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/19\">",
"      Caird MS, Flynn JM, Leung YL, et al. Factors distinguishing septic arthritis from transient synovitis of the hip in children. A prospective study. J Bone Joint Surg Am 2006; 88:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/20\">",
"      Nelson JD. Acute osteomyelitis in children. Infect Dis Clin North Am 1990; 4:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/21\">",
"      Morrison WB, Schweitzer ME, Bock GW, et al. Diagnosis of osteomyelitis: utility of fat-suppressed contrast-enhanced MR imaging. Radiology 1993; 189:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/22\">",
"      Landin LA, Danielsson LG, Wattsg&aring;rd C. Transient synovitis of the hip. Its incidence, epidemiology and relation to Perthes' disease. J Bone Joint Surg Br 1987; 69:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/23\">",
"      Haueisen DC, Weiner DS, Weiner SD. The characterization of \"transient synovitis of the hip\" in children. J Pediatr Orthop 1986; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/24\">",
"      Do TT. Transient synovitis as a cause of painful limps in children. Curr Opin Pediatr 2000; 12:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/25\">",
"      Kallio P, Ry&ouml;ppy S, Kunnamo I. Transient synovitis and Perthes' disease. Is there an aetiological connection? J Bone Joint Surg Br 1986; 68:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/26\">",
"      Uziel Y, Butbul-Aviel Y, Barash J, et al. Recurrent transient synovitis of the hip in childhood. Longterm outcome among 39 patients. J Rheumatol 2006; 33:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/27\">",
"      Tolat V, Carty H, Klenerman L, Hart CA. Evidence for a viral aetiology of transient synovitis of the hip. J Bone Joint Surg Br 1993; 75:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/28\">",
"      Miron D, Luder A, Horovitz Y, et al. Acute human parvovirus B-19 infection in hospitalized children: A serologic and molecular survey. Pediatr Infect Dis J 2006; 25:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/29\">",
"      Royle SG, Galasko CS. The irritable hip. Scintigraphy in 192 children. Acta Orthop Scand 1992; 63:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/30\">",
"      Uren RF, Howman-Giles R. The 'cold hip' sign on bone scan. A retrospective review. Clin Nucl Med 1991; 16:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/31\">",
"      Kermond S, Fink M, Graham K, et al. A randomized clinical trial: should the child with transient synovitis of the hip be treated with nonsteroidal anti-inflammatory drugs? Ann Emerg Med 2002; 40:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/32\">",
"      Kallio PE, Paterson DC, Foster BK, Lequesne GW. Classification in slipped capital femoral epiphysis. Sonographic assessment of stability and remodeling. Clin Orthop Relat Res 1993; :196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/33\">",
"      Keenan WN, Clegg J. Perthes' disease after \"irritable hip\": delayed bone age shows the hip is a \"marked man\". J Pediatr Orthop 1996; 16:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/34\">",
"      Wenger DR, Ward WT, Herring JA. Legg-Calv&eacute;-Perthes disease. J Bone Joint Surg Am 1991; 73:778.",
"     </a>",
"    </li>",
"    <li>",
"     Sherry  DD, Malleson PN. Nonrheumatic musculoskeletal pain. In: Textbook of Pediatric Rheumatology, 4th, Cassidy JT, Petty RE (Eds), WB Saunders, Philadelphia 2001. p.362.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/36\">",
"      Gaughan DM, Mofenson LM, Hughes MD, et al. Osteonecrosis of the hip (Legg-Calv&eacute;-Perthes disease) in human immunodeficiency virus-infected children. Pediatrics 2002; 109:E74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/37\">",
"      Wang NH, Lee FT, Chin LS, Lo WH. Legg-Calve-Perthes disease: clinical analysis of 57 cases. J Formos Med Assoc 1990; 89:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/38\">",
"      Glueck CJ, Crawford A, Roy D, et al. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg Am 1996; 78:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/39\">",
"      Glueck CJ, Brandt G, Gruppo R, et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop Relat Res 1997; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/40\">",
"      Balasa VV, Gruppo RA, Glueck CJ, et al. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am 2004; 86-A:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/41\">",
"      Glueck CJ, Tracy T, Wang P. Legg-Calve-Perthes disease, venous and arterial thrombi, and the factor V Leiden mutation in a four-generation kindred. J Pediatr Orthop 2007; 27:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/42\">",
"      Vosmaer A, Pereira RR, Koenderman JS, et al. Coagulation abnormalities in Legg-Calv&eacute;-Perthes disease. J Bone Joint Surg Am 2010; 92:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/43\">",
"      Kealey WD, Mayne EE, McDonald W, et al. The role of coagulation abnormalities in the development of Perthes' disease. J Bone Joint Surg Br 2000; 82:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/44\">",
"      Hresko MT, McDougall PA, Gorlin JB, et al. Prospective reevaluation of the association between thrombotic diathesis and legg-perthes disease. J Bone Joint Surg Am 2002; 84-A:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/45\">",
"      Kenet G, Ezra E, Wientroub S, et al. Perthes' disease and the search for genetic associations: collagen mutations, Gaucher's disease and thrombophilia. J Bone Joint Surg Br 2008; 90:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/46\">",
"      Weinstein SL. Bristol-Myers Squibb/Zimmer award for distinguished achievement in orthopaedic research. Long-term follow-up of pediatric orthopaedic conditions. Natural history and outcomes of treatment. J Bone Joint Surg Am 2000; 82-A:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/47\">",
"      Glueck CJ, Freiberg RA, Crawford A, et al. Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease. Clin Orthop Relat Res 1998; :159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/48\">",
"      Garc&iacute;a Mata S, Ardanaz Aicua E, Hidalgo Ovejero A, Martinez Grande M. Legg-Calv&eacute;-Perthes disease and passive smoking. J Pediatr Orthop 2000; 20:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/49\">",
"      Bahmanyar S, Montgomery SM, Weiss RJ, Ekbom A. Maternal smoking during pregnancy, other prenatal and perinatal factors, and the risk of Legg-Calv&eacute;-Perthes disease. Pediatrics 2008; 122:e459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/50\">",
"      Margetts BM, Perry CA, Taylor JF, Dangerfield PH. The incidence and distribution of Legg-Calv&eacute;-Perthes' disease in Liverpool, 1982-95. Arch Dis Child 2001; 84:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/51\">",
"      Molloy MK, Macmahon B. Birth weight and Legg-Perthes disease. J Bone Joint Surg Am 1967; 49:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/52\">",
"      Dillman JR, Hernandez RJ. MRI of Legg-Calve-Perthes disease. AJR Am J Roentgenol 2009; 193:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/53\">",
"      Uno A, Hattori T, Noritake K, Suda H. Legg-Calv&eacute;-Perthes disease in the evolutionary period: comparison of magnetic resonance imaging with bone scintigraphy. J Pediatr Orthop 1995; 15:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/54\">",
"      Yrj&ouml;nen T. Long-term prognosis of Legg-Calv&eacute;-Perthes disease: a meta-analysis. J Pediatr Orthop B 1999; 8:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/55\">",
"      Herring JA, Kim HT, Browne R. Legg-Calve-Perthes disease. Part II: Prospective multicenter study of the effect of treatment on outcome. J Bone Joint Surg Am 2004; 86-A:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/56\">",
"      Wiig O, Terjesen T, Svenningsen S. Prognostic factors and outcome of treatment in Perthes' disease: a prospective study of 368 patients with five-year follow-up. J Bone Joint Surg Br 2008; 90:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/57\">",
"      Canavese F, Dimeglio A. Perthes' disease: prognosis in children under six years of age. J Bone Joint Surg Br 2008; 90:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/58\">",
"      Matava MJ, Patton CM, Luhmann S, et al. Knee pain as the initial symptom of slipped capital femoral epiphysis: an analysis of initial presentation and treatment. J Pediatr Orthop 1999; 19:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/59\">",
"      Ledwith CA, Fleisher GR. Slipped capital femoral epiphysis without hip pain leads to missed diagnosis. Pediatrics 1992; 89:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/60\">",
"      Kocher MS, Bishop JA, Weed B, et al. Delay in diagnosis of slipped capital femoral epiphysis. Pediatrics 2004; 113:e322.",
"     </a>",
"    </li>",
"    <li>",
"     Renshaw TS.. Pediatric Orthopedics, Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/62\">",
"      Cohen MD, Harrington TM, Ginsburg WW. Osteoid osteoma: 95 cases and a review of the literature. Semin Arthritis Rheum 1983; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/63\">",
"      Spilberg I, Meyer GJ. The arthritis of leukemia. Arthritis Rheum 1972; 15:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/64\">",
"      Rogalsky RJ, Black GB, Reed MH. Orthopaedic manifestations of leukemia in children. J Bone Joint Surg Am 1986; 68:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/65\">",
"      Cabral DA, Tucker LB. Malignancies in children who initially present with rheumatic complaints. J Pediatr 1999; 134:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/66\">",
"      Jordanov MI, Block JJ, Gonzalez AL, Green NE. Transarticular spread of Ewing sarcoma mimicking septic arthritis. Pediatr Radiol 2009; 39:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/67\">",
"      Jones OY, Spencer CH, Bowyer SL, et al. A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. Pediatrics 2006; 117:e840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/68\">",
"      Orava S, Jormakka E, Hulkko A. Stress fractures in young athletes. Arch Orthop Trauma Surg 1981; 98:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/69\">",
"      Walker RN, Green NE, Spindler KP. Stress fractures in skeletally immature patients. J Pediatr Orthop 1996; 16:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/70\">",
"      Clement DB, Ammann W, Taunton JE, et al. Exercise-induced stress injuries to the femur. Int J Sports Med 1993; 14:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/71\">",
"      Adib N, Owers KL, Witt JD, et al. Isolated inflammatory coxitis associated with protrusio acetabuli: a new form of juvenile idiopathic arthritis? Rheumatology (Oxford) 2005; 44:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16729/abstract/72\">",
"      del Couz Garc&iacute;a A, Fern&aacute;ndez PL, Gonz&aacute;lez MP, et al. Idiopathic chondrolysis of the hip: long-term evolution. J Pediatr Orthop 1999; 19:449.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2856 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16729=[""].join("\n");
var outline_f16_21_16729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Additional history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hip examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RADIOGRAPHIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transient synovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Legg-Calv&eacute;-Perthes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Slipped epiphysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Systemic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Osteoid osteoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Stress fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Idiopathic chondrolysis of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2856|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/55/30581\" title=\"diagnostic image 1\">",
"      Osteomyelitis femur",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/51/35632\" title=\"diagnostic image 2\">",
"      Avascular necrosis hip MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/43/10943\" title=\"diagnostic image 3\">",
"      Avascular necrosis hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/45/7890\" title=\"diagnostic image 4\">",
"      Osteoid osteoma xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/6/33903\" title=\"diagnostic image 5\">",
"      Osteoid osteoma CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2856|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/54/32608\" title=\"figure 1\">",
"      Prone hip exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/55/6015\" title=\"figure 2\">",
"      FABERE test (Patrick test, \"figure of four\" test)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2856|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/42/39599\" title=\"picture 1\">",
"      Nail changes in psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/44/39628\" title=\"table 1\">",
"      Causes acute hip pain children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/9/22683\" title=\"table 2\">",
"      Epidemiology hip pain children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/47/8955\" title=\"table 3\">",
"      History for childhood hip pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=related_link\">",
"      Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28186?source=related_link\">",
"      Bacterial arthritis: Treatment and outcome in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17416?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7225?source=related_link\">",
"      Lyme disease: Clinical manifestations in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22839?source=related_link\">",
"      Psoas abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25097?source=related_link\">",
"      Radiologic evaluation of the hip in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_21_16730="Rare (recessively inherited) coagulation disorders";
var content_f16_21_16730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rare (recessively inherited) coagulation disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Pier Mannuccio Mannucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Stefano Duga, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Flora Peyvandi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/21/16730/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/21/16730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4444056\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The X-linked inherited coagulation disorders, hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency), together with von Willebrand disease, comprise 95 to 97 percent of all the inherited deficiencies of coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The remaining defects are rare and generally transmitted as autosomal recessive disorders, with prevalences ranging from approximately 1 in 500,000 to 1 in 2 million [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Higher prevalences are found in countries with large Jewish communities (factor XI deficiency) and regions (eg, Middle Eastern countries, Southern India) where consanguineous marriages are relatively common [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The molecular, clinical, and therapeutic aspects of recessively inherited coagulation disorders (RICDs) associated with bleeding will be presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/5\">",
"     5",
"    </a>",
"    ]. Factor XI deficiency and genetic disorders involving fibrinogen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link\">",
"     \"Factor XI deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"     \"Disorders of fibrinogen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding disorders due to acquired inhibitors of these coagulation factors (ie, prothrombin and factors V, VII, X, XI, XIII) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinically significant manifestations of a recessively inherited coagulation disorder are usually homozygous or compound heterozygous for a mutation in the affected gene. Heterozygotes (eg, parents and children of the affected patient) have approximately half-normal levels of coagulation factors and are usually asymptomatic (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    below). Rarely, pseudodominant transmission has been reported from an affected homozygous parent due to heterozygosity for a defect in the same coagulation factor in the other, clinically normal, parent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most recessively inherited coagulation disorders are expressed via a parallel reduction of the affected plasma factor, as measured by both functional assays and immunoassays (ie, type I deficiencies). Qualitative gene defects, characterized by normal to increased levels of antigen with low or undetectable functional activity (ie, type II deficiencies), are less frequently seen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genotype-phenotype relationships",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe type I deficiencies, functional levels of the deficient coagulation factor are frequently below the detection limit of available assays, although low antigen levels can often be detected by sensitive immunoassays.",
"   </p>",
"   <p>",
"    Complete absence of a coagulation factor probably occurs only with large gene deletions and nonsense mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/8\">",
"     8",
"    </a>",
"    ]. Such \"null\" mutations predicting the production of truncated proteins or an unstable mRNA are usually associated with very low or undetectable plasma factors and severe clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of missense mutations is more variable. In some instances they lead to severe factor deficiency, while in others they are associated with partial deficiencies and milder clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4\">",
"     4",
"    </a>",
"    ]. In some instances as, for example, due to missense mutations in the genes coding for fibrinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/9\">",
"     9",
"    </a>",
"    ], factor VII [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/10\">",
"     10",
"    </a>",
"    ], factor X [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/11\">",
"     11",
"    </a>",
"    ], or factor XI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/12\">",
"     12",
"    </a>",
"    ], mutant proteins are produced normally but not secreted because conformational changes cause them to be retained within the secretory pathway, with resulting intracellular degradation or accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some missense mutations cause the production of mutant proteins with heightened procoagulant properties associated with thrombotic phenotypes, usually transmitted as autosomal dominant traits [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H11#H11\">",
"     \"Disorders of fibrinogen\", section on 'Thrombotic variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RICDs are usually due to defects in the DNA of genes encoding the corresponding coagulation factor. Exceptions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A combined deficiency of both factor V and factor VIII is characterized by defects in genes encoding proteins involved in intracellular transport of these factors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=see_link&amp;anchor=H5#H5\">",
"       \"Genetics of the hemophilias\", section on 'Deficiency of factors VIII and V'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Combined deficiency of the vitamin K&ndash;dependent factors (ie, factors II, VII, IX, and X) are characterized by defects in the genes encoding enzymes involved in posttranslational modifications of these factors or vitamin K metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link&amp;anchor=H10#H10\">",
"       \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Mutations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RICDs are often due to mutations unique for each kindred and are scattered throughout the corresponding gene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In approximately 10 to 20 percent of patients, no mutation is found. These cases may be due to defects in noncoding regions, to large heterozygous deletions, or to large genomic rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. A review article listing all the gene mutations identified for each RICD up to 2002 has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4\">",
"     4",
"    </a>",
"    ]. A large collection of mutations can also be obtained from the Human Gene Mutation Database maintained at the Institute of Medical Genetics in Cardiff and from the",
"    <span class=\"nowrap\">",
"     registries/databases",
"    </span>",
"    section of the International Society on Thrombosis and Haemostasis (ISTH)",
"    <a class=\"external\" href=\"file://www.isth.org/?page=RegistriesDatabases\">",
"     website",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Registries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major registries of the RICDs exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Iran, a country where the custom of marriages among first cousins makes RICDs three to five times more frequent than in Western countries [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4\">",
"       4",
"      </a>",
"      ], a registry of bleeding disorders has been kept since the early 1970s. A cohort of 750 patients, now being prospectively followed, is likely to be the largest investigated thus far [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4,22-28\">",
"       4,22-28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A European network of treatment centers, the European Network of Rare Bleeding Disorders (EN-RBD), started collecting data in 2007. This network and registry (available at",
"      <a class=\"external\" href=\"file://www.rbdd.eu/\">",
"       www.rbdd.eu",
"      </a>",
"      ) established and funded by the European Union in the frame of the Public Health Executive Agency and the Directorate-General for health and Consumers (DG SANCO) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/29\">",
"       29",
"      </a>",
"      ], provides information on more than 600 patients with RICD.",
"     </li>",
"     <li>",
"      The third large set of data stems from the North American registry, including patients with afibrinogenemia as well as deficiencies of factors II, VII, X, V, and XIII [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At variance with the Iranian registry that gathered information only on patients with factor levels below 10 percent, about half of the North American registry contains information on presumably heterozygous individuals (eg, factor levels &ge;20 percent of normal) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/30\">",
"     30",
"    </a>",
"    ]. Approximately 40 percent of these presumed heterozygotes are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/30\">",
"     30",
"    </a>",
"    ]. However, such surveys have inherent limitations. As an example, bleeding symptoms have been reported in up to one-half of apparently healthy persons using such surveys [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding symptoms that endanger life or cause long-term musculoskeletal handicaps appear to be less frequent in patients with RICDs as a whole than in hemophiliacs with a comparable degree of factor deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/5\">",
"     5",
"    </a>",
"    ]. Measurement of plasma levels of factor activity usually helps to predict the severity and frequency of clinical manifestations, but the relationship between factor levels and bleeding tendency is sometimes poor, particularly for deficiencies of factors VII and XI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/24,27,30,33\">",
"     24,27,30,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most typical symptoms in the RICDs are the occurrence of excessive bleeding at the time of invasive procedures (eg, circumcision, dental extraction) as well as mucosal bleeding (eg, epistaxis, menorrhagia). Menorrhagia may be severe enough to cause iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/22-28,30\">",
"     22-28,30",
"    </a>",
"    ]. Postpartum bleeding often occurs in these patients if replacement therapy is not administered for two to three days after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/22-28\">",
"     22-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some symptoms are more common in specific RICDs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired wound healing, due to the presence of defective fibrin crosslinking, is typical of factor XIII deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H7#H7\">",
"       \"Disorders of fibrinogen\", section on 'Fibrin crosslinking'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Life-threatening symptoms such as umbilical cord bleeding, intracranial bleeding, and recurrent hemoperitoneum during ovulation, as well as limb-endangering hemarthroses and soft tissue hematomas, occur with higher frequency in patients with prothrombin, factor X, and factor XIII deficiency than in other RICDs.",
"     </li>",
"     <li>",
"      Afibrinogenemia is sometimes associated with thrombotic episodes, thought to be triggered by thrombin-induced platelet aggregation in vivo due to the absence of the thrombin-neutralizing properties of fibrin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H11#H11\">",
"       \"Disorders of fibrinogen\", section on 'Thrombotic variants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factor VII deficiency presents with a wide spectrum of clinical severity, correlating poorly with factor VII levels [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]; some patients with undetectable levels are asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/24,30\">",
"       24,30",
"      </a>",
"      ]. Intracranial bleeding, reported to be frequent and severe after birth in one series of factor VII-deficient patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/37\">",
"       37",
"      </a>",
"      ] was rare in the Iranian, Italian, and American cohorts [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/24,30\">",
"       24,30",
"      </a>",
"      ]. This severe clinical manifestation is rare in patients with the other RICDs, except in approximately 25 percent of patients with factor XIII deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One report found little evidence for an increased risk of thrombosis in factor VII deficiency and concluded that this deficiency does not protect the patient from developing clinical thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent miscarriage, frequently described in afibrinogenemic and factor XIII-deficiency women [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/22,28\">",
"       22,28",
"      </a>",
"      ], is not prominent in women with other RICDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433034\">",
"    <span class=\"h2\">",
"     Definitions of bleeding severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Network of Rare Bleeding disorders has classified and defined bleeding severity for the RICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/39\">",
"     39",
"    </a>",
"    ]. These definitions will be used throughout this review to delineate the factor levels at which patients in their database were either asymptomatic or developed clinical bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Asymptomatic",
"      </strong>",
"      &mdash; No documented bleeding episodes",
"     </li>",
"     <li>",
"      <strong>",
"       Grade I bleeding",
"      </strong>",
"      &mdash; Bleeding after trauma or antiplatelet or anticoagulant therapy",
"     </li>",
"     <li>",
"      <strong>",
"       Grade II bleeding",
"      </strong>",
"      &mdash; Spontaneous minor bleeding (eg, bruising, ecchymosis, minor wounds, oral cavity bleeding, epistaxis, menorrhagia)",
"     </li>",
"     <li>",
"      <strong>",
"       Grade III bleeding",
"      </strong>",
"      &mdash; Spontaneous major bleeding (eg, intramuscular hematomas requiring hospitalization; hemarthrosis; central nervous system, gastrointestinal, or umbilical cord bleeding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of both a prothrombin time (PT) and activated partial thromboplastin time (aPTT) is usually sufficient to identify RICDs of clinically significant severity (",
"    <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical use of coagulation tests\", section on 'Evaluation of abnormal clotting times'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prolonged aPTT with a normal PT is indicative of factor XI deficiency, provided that hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency), von Willebrand disease, and the asymptomatic defects of the contact phase are ruled out.",
"     </li>",
"     <li>",
"      A normal aPTT and prolonged PT is typical of factor VII deficiency",
"     </li>",
"     <li>",
"      Prolongation of both the aPTT and PT suggests either a single deficiency involving factor X, V, prothrombin, or fibrinogen or for a RICD due to combined factor deficiencies.",
"     </li>",
"     <li>",
"      Patients with severe homozygous factor XIII deficiency will have normal values for the aPTT, PT, and thrombin time, but will have an abnormal clot that is lysed in vitro in 5 molar urea, 2 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      , or 1 percent monochloroacetic acid (",
"      <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. This test will detect severe factor XIII deficiency, but is not sufficiently sensitive to detect heterozygous, mild or moderate deficiency states, which can only be identified by specific assays [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H20#H20\">",
"       \"Approach to the adult patient with a bleeding diathesis\", section on 'Urea clot solubility'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific assays of factor coagulant activity are necessary when the degree of prolongation of the global tests suggests the presence of severe, clinically significant deficiencies. These assays are routinely available in the average coagulation laboratory in Europe and North America. Factor antigen assays are not strictly necessary for diagnosis and treatment but allow one to distinguish type I from type II deficiencies (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     REPLACEMENT PRODUCTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Factor concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma concentrates of single coagulation factors are available for replacement therapy in a few European countries, but not in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/5\">",
"     5",
"    </a>",
"    ]. The main advantages of single factor concentrates include a smaller volume of infusion, fewer allergic reactions, as well as the adoption of virus-inactivation procedures during manufacturing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H923514\">",
"    <span class=\"h2\">",
"     Recombinant proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant coagulation factors have the advantage of being free of human or animal proteins, and thus may provide a higher level of confidence against future microbiologic contamination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"       Recombinant human factor VIIa",
"      </a>",
"      is commercially available, and is approved in Europe for the treatment of patients with congenital factor VII deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link\">",
"       \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recombinant human factor XIII A subunit is currently in human trials. (See",
"      <a class=\"local\" href=\"#H24790588\">",
"       'Recombinant factor XIII A subunit'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prothrombin complex concentrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-activated prothrombin complex concentrates (PCCs, also called factor IX complex), licensed for the treatment of factor IX deficiency, but also containing large amounts of factors II, VII, and X, can also be used to treat these deficiencies, even though not all the available products are labeled in terms of coagulation factor activity other than factor IX. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link&amp;anchor=H14#H14\">",
"     \"Plasma derivatives and recombinant DNA-produced coagulation factors\", section on 'Prothrombin complex concentrates'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fresh frozen plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment of the RICDs is single-donor fresh-frozen plasma (FFP), which contains all coagulation factors. This relatively inexpensive product is widely available. However, the risk of volume overload is real when repeated infusions are administered. Hence, single factor concentrates are preferred for major surgical procedures or when the severity of the clinical manifestations requires long-term replacement.",
"   </p>",
"   <p>",
"    Infectious complications with bloodborne viruses (eg, hepatitis viruses or human immunodeficiency virus) are still perceived as a threat following the use of FFP. Therefore, virus-inactivated FFP, such as",
"    <span class=\"nowrap\">",
"     solvent/detergent-treated",
"    </span>",
"    FFP",
"    <span class=\"nowrap\">",
"     (S/D",
"    </span>",
"    FFP) is preferable to standard FFP. Several",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma products are available in European countries, and a",
"    <span class=\"nowrap\">",
"     solvent/detergent-treated",
"    </span>",
"    FFP was approved in the United States in 2013. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link&amp;anchor=H15#H15\">",
"     \"Preparation of blood components\", section on 'Fresh frozen plasma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogen inactivation of blood products\", section on 'Pathogen inactivation of fresh frozen plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjuvant treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytic agents may be useful, alone or in combination with replacement therapy, in the management of the less severe forms of mucosal tract hemorrhages. Epsilon",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    (50-60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 4 to 6 hours) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (20-25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 8 to 12 hours) can be administered orally or intravenously for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link&amp;anchor=H22#H22\">",
"     \"Factor XI deficiency\", section on 'Antifibrinolytic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term use of estrogen-progesterone preparations may help to reduce menstrual blood loss in women with menorrhagia and secondary iron deficiency. Levels of the deficient coagulation factors are usually not significantly modified by these preparations, suggesting that their efficacy is due to local endometrial changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment recommendations, as discussed below, are based on the hemostatic level required for each factor, as well as the plasma half-life of the infused factor (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"UTD.htm?9/38/9836\">",
"     table 2",
"    </a>",
"    ). These govern the frequency of dose administration, as well as safety issues such as volume overload and excessive post-treatment factor levels.",
"   </p>",
"   <p>",
"    Replacement of the deficient coagulation factor is the mainstay of treatment for RICDs, although safe and efficacious products are few and experience with their optimal use limited. Recommendations presented here are mainly based on our clinical experience gained with Iranian, Italian and United States series of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/22-28,30,44\">",
"     22-28,30,44",
"    </a>",
"    ]. The strength of these recommendations is limited by the small number of patients treated, as well as the lack of accurate pharmacokinetic studies.",
"   </p>",
"   <p>",
"    For each of the conditions listed below, the recommended hemostatic level for each factor (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"UTD.htm?9/38/9836\">",
"     table 2",
"    </a>",
"    ) should be maintained for the following periods of time:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous bleeding &mdash; until bleeding stops",
"     </li>",
"     <li>",
"      Minor surgery &mdash; for two to three days",
"     </li>",
"     <li>",
"      Major surgery &mdash; until healing is complete",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fibrinogen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinogen deficiency, which can present phenotypically as afibrinogenemia, hypofibrinogenemia, or dysfibrinogenemia, is due to mutations in any of the genes encoding the three fibrinogen chains. This disorder and its treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link\">",
"     \"Disorders of fibrinogen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the 26 subjects with fibrinogen deficiency studied by the European Network of Rare Bleeding Disorders (EN-RBD), fibrinogen levels for asymptomatic subjects and those with grades I, II, and III bleeding were 113",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (95% CI 23 to 204), 73",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (95% CI 0 to 164), 33",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (95% CI 0 to 126), and 0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (95% CI 0 to 91), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prothrombin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoprothrombinemia, with an estimated incidence of 1 in 2,000,000, is characterized by concomitantly low activity and antigen levels in plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/45\">",
"     45",
"    </a>",
"    ]. Missense mutations in the prothrombin gene are the most frequent defects in the relatively few patients with hypoprothrombinemia genotyped so far [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4,45\">",
"     4,45",
"    </a>",
"    ]. Several cases of dysprothrombinemia, characterized by normal levels of a dysfunctional protein, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. No case of aprothrombinemia has been reported, suggesting that this deficiency is incompatible with life.",
"   </p>",
"   <p>",
"    The most commonly reported clinical symptoms, other than excessive bleeding after invasive procedures, include umbilical cord, joint, muscle, and mucosal bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to our experience and that of others [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/42\">",
"     42",
"    </a>",
"    ], the minimal coagulation factor levels necessary for hemostasis are somewhat higher for prothrombin (20 to 30 percent) than for most other RICDs (15 to 20 percent) (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"UTD.htm?9/38/9836\">",
"     table 2",
"    </a>",
"    ). Available replacement products include FFP and PCC. The latter raise factors VII, IX, and X to very high plasma levels, particularly when repeated infusions are administered. Such high levels may increase the risk of thrombosis, so that laboratory monitoring is advisable to avoid levels in excess of 150 percent when prolonged treatment is required.",
"   </p>",
"   <p>",
"    The recommended dose of FFP is 15 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    and that for PCC is 20 to 30",
"    <span class=\"nowrap\">",
"     U/kg,",
"    </span>",
"    with a target prothrombin level &gt;30 percent. Successful prophylactic use of PCC to prevent recurrent bleeding events has been reported for two subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Factor V deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;FV deficiency, with an estimated incidence of 1 in 1,000,000, is almost invariably expressed phenotypically as a type I deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/3\">",
"     3",
"    </a>",
"    ]. The in-trans association of the factor V Leiden mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/13\">",
"     13",
"    </a>",
"    ] with factor V gene mutations causing type I deficiency leads to the so-called \"pseudohomozygous\" activated protein C resistance phenotype, characterized by reduced factor V antigen levels, no bleeding symptoms, but a thrombotic tendency similar to that of factor V Leiden homozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe factor V deficiency is associated with a mild to severe bleeding diathesis, but many patients with factor V levels &lt;1 percent bleed less than anticipated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/51\">",
"     51",
"    </a>",
"    ]. The explanation for this observation is unknown, although residual platelet factor V activity may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The most common clinical symptom, other than excessive bleeding after invasive procedures, is mucosal tract bleeding.",
"   </p>",
"   <p>",
"    For the 50 subjects with factor V deficiency studied by the EN-RBD, factor V levels",
"    <span class=\"nowrap\">",
"     (Units/dL;",
"    </span>",
"    95% CI) for asymptomatic subjects and those with grades I, II, and III bleeding were 12 (zero to 34), 6 (zero to 28), zero (zero to 23), and zero (zero to 19), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No factor V concentrate is available; the main replacement material is FFP, preferably virus-inactivated. The recommended starting dosage is 15 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    IV, repeated daily to keep factor V at hemostatic levels (ie, &gt;20 percent of normal). In some instances this schedule may cause volume overload, so that surveillance is mandatory and diuretics are sometimes needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Combined deficiencies of factors V and VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated overall incidence of this combined deficiency is 1:2,000,000, although it is more common in Mediterranean countries, Middle Eastern Jews, and non-Jewish Iranians, in whom its incidence is estimated at 1:100,000. Such patients have low but detectable levels (eg, 5 to 20 percent of normal) of coagulant activity and antigen of both factors. Mutations in two genes coding for proteins of the secretory pathway are associated with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In approximately two thirds of cases, mutations are located in a gene on chromosome 18 that encodes a lectin mannose-binding protein (LMAN1, also called ERGIC-53) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. LMAN1 binds both FV and FVIII in the endoplasmic",
"      <span class=\"nowrap\">",
"       reticulum/Golgi",
"      </span>",
"      intermediate compartment (ERGIC) and functions as chaperone in the intracellular transport of both factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=see_link&amp;anchor=H5#H5\">",
"       \"Genetics of the hemophilias\", section on 'Deficiency of factors VIII and V'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the remaining kindreds, the combined deficiency is associated with mutations in a gene on chromosome 2 called multiple coagulation factor deficiency 2 gene (MCFD2) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/15\">",
"       15",
"      </a>",
"      ]. MCFD2 encodes a protein that forms a Ca",
"      <sup>",
"       ++",
"      </sup>",
"      -dependent stoichiometric complex with LMAN1 and acts as a cofactor in the intracellular trafficking of factors V and VIII [",
"      <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/15,54\">",
"       15,54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most commonly reported clinical symptom in this condition, other than excessive bleeding after invasive procedures, is mucosal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/25,56\">",
"     25,56",
"    </a>",
"    ]. Hemarthroses typical of hemophilia A (isolated factor VIII deficiency) occur in less than one-third of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the 18 subjects with combined deficiencies of factors V and VIII studied by the EN-RBD, factor levels",
"    <span class=\"nowrap\">",
"     (Units/dL;",
"    </span>",
"    95% CI) for asymptomatic subjects and those with grades I, II, and III bleeding were 43 (25 to 62), 34 (16 to 52), 24 (5 to 44), and 15 (zero to 37), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;FFP is recommended for treatment of the combined deficiencies of factors V and VIII, with the advantage that in these patients baseline factor V levels are usually higher than in isolated factor V deficiency. The half-life of factor VIII (10 to 14 hours) is approximately one third of that of factor V (36 hours), so that relatively frequent doses of FFP must be given if factor VIII levels are to be kept at the same levels as those of factor V.",
"   </p>",
"   <p>",
"    The recommended starting dosage of FFP is 15 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    IV, repeated daily to keep factor V at hemostatic levels (&gt;20 percent). In some instances this schedule may cause volume overload, so that surveillance is mandatory and diuretics are sometimes needed.",
"   </p>",
"   <p>",
"    We and others [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/58-60\">",
"     58-60",
"    </a>",
"    ] have sometimes successfully used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) to further raise factor VIII levels when the post-FFP trough levels of this factor were thought to be inadequate for hemostasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of von Willebrand disease\", section on 'Desmopressin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Factor VII deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VII deficiency has an estimated incidence of 1:500,000. More than two thirds of factor VII mutations are missense mutations; the remainder are null mutations that decrease or abolish the expression of factor VII [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4,61-63\">",
"     4,61-63",
"    </a>",
"    ]. In general, patients with mild to moderate clinical phenotypes are homozygous or compound heterozygous for missense mutations, whereas more severe phenotypes are associated with deletions, nonsense mutations, splicing, and promoter mutations. However, some missense mutations are also associated with a severe phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common clinical symptoms, other than excessive bleeding after invasive procedures, include mucosal tract, joint, and muscle bleeding. As noted above, factor VII deficiency presents with a wide spectrum of clinical severity, sometimes correlating poorly with factor VII levels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]; some patients with undetectable levels are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]; there is no explanation for this observation. Intracranial bleeding, reported to be frequent and severe after birth in one series of factor VII-deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/37\">",
"     37",
"    </a>",
"    ] was rare in the Iranian, Italian, and American cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/24,30\">",
"     24,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perioperative bleeding in patients with factor VII deficiency was evaluated in a retrospective analysis of 83 unrelated factor VII deficient patients (mean factor VII level 5 percent; range 0.6 to 35 percent) who had undergone 157 surgical procedures without preoperative replacement therapy, 24 of which were complicated by bleeding (15.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/65\">",
"     65",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant relationship between previous deep traumatic hematomas and bleeding at the time of surgery.",
"     </li>",
"     <li>",
"      The procedures most likely to be associated with bleeding were tonsillectomy-adenoidectomy (20 percent risk of bleeding), abdominal hernia repair (25 percent risk), and circumcision (40 percent risk).",
"     </li>",
"     <li>",
"      Using an optimum point on the receiver-operating characteristics curve, a factor VII level of greater than 7 percent had a negative predictive value of 94 percent for intra- or postoperative bleeding, while a level less than 7 percent had a positive predictive value of 25 percent for such bleeding.",
"      <br/>",
"      <br/>",
"      Taking variability of assays for factor VII into account, it was concluded from this retrospective analysis that subjects undergoing major surgery with factor VII levels &lt;10 percent and those with levels of 10 to 30 percent with a positive clinical history should receive preoperative replacement therapy, while those with levels &gt;10 percent and a negative clinical history would not need preoperative replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the 203 subjects with factor VII deficiency studied by the EN-RBD, factor VII levels",
"    <span class=\"nowrap\">",
"     (Units/dL;",
"    </span>",
"    95% CI) for asymptomatic subjects and those with grades I, II, and III bleeding were 25 (15 to 35), 19 (8 to 30), 13 (2 to 25), and 8 (0 to 21), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The very short half-life of factor VII (four to six hours) makes it difficult to use FFP without causing volume overload. Recombinant human activated factor VII is licensed for use in factor VII deficiency in both Europe and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4,66,67\">",
"     4,66,67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended dosage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    , 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    intravenously, repeated every six to eight hours, according to the given clinical situation, is able to keep factor VII levels above 15 to 20 percent. Higher doses may be required in the case of life-threatening hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virus-inactivated factor VII concentrates have been used successfully in small series of patients, but are not available within the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The recommended starting dose is 30 to 40",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    IV, repeated every 6 to 12 hours as necessary.",
"   </p>",
"   <p>",
"    The management of bleeding in patients with factor VII deficiency was evaluated in a cohort of 75 patients from the Seven Treatment Evaluation Registry (STER), a registry of patients with congenital factor VII deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/68,71\">",
"     68,71",
"    </a>",
"    ]. All patients had previously shown bleeding symptoms, and factor VII levels ranged from 0 to 20 percent (88 percent of patients had factor VII levels below 5 percent). The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For 101 bleeding episodes in 75 patients, half required a single dose of factor VII, a third required two to four doses, and the remaining 16 (mostly CNS bleeds) required five or more doses.",
"     </li>",
"     <li>",
"      Recombinant factor VIIa was used to treat 79 of the episodes. The remaining episodes were treated with room temperature stable recombinant factor VIIa, plasma-derived factor VII concentrates, fresh frozen plasma (FFP), or prothrombin complex concentrates (PCC).",
"     </li>",
"     <li>",
"      The median total dose of recombinant factor VIIa was 60",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      (range 10 to 3600",
"      <span class=\"nowrap\">",
"       mcg/kg).",
"      </span>",
"     </li>",
"     <li>",
"      Bleeding and pain were completely controlled in all but five cases following one or more doses of factor. In the remaining five cases, symptoms were slower to subside and there was only partial return of joint mobility.",
"     </li>",
"     <li>",
"      No thrombotic episodes were reported during the 30-day follow-up period.",
"     </li>",
"     <li>",
"      Two inhibitors were detected, one after recombinant and one after plasma-derived factor VII.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Factor X deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor X deficiency has an estimated incidence of 1 in 1,000,000. Approximately 75 percent of patients with factor X deficiency have missense mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/4,11,72-76\">",
"     4,11,72-76",
"    </a>",
"    ]. Most affected individuals have low but measurable levels of factor X activity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/73\">",
"     73",
"    </a>",
"    ], suggesting that complete absence of factor X in plasma may be incompatible with adult life.",
"   </p>",
"   <p>",
"    The most common clinical symptoms, other than excessive bleeding after invasive procedures, include intracranial, umbilical cord, joint, and muscle bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the 34 subjects with factor X deficiency studied by the EN-RBD, factor X levels",
"    <span class=\"nowrap\">",
"     (Units/dL;",
"    </span>",
"    95% CI) for asymptomatic subjects and those with grades I, II, and III bleeding were 56 (29 to 83), 40 (14 to 67), 25 (0 to 52), and 10 (zero to 39), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;This deficiency can be treated in a way similar to prothrombin deficiency (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Prothrombin deficiency'",
"    </a>",
"    above), although the plasma half-life of factor X (40 to 60 hours) is shorter than that of prothrombin (72 to 96 hours).",
"   </p>",
"   <p>",
"    Daily infusions of 20 to 30",
"    <span class=\"nowrap\">",
"     Units/kg",
"    </span>",
"    of PCC or 15 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of FFP are necessary when a relatively long-lasting treatment is needed, in order to keep the factor X level &gt;20 percent of normal. Patients should be closely monitored to avoid allowing the levels of factors II, VII, and IX to rise in excess of 150 percent of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Factor XI deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of factor XI deficiency is 1 in 1,000,000, although a founder effect appears to underlie the high frequency of factor XI deficiency among communities with a high Jewish population. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=see_link\">",
"     \"Factor XI deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the 125 subjects with factor XI deficiency studied by the EN-RBD, factor XI levels",
"    <span class=\"nowrap\">",
"     (Units/dL;",
"    </span>",
"    95% CI) for asymptomatic subjects and those with grades I, II, and III bleeding were 26 (14 to 39), 26 (13 to 38), 25 (11 to 39), and 25 (9 to 41), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Factor XIII deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of factor XIII deficiency worldwide is 1 in 2,000,000 although its prevalence has been reported to be higher in southeastern Iran, likely because consanguineous marriage is commonly practiced in this region [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor XIII is a heterotetramer composed of two A catalytic subunits synthesized and released by cells of bone marrow origin and two B carrier subunits synthesized and secreted by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/81\">",
"     81",
"    </a>",
"    ]. Most cases of factor XIII deficiency are associated with alterations in the gene that encodes the catalytic A subunit of this factor, while a minority are due to defects of the carrier B subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=see_link&amp;anchor=H7#H7\">",
"     \"Disorders of fibrinogen\", section on 'Fibrin crosslinking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most commonly reported clinical symptoms, other than excessive bleeding after invasive procedures, include umbilical cord, intracranial, muscle, and joint bleeding, as well as recurrent miscarriages and impaired wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/42,82,83\">",
"     42,82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the 33 subjects with factor XIII deficiency studied by the EN-RBD, factor XIII levels",
"    <span class=\"nowrap\">",
"     (Units/dL;",
"    </span>",
"    95% CI) for asymptomatic subjects and those with grades I, II, and III bleeding were 31 (11 to 51), 17 (zero to 37), 3 (zero to 24), and zero (zero to 11), respectively. (See",
"    <a class=\"local\" href=\"#H6433034\">",
"     'Definitions of bleeding severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical severity of this deficiency requires regular prophylaxis from the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/28,30,42,84\">",
"     28,30,42,84",
"    </a>",
"    ], which is feasible because of two highly beneficial qualities of factor XIII (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"UTD.htm?9/38/9836\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Effective hemostatic levels may be as low as 2 to 5 percent",
"     </li>",
"     <li>",
"      The plasma half-life of factor XIII is long (11 to 14 days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, replacement material can be infused at intervals as long as every 20 to 30 days.",
"   </p>",
"   <p>",
"    Three types of factor XIII-containing product are available: fresh frozen plasma (FFP, preferably virus-inactivated), cryoprecipitate, and two pasteurized plasma concentrates (Fibrogammin-P, CSL Behring UK, Ltd and Corifact, CSL Behring LLC, Kankakee, IL) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/85-90\">",
"     85-90",
"    </a>",
"    ]. The pasteurized concentrates and virus-inactivated FFP, when available, are preferred to cryoprecipitate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute bleeding episode &mdash; A single dose of FFP of 2 to 3",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      is sufficient to raise the factor XIII level to &gt;5 percent, which is sufficient for immediate hemostasis.",
"     </li>",
"     <li>",
"      Replacement dosage &mdash; Recommended dosages for factor XIII replacement (every 20 to 30 days) are 15 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for FFP, 10 to 20",
"      <span class=\"nowrap\">",
"       Units/kg",
"      </span>",
"      for Fibrogammin P, 40",
"      <span class=\"nowrap\">",
"       Units/kg",
"      </span>",
"      for Corifact (",
"      <a class=\"external\" href=\"file://www.corifact.com/docs/Corifact-Prescribing-Information.pdf\">",
"       Corifact drug information",
"      </a>",
"      ), and 1 bag of cryo per 10 kg body weight. Prophylaxis is recommended in all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24790588\">",
"    <span class=\"h4\">",
"     Recombinant factor XIII A subunit",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recombinant preparation of the A subunit of factor XIII prepared in yeast and containing no human or mammalian products has undergone clinical studies in subjects with congenital factor XIII deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/91\">",
"     91",
"    </a>",
"    ]. This product was tested in 41 subjects with congenital factor XIII subunit A deficiency at a prophylactic intravenous dose of 35 International",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per month [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/92\">",
"     92",
"    </a>",
"    ]. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were only five bleeding episodes requiring treatment with a factor XIII-containing product; all were trauma related.",
"     </li>",
"     <li>",
"      The crude mean bleeding rate during this period was numerically lower than the historic bleeding rate for patients on regular replacement treatment (0.138 versus 0.33 bleeds per year, respectively) and significantly lower than the historic bleeding rate for patients receiving on-demand treatment (2.91",
"      <span class=\"nowrap\">",
"       bleeds/year).",
"      </span>",
"     </li>",
"     <li>",
"      Transient, non-neutralizing anti-factor XIII antibodies developed in four subjects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Multiple vitamin K-dependent factor deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of these disorders is approximately 1 in 2,000,000. Plasma defects are not limited to the procoagulant factors (ie, factors II, VII, IX, and X) but also involve the naturally occurring anticoagulants (ie, proteins C and S), as well as the vitamin K&ndash;dependent bone proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/16,93,94\">",
"     16,93,94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link&amp;anchor=H10#H10\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular bases of the multiple deficiency state are missense mutations in the gamma-glutamyl carboxylase gene located on chromosome 2, which lead to the production of a dysfunctional enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/16,95\">",
"     16,95",
"    </a>",
"    ]. The multiple deficiency can also be associated with missense mutations in the gene for vitamin K epoxide reductase complex subunit 1 (VKORC1), which encodes a small transmembrane protein of the endoplasmic reticulum necessary for the full function of vitamin K in the carboxylase reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasma factor activities range from less than 1 percent to 30 percent; clinical manifestations occur early in life and may be fatal, and include umbilical cord and central nervous system bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/16,93\">",
"     16,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most families, the activity of the vitamin K-dependent coagulation factors can be normalized or partially corrected by either oral or parenteral vitamin K supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/42,93,94,97-99\">",
"     42,93,94,97-99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link&amp;anchor=H10#H10\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the rare circumstance when vitamin K is ineffective, treatment with FFP has been successful in a limited number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. Since such experience is limited, it would appear most prudent to correct factor levels to 20 to 30 percent, similar to that recommended for prothrombin deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the North American registry, 3 percent of patients with factor V and factor XIII deficiency developed alloantibodies following treatment with FFP and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/772?source=see_link\">",
"     factor XIII concentrates",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/30\">",
"     30",
"    </a>",
"    ]. A few cases of anti-factor XIII inhibitors were also mentioned in a European questionnaire survey [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/103\">",
"     103",
"    </a>",
"    ]. Factor XI deficient patients of Jewish ancestry carrying the so-called type II common mutation develop alloantibodies to factor XI when they are exposed to replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bloodborne viral infections are a potential complication of treatment of RICDs, but there are few published data. According to the North American registry, seropositivity was 15.6 percent for hepatitis B, 25 percent for hepatitis C, and 1 percent for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/30\">",
"     30",
"    </a>",
"    ]. Among Iranian patients, the prevalence of hepatitis C infection was 50 percent for patients with factor XI and factor XIII deficiency, with no patient positive for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;RICDs are relatively neglected diseases. Accordingly, patients and their families usually have less extensive information on their ailments than those with hemophilia. Prevention of RICDs relies on two major strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic counseling in marriages between consanguineous couples",
"     </li>",
"     <li>",
"      Prenatal diagnosis in at-risk kindreds",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither of these strategies is easily carried out for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The custom of consanguineous marriages is deeply rooted among some communities.",
"     </li>",
"     <li>",
"      The implementation of prenatal diagnosis is technically demanding due to the need to sequence the entire coding region of the gene to find the causative mutation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271758329\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information concerning blood coagulation proteins (eg, sequence, structure, mutations, function, associated diseases, related literature) is available on ClotBase at",
"    <a class=\"external\" href=\"file://www.clotbase.bicnirrh.res.in/\">",
"     file://www.clotbase.bicnirrh.res.in",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/21/16730/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20130435\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital deficiencies of fibrinogen, prothrombin, factors V, VII, X, XI, and XIII (recessively inherited coagulation disorders, RICDs) are rare autosomal recessive disorders, with prevalences ranging from approximately 1 in 500,000 to 1 in 2 million. Higher prevalences are found in countries with large Jewish communities (factor XI deficiency) and regions (eg, Middle Eastern countries, Southern India) where consanguineous marriages are relatively common.",
"     </li>",
"     <li>",
"      Most RICDs are characterized by a reduction in both functional and quantitative assays of the affected factor (ie, type I deficiencies). Qualitative gene defects (ie, normal to increased levels of factor with low or undetectable functional activity, type II deficiencies), are less frequently seen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genotype-phenotype relationships'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most typical symptoms of the rare factor deficiencies are excessive bleeding at the time of invasive procedures as well as mucosal bleeding (eg, epistaxis, menorrhagia). Some symptoms are more common in specific deficiencies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prothrombin time (PT) and activated partial thromboplastin time (aPTT) assays are usually sufficient to identify RICDs of clinically significant severity (",
"      <a class=\"graphic graphic_table graphicRef79969 \" href=\"UTD.htm?42/45/43740\">",
"       table 1",
"      </a>",
"      ). Specific assays of factor coagulant activity are necessary when the degree of prolongation of the PT and aPTT tests suggests the presence of severe, clinically significant deficiencies. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Replacement of the deficient factor is the mainstay of treatment for these deficiencies. Treatment recommendations for each of the RICDs, as discussed above, are based on the hemostatic level required for each factor, as well as the plasma half-life of the infused factor (",
"      <a class=\"graphic graphic_table graphicRef51595 \" href=\"UTD.htm?9/38/9836\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/1\">",
"      Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/2\">",
"      Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost 2003; 1:1349.",
"     </a>",
"    </li>",
"    <li>",
"     Tuddenham EG, Cooper DN. The Molecular Genetics of Haemostasis and Its Inherited Disorders. Oxford, United Kingdom: Oxford Medical Publications; 1994. Oxford Monography on Medical Genetics No. 25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/4\">",
"      Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002; 8:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/5\">",
"      Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/6\">",
"      Menegatti M, Karimi M, Garagiola I, et al. A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency. Am J Hematol 2004; 77:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/7\">",
"      Tagliabue L, Duca F, Peyvandi F. Apparently dominant transmission of a recessive disease: deficiency of factor VII in Iranian Jews. Ann Ital Med Int 2000; 15:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/8\">",
"      Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest 1999; 103:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/9\">",
"      Duga S, Asselta R, Santagostino E, et al. Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 2000; 95:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/10\">",
"      Hunault M, Arbini AA, Carew JA, et al. Characterization of two naturally occurring mutations in the second epidermal growth factor-like domain of factor VII. Blood 1999; 93:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/11\">",
"      Watzke HH, Wallmark A, Hamaguchi N, et al. Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/12\">",
"      Zivelin A, Bauduer F, Ducout L, et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood 2002; 99:2448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/13\">",
"      Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/14\">",
"      Cunningham MA, Pipe SW, Zhang B, et al. LMAN1 is a molecular chaperone for the secretion of coagulation factor VIII. J Thromb Haemost 2003; 1:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/15\">",
"      Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 2003; 34:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/16\">",
"      Brenner B. Hereditary deficiency of vitamin K-dependent coagulation factors. Thromb Haemost 2000; 84:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/17\">",
"      Sadler JE. Medicine: K is for koagulation. Nature 2004; 427:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/18\">",
"      Spena S, Asselta R, Plat&eacute; M, et al. Pseudo-exon activation caused by a deep-intronic mutation in the fibrinogen gamma-chain gene as a novel mechanism for congenital afibrinogenaemia. Br J Haematol 2007; 139:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/19\">",
"      Guella I, Paraboschi EM, van Schalkwyk WA, et al. Identification of the first Alu-mediated large deletion involving the F5 gene in a compound heterozygous patient with severe factor V deficiency. Thromb Haemost 2011; 106:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/20\">",
"      Giansily-Blaizot M, Thorel D, Khau Van Kien P, et al. Characterisation of a large complex intragenic re-arrangement in the FVII gene (F7) avoiding misdiagnosis in inherited factor VII deficiency. Br J Haematol 2007; 138:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/21\">",
"      Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/22\">",
"      Lak M, Keihani M, Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/23\">",
"      Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/24\">",
"      Peyvandi F, Mannucci PM, Asti D, et al. Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia 1997; 3:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/25\">",
"      Peyvandi F, Tuddenham EG, Akhtari AM, et al. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998; 100:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/26\">",
"      Peyvandi F, Mannucci PM, Lak M, et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/27\">",
"      Peyvandi F, Lak M, Mannucci PM. Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. Haematologica 2002; 87:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/28\">",
"      Lak M, Peyvandi F, Ali Sharifian A, et al. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1:1852.",
"     </a>",
"    </li>",
"    <li>",
"     www.rbdd.org (Accessed on July 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/30\">",
"      Acharya SS, Coughlin A, Dimichele DM, North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/31\">",
"      Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, et al. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/32\">",
"      Sr&aacute;mek A, Eikenboom JC, Bri&euml;t E, et al. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/33\">",
"      Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/34\">",
"      Giansily-Blaizot M, Verdier R, Biron-Adr&eacute;ani C, et al. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk? Haematologica 2004; 89:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/35\">",
"      Barnett JM, Demel KC, Mega AE, et al. Lack of bleeding in patients with severe factor VII deficiency. Am J Hematol 2005; 78:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/36\">",
"      Mariani G, Herrmann FH, Dolce A, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/37\">",
"      Ragni MV, Lewis JH, Spero JA, Hasiba U. Factor VII deficiency. Am J Hematol 1981; 10:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/38\">",
"      Mariani G, Herrmann FH, Schulman S, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost 2003; 1:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/39\">",
"      Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/40\">",
"      Girolami A, Sartori MT, Simioni P. An updated classification of factor XIII defect. Br J Haematol 1991; 77:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/41\">",
"      Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001; 86:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/42\">",
"      Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/43\">",
"      Lawrie AS, Green L, Mackie IJ, et al. Factor XIII--an under diagnosed deficiency--are we using the right assays? J Thromb Haemost 2010; 8:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/44\">",
"      Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001; 7(suppl 1):16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/45\">",
"      Akhavan S, Mannucci PM, Lak M, et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost 2000; 84:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/46\">",
"      Akhavan S, De Cristofaro R, Peyvandi F, et al. Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. Blood 2002; 100:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/47\">",
"      De Cristofaro R, Akhavan S, Altomare C, et al. A natural prothrombin mutant reveals an unexpected influence of A-chain structure on the activity of human alpha-thrombin. J Biol Chem 2004; 279:13035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/48\">",
"      Lobel JS, Majumdar S, Kovats-Bell S. Successful prophylactic treatment for bleeding in a girl with severe hereditary prothrombin deficiency using a prothrombin complex concentrate (Bebulin VH). J Pediatr Hematol Oncol 2004; 26:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/49\">",
"      Mathias M, Pollard D, Riddell A. Prophylaxis in severe prothrombin deficiency. Br J Haematol 2011; 152:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/50\">",
"      Castaman G, Lunghi B, Missiaglia E, et al. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol 1997; 99:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/51\">",
"      Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/52\">",
"      Duckers C, Simioni P, Rosing J, Castoldi E. Advances in understanding the bleeding diathesis in factor V deficiency. Br J Haematol 2009; 146:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/53\">",
"      Duckers C, Simioni P, Spiezia L, et al. Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. Blood 2010; 115:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/54\">",
"      Zhang B, McGee B, Yamaoka JS, et al. Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 2006; 107:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/55\">",
"      Zhang B. Recent developments in the understanding of the combined deficiency of FV and FVIII. Br J Haematol 2009; 145:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/56\">",
"      Mansouritorgabeh H, Rezaieyazdi Z, Pourfathollah AA, et al. Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 2004; 10:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/57\">",
"      Viswabandya A, Baidya S, Nair SC, et al. Clinical manifestations of combined factor V and VIII deficiency: a series of 37 cases from a single center in India. Am J Hematol 2010; 85:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/58\">",
"      Chuansumrit A, Mahaphan W, Pintadit P, et al. Combined factor V and factor VIII deficiency with congenital heart disease:response to plasma and DDAVP infusion. Southeast Asian J Trop Med Public Health 1994; 25:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/59\">",
"      Bauduer F, Guichandut JP, Ducout L. Successful use of fresh frozen plasma and desmopressin for transurethral prostatectomy in a French Basque with combined factors V +VIII deficiency. J Thromb Haemost 2004; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/60\">",
"      Chapin J, Cardi D, Gibb C, Laurence J. Combined factor V and factor VIII deficiency: a report of a case, genetic analysis, and response to desmopressin acetate. Clin Adv Hematol Oncol 2012; 10:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/61\">",
"      Peyvandi F, Jenkins PV, Mannucci PM, et al. Molecular characterisation and three-dimensional structural analysis of mutations in 21 unrelated families with inherited factor VII deficiency. Thromb Haemost 2000; 84:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/62\">",
"      Wulff K, Herrmann FH. Twenty two novel mutations of the factor VII gene in factor VII deficiency. Hum Mutat 2000; 15:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/63\">",
"      Peyvandi F, Carew JA, Perry DJ, et al. Abnormal secretion and function of recombinant human factor VII as the result of modification to a calcium binding site caused by a 15-base pair insertion in the F7 gene. Blood 2001; 97:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/64\">",
"      McVey JH, Boswell E, Mumford AD, et al. Factor VII deficiency and the FVII mutation database. Hum Mutat 2001; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/65\">",
"      Benlakhal F, Mura T, Schved JF, et al. A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients. J Thromb Haemost 2011; 9:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/66\">",
"      Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/67\">",
"      Mariani G, Testa MG, Di Paolantonio T, et al. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/68\">",
"      Farah RA, Hamod D, Melick N, et al. Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency. J Thromb Haemost 2007; 5:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/69\">",
"      Mariani G, Mannucci PM, Mazzucconi MG, Capitanio A. Treatment of congenital factor VII deficiency with a new concentrate. Thromb Haemost 1978; 39:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/70\">",
"      Cohen LJ, McWilliams NB, Neuberg R, et al. Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: a summary of case reports. Am J Hematol 1995; 50:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/71\">",
"      Mariani G, Napolitano M, Dolce A, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A&nbsp;prospective evaluation. Thromb Haemost 2013; 109:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/72\">",
"      Cooper DN, Millar DS, Wacey A, et al. Inherited factor X deficiency: molecular genetics and pathophysiology. Thromb Haemost 1997; 78:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/73\">",
"      Peyvandi F, Menegatti M, Santagostino E, et al. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol 2002; 117:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/74\">",
"      Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002; 16:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/75\">",
"      Pinotti M, Camire RM, Baroni M, et al. Impaired prothrombinase activity of factor X Gly381Asp results in severe familial CRM+ FX deficiency. Thromb Haemost 2003; 89:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/76\">",
"      Deam S, Uprichard J, Eaton JT, et al. Factor X Leicester: Ile411Phe associated with a low antigen level and a disproportionately low functional activity of factor X. J Thromb Haemost 2003; 1:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/77\">",
"      McMahon C, Smith J, Goonan C, et al. The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. Br J Haematol 2002; 119:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/78\">",
"      Romagnolo C, Burati S, Ciaffoni S, et al. Severe factor X deficiency in pregnancy: case report and review of the literature. Haemophilia 2004; 10:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/79\">",
"      Eshghi P, Abolghasemi H, Sanei-Moghaddam E, et al. Factor XIII deficiency in south-east Iran. Haemophilia 2004; 10:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/80\">",
"      Trinh CH, Sh Elsayed W, Eshghi P, et al. Molecular analysis of sixteen unrelated factor XIIIA deficient families from south-east of Iran. Br J Haematol 2008; 140:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/81\">",
"      Kohler HP. Novel treatment for congenital FXIII deficiency. Blood 2012; 119:5060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/82\">",
"      Kasahara K, Souri M, Kaneda M, et al. Impaired clot retraction in factor XIII A subunit-deficient mice. Blood 2010; 115:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/83\">",
"      Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/84\">",
"      Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/85\">",
"      Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998; 5:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/86\">",
"      Rodeghiero F, Castaman GC, Di Bona E, et al. Successful pregnancy in a woman with congenital factor XIII deficiency treated with substitutive therapy. Report of a second case. Blut 1987; 55:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/87\">",
"      Brackmann HH, Egbring R, Ferster A, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/88\">",
"      Winkelman L, Sims GE, Haddon ME, et al. A pasteurised concentrate of human plasma factor XIII for therapeutic use. Thromb Haemost 1986; 55:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/89\">",
"      Caudill JS, Nichols WL, Plumhoff EA, et al. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. Transfusion 2009; 49:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/90\">",
"      Dreyfus M, Barrois D, Borg JY, et al. Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(&reg;) P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost 2011; 9:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/91\">",
"      Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/92\">",
"      Inbal A, Oldenburg J, Carcao M, et al. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119:5111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/93\">",
"      Brenner B, Tavori S, Zivelin A, et al. Hereditary deficiency of all vitamin K-dependent procoagulants and anticoagulants. Br J Haematol 1990; 75:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/94\">",
"      Boneh A, Bar-Ziv J. Hereditary deficiency of vitamin K-dependent coagulation factors with skeletal abnormalities. Am J Med Genet 1996; 65:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/95\">",
"      Darghouth D, Hallgren KW, Shtofman RL, et al. Compound heterozygosity of novel missense mutations in the gamma-glutamyl-carboxylase gene causes hereditary combined vitamin K-dependent coagulation factor deficiency. Blood 2006; 108:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/96\">",
"      Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/97\">",
"      Oldenburg J, von Brederlow B, Fregin A, et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/98\">",
"      Spronk HM, Farah RA, Buchanan GR, et al. Novel mutation in the gamma-glutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 2000; 96:3650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/99\">",
"      Marchetti G, Caruso P, Lunghi B, et al. Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. J Thromb Haemost 2008; 6:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/100\">",
"      Brenner B, S&aacute;nchez-Vega B, Wu SM, et al. A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 1998; 92:4554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/101\">",
"      Vicente V, Maia R, Alberca I, et al. Congenital deficiency of vitamin K-dependent coagulation factors and protein C. Thromb Haemost 1984; 51:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/102\">",
"      McMahon MJ, James AH. Combined deficiency of factors II, VII, IX, and X (Borgschulte-Grigsby deficiency) in pregnancy. Obstet Gynecol 2001; 97:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/103\">",
"      Seitz R, Duckert F, Lopaciuk S, et al. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group. Semin Thromb Hemost 1996; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/21/16730/abstract/104\">",
"      Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101:4783.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clotbase.bicnirrh.res.in (Accessed on August 19, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1336 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16730=[""].join("\n");
var outline_f16_21_16730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20130435\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4444056\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genotype-phenotype relationships",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Registries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6433034\">",
"      Definitions of bleeding severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      REPLACEMENT PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Factor concentrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H923514\">",
"      Recombinant proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prothrombin complex concentrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fresh frozen plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjuvant treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fibrinogen deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prothrombin deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Factor V deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Combined deficiencies of factors V and VIII",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Factor VII deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Factor X deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Factor XIII deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24790588\">",
"      Recombinant factor XIII A subunit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Multiple vitamin K-dependent factor deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H271758329\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20130435\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1336|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24558\" title=\"figure 1\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1336|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43740\" title=\"table 1\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/38/9836\" title=\"table 2\">",
"      Properties of coagulation factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8218?source=related_link\">",
"      Disorders of fibrinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37097?source=related_link\">",
"      Factor XI deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=related_link\">",
"      Genetics of the hemophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_21_16731="Types peripartum hysterectomy";
var content_f16_21_16731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of peripartum hysterectomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Circumstances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Supracervical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical context",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Planned cesarean birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency cesarean birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postpartum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Salpingo-oophorectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unilateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16731=[""].join("\n");
var outline_f16_21_16731=null;
var title_f16_21_16732="Radiation toxicity hematopoietic";
var content_f16_21_16732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Levels of hematopoietic toxicity following radiation exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Degree",
"       </td>",
"       <td class=\"subtitle1\">",
"        ALC",
"       </td>",
"       <td class=\"subtitle1\">",
"        ANC",
"       </td>",
"       <td class=\"subtitle1\">",
"        Platelet count",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bleeding and anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0*",
"       </td>",
"       <td>",
"        1400 to 3500",
"       </td>",
"       <td>",
"        4000 to 9000",
"       </td>",
"       <td>",
"        140 to 400,000",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        1",
"       </td>",
"       <td rowspan=\"2\">",
"        &ge;1500",
"       </td>",
"       <td rowspan=\"2\">",
"        &ge;2000",
"       </td>",
"       <td rowspan=\"2\">",
"        &ge;100,000",
"       </td>",
"       <td>",
"        Petechie, bruising",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal Hgb level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        1000 to 1500",
"       </td>",
"       <td rowspan=\"2\">",
"        1000 to 2000",
"       </td>",
"       <td rowspan=\"2\">",
"        50 to 100,000",
"       </td>",
"       <td>",
"        Mild blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;10 percent decrease in Hgb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        3",
"       </td>",
"       <td rowspan=\"2\">",
"        500 to 1000",
"       </td>",
"       <td rowspan=\"2\">",
"        500 to 1000",
"       </td>",
"       <td rowspan=\"2\">",
"        20 to 50,000",
"       </td>",
"       <td>",
"        Gross blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 to 20 percent decrease in Hgb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        4",
"       </td>",
"       <td rowspan=\"2\">",
"        &lt;500",
"       </td>",
"       <td rowspan=\"2\">",
"        &lt;500",
"       </td>",
"       <td rowspan=\"2\">",
"        &lt;20,000",
"       </td>",
"       <td>",
"        Spontaneous bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;20 percent decrease in Hgb",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALC: absolute lymphocyte count in cells/microL; ANC: absolute neutrophil count in cells/microL; Platelet count: platelet count in cells/microL; Hgb: hemoglobin concentration.",
"     <br>",
"      * Degree 0 represents normal reference values.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Int Med 2004; 140:1039. Copyright &copy; 2004 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16732=[""].join("\n");
var outline_f16_21_16732=null;
var title_f16_21_16733="Causes of dizziness";
var content_f16_21_16733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of dizziness in different clinical settings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Kroenke, et al 1992",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drachman and Hart 1972",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nedzelski, et al 1986",
"       </td>",
"       <td class=\"subtitle1\">",
"        Herr, et al 1989",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary care",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dizziness clinic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dizziness clinic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Emergency room",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Patients",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        2222",
"       </td>",
"       <td>",
"        125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Average age",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Cause, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Vertigo",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        54",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        46",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        45",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Benign positional vertigo",
"       </td>",
"       <td class=\"sublist_other\">",
"        16",
"       </td>",
"       <td class=\"sublist_other\">",
"        12",
"       </td>",
"       <td class=\"sublist_other\">",
"        17",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vestibular neuronitis",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Other vestibular",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Central",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Migraine",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nonspecific",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        10",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"       <td class=\"sublist_other\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychiatric disorder",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Presyncope",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disequilibrium",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hyperventilation",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multicausal",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unknown",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Kroenke, K, Lucas, CA, Rosenberg, ML, et al, Ann Intern Med 1992; 117:898.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16733=[""].join("\n");
var outline_f16_21_16733=null;
var title_f16_21_16734="Penis aspiration";
var content_f16_21_16734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Glans penis aspiration for reduction of paraphimosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 218px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 20 gauge needle attached to a 10 mL syringe is advanced parallel to the urethra. After aspiration of blood, the foreskin is reduced over the decompressed glans penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16734=[""].join("\n");
var outline_f16_21_16734=null;
var title_f16_21_16735="How to stop a nosebleed PI";
var content_f16_21_16735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F62213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F62213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    How to stop a nosebleed",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 337px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFRAPoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDswlKVqbbzSEV8qz0SHbzzUoFBFPUUgFUVIBxQq1KBTENAp4FKBTwtO5IgHsKcBTgKcBTEJinAUAc9KeB1pgNAp+KUCnAUwGbacBTgKcFzVCGAUoXFPxS4oAaBTtuaXFOC0wGYpQKftpdtADKY44H1qfHFMkA+X61cPiQnsZl87MRH5OSehNZFzbTtcTPaSCOTOMkZrqSgPUZqs0cUDFyD8x6AZ5rpqxk7crsQrHMWejs1z5+psbqXHCj7o/Ct/wDs+JiHEaxnHG0dKsiVAfkjk9OExUyHcoOCPY9aqNNLzBsgjgWKLaPz71nX1sssLKp4z1xWuwIUkDcfSoCHwQsCD/gVOpDnjyiTsYdvZyofnZSOwAqo6zb26dfSukNqJFBlXa3+yaZ9ij/55n864ZYWTL5iiVppUA1OR7UxlHtXMbEO3mnovrTtuTUijFIGxAOKkVaFFSKMCmIQCnAUuKcopoQgHanClpwHNUAAdqcBQBTgKoQYpwFAFPA/OmgEANOAp2KAB0piEx9aXHFOwKXFADdtLWNrXiKy0zKO++UDOxOcfWuPuviYYJSv2EbexLEULXYdj0oClArjfD/juz1IYuI/s7g45bIrrre4huVDQSK6+qnNMRLimSdV+tS0yWFZV2tnHscVUXZ3BkYySc4x2pCQOpH50n2GDuHP1c0osbYf8ss/Umuj267Ecg0ug/iX86Tzox1kX86kFnbD/lgn5Uv2aAdIUH4Uvb+QchXa5hH/AC0X86YbqD++Pyq75SDoiD8KXYB2H5UvbvsPkM83kOeCx+imk+2R/wB2T/vg1o4oo9u+w+Uw2HtTcVMRmmFcV55qR45p6ijFPUetIQKMc1JSCnDrTEAFOApKcBTQCinrTRTwKoQAU4UgFOUUwFAp68UCnY4qrAAFOAoWlYhVLOQFHJJ7UAVdRvbfTbOS6vZVigQcsf5V5z4l8aXN6xTSyba0Cgln4d8/yFZHjTxLLr16Y4GC6dCxEQz99h1c/wBBXHX91CskUEUrNsXcxXkDPQe5renS5ldkt2NXU7mQxfvJVjaQ8kHLVl7CVEMZCp1Z2OS5otrV55RJIxcsuSByR7E+tSz39tOqgQOGT5QAOre9bOnYFMvaY6W0YAbgc5IrWh8RXOm3YMDyknAwT1/CuSiv3lLw/JHK56k5Ax2q/byTOiMFG0ADcw/rWTp66l8yZ6nofjKWeQRXMOZTznOB/wDrrtLC9ivYy0ROV6qeorwWzNwHLW2cj1PNdZ4a8StYXBkmYucbWjPf3zWbjy7CPWKWqelajBqVss1s2QQCR3FXKQCUGlooAbikxmnUUANNJj6U4ikwaQGOR3ppH51x5+JOgIv717iM46GMn+VSW3jqwvP+PG1u5/faFH6msFFvZFWZ1RBpVrlp/FyQqXeycY6r5qlv51r6DrdlrdsZbFzuU4kjYYZD7ihxcdwNWnYpKdSQBTqRRThVCFHanimgU7tTEOFOUc01aeOvFUgHDHFOFNFPFMBRXAfF7xCml6OmnpMI7i8+8e6xjqR9eld87LHG8khCooySewr5d+JXiIeJvFc95bMVtIB5URPdVPXHua1o0/aSsJuxnXl/IQkcZJVV78YB602zuZBG08yYTJzxgn6VmwxyzOJ5mUAnuepqfEl1IEhlViv3edqqK9JQSRjc3VvpGhAANvGrZUZxu9venNMCsYlxAhO5lUfO4HWsEXEsdwHy03lMOUU4pBDd3JSWaZ0GcbejHPap5Bm9LdpdIptwwiZxvKqMqvt71ppp0A1F41nZ4JBlVLcA1z9rfNCjRC1UITsyTjBret7S3+zoWmc3cnzMU52Ae9ZSVik7mzdadHbW26JWEi52jPymsOLUZGdiVYupxlh0+nvV6a+JtmWaSSVojtPOMj1rMl8rdiN1JPzZwTgVk/MtHqfwx1R2ukhIxG649/qa9OxXgvgC4FlqsUxld2TgAdOfaveIXEkSOOjDNYNWYx1GKXFBFIAxSUtFADT1pKcRSYFAz45aZpo2LdRWr4f1B4sxnNYsYwzofWrek8Xqqe9dXKki73Oyjud/3sc1Fa6pL4d8R2mowE+TIwjnQHh1Pr9OtMntzEAwz+FZWuvutQD2OazavoJH0ihDorKcqwyD6inqKxfBM7XXhLSZXOWNuoJ+nFbFxPFbRGSd1RPU1yRpylLkirsltJXZKBS4rJj8Q6fuwTJ+IxV631m3kz5IUe5r1aWS4iWs/dOWWLprZ3LqRO3RTQFO7HJ+nNIt5uid89FJpumyNckRQ5Mh7V1yyqlRpucryt2MliXOXKtCXbgkEHj1pyrV5dHvSM+T+ZqzDoVyxHmFUH1zXjujOUvdjZHYpJLVmUPatDRLRL5xLlXt1baSDkEjtU2t6XHaeH79lLGfyH2v/dO08itTRrSDTtHsobJQtvHEqqqjjGOtb0sK1K8yJVOx8weK/FniEz6/aTNdrbxzSWj7kATBJHy/h3ryOUyIBGDnDYPFfVvxK01E1i4V41aK7j3jjjPQ14hqvhG4a4xCox69OKKVaNOcotHROk5xUonDwts+8h+bIWuw0HwhcXdkLq6nj061YjDzgln+iDmtrSvCFtB5Mt98zxnIUdOKd4h1JBc52yMV+VAgzsH0rLEYt/DTOnDYNNc1Qw9X0668P3cSmaG4hmXMcyLhW9vrWTm4k3kEFgQcAciukmhnvtJaOcOQZA8QfqP8KwiUtZNgz5icFgehp0Kzkve3MsTQUH7uw2GznnnEly6qAcgBcmuihfyiBEn7wqEwe/rWfYRylPNLK6/wsTzWlaQxwnzpXJLDP1NaTn3OeMb7FZpzPO8QgLMFwxHAOOtV5LQLalIN4LfNxW7DbpEpbgsePw96kuTHbxcj6YrknV10OynRsncZ4Hs5mmSQ4J3fdP8AM17fYXhiSC2Kxlwo4MgDY9cV41pOoC0ItVjIkk+dmPG0dc11MOoX2uzE6daYAx/pD8dPSvpMNl9OcLzWp49evKMvdPUlZSOCKdWXYSzNHGl1sE4UbyrA81qDoM152NwKoLmi7o1o1ufRiGkp1JXmnQIaT8KUmjFAHxo+HZJEIII5xUiv5V1HJ6EGuxj+E/iC3XavkuB3WQVGfhX4nuHxmCJP9uQV1c0HopaDTdthtzr1p9mXDZfHaucu9QS5byYkMk0hwqjnmuxtfg1qrkfa9Tto177QWru/B3w10vw7drdvI15dr91nXCqfUCpc6cetxXZ1XhPT30/w/pti3+sigVX9jjmtm9WwNoI77yio5G7rWDrupPbxG3tGInbuvWq+neHXuIxJqBuHkYZPzYA/rX0GWZf7GHtqjtJnmYnEc8uSK0RT1y58PW8L7ISzeu6uHOrYm/0SORVJ425Jr2C28I6LgF7IO/8Aely39avjw9bgYhjt0X08oV7Ua9OGmr9TicGzy2w1+/j4EZZDwQ/cV1uj+Lhbx4XSsE9SJP8A61bN34YjkO4wxH/cyKu2Hhq2jQGVApqZVaUlqgUZLYdp3jMyADycHrtY8fnXWaRqB1HTku3i8kMSNpOe/Wufj0mzhcMkYwOTmpdLvGSWUdLZmwBj7uO9ebiaUJRbprU66M5J2kzo7oCeCSKQfJIpU59xjJrB8GXnnaELSSTfPZFrWQ9yUOAfxGD+NbJkCr+9+52Of51wN5P/AGD8QHfdtstTjEmCekq8Hj3X+VePJ6nYaHxCshd6XHOgzJbNuyB/CRzXk93IVc4+7Xt90Y7u1dVw8TAg+mP/ANVeNa5a/Yb6a3kwSjcH1U9K8rGQtJTXU9HCTvHkMlpC6tn0xXK63pwklia2ZxI77JHHO3nr+VdaiCUMnQGqoRnuT5iptX+L1rkba1R6MZWjYmi06NgjqCFAAHvXIa74Vuzd5smV45Gy2TytdyLkAYBGFH5VHLJ5nK9fWppVZUtUYzgpuzMKz8NwWduokO6QjJPvUn2GOMkRgZ9at6i8iWrPGC5UZwK5ObxXbW4AuVeN+vA3CqUqlXbUOWMEdQkGFHqeaqx2Uk+pqwBaOPJZj0z2Fc/aeIpdUn2WqSJDnBlIwAPb3rvNCt5Jol8sBIhxvY8f/XpR9pRmpPdGjcZwa6Mu+HoLSK5ZruESyS8Nu7j0+ldQtjCGDxKQAMKAeAPSsq2srSGQPtluLgdGJwo/CtFPtZkDSgLD1wKpYmum2pu78zGVKnLRpaEss8du6tGio4PzugycfSn6X4mVpQsrq8THh+mef51kzTESl40ZRu4PrWdcon2xIoQis0gKA+rDoMV7eXY6WKToVtdNzy8Xho0v3kND1RGDIGXlSMinDpUNqrR20Ub/AHlQA/XFTCvPaV9CkMPWjBpxHJopDMgjvTaJZEjQvIwRR1JOBVY6hZl1QXUJdug3jmuUonNV9QuvssBYDLkflU7uqIXbG0DNcmt4NX1eUKS1rByQP4z2Fe3k+B9rL2017qOPF1uRckd2XbGAM32m56k5Ge9dLaazGx2eWSw4471l2tj9obe+7b24wK1YII4htQAe6ivpZSvueclY2orhWUMOMjpVgSBlwOBWKi7esuf51YWVYwW+Y47k1nYo1VlBcIvJ659BUrkEY54rGgklDbtreYxyeOg7VfRpNh3NuPvSaAbeSMsTLENztwPrVWLK4jX5WUdD396h1O4MC/Jw3qahsLlrpcTcMD8p71QG1FO2zy5SQo5BPY1ieNrM6jpBnjXdeWhFxDt7lecfjyK1Wfy4dzsMDjLVRlnyWU8Dpj1rhrYRVHeOjOiFWyszM0zUGSCKSF1a3uYxJG2c8+n8xXD/ABCLPDHeqfnU+XJ9Oxrp00mPTEmitZJEhdzKIychGPPy+gz2rl/EV9HbeZFexN9nkGGYDK/5zXDWwU2rNXOmjiFCXMmc1aX2V55OKYZs7hnrzWCt5BBfeQk6SZ5XDdRV6V9yZBx6V5c6HJoz1Y1FLVF7zsHGetPjudvAaslZTnPOPelRiWB5z71wzgbxNCa9IidcZGK8/ns1v7uQ7OAcnFdfcvtjYdWIOBWBYoYomVJ2MjtmVdmcfQ9qqgnFtx3Lkk1qdL4Tsrf7KEmQeUDlUx19zWydZktZRa21q08p4VV6VleG9Nv9QuxaWMU0gUZLAYCj3Jrqta8MarokNtPYqZ3YnzREu4r+PetVQ5k5yf8AmzCVZRnyI0La/bSIoZtSKSzvy0a/dj9vc0/XfGsX2eOK3fLyH5IlGWY+wqjZaHcmBbnxHOLCx+8Vc/vJPYCoIX0i18QyahFYpb5QJDnkhR657msHCy1KUlJl+O4ne2H2qMw4XeVPWul8L6E0TLfakAZ87oo+uz0J98VW0rRLjUL1NQviUg+8sR6t6Z9q7EfStsNzUk2uuhx4mSm0uwopaaKWtTEXNJmkpc+1AHnPiPWYbixeFikRIJwXHNYU+pW0FlaLpsFvd3c2xRErAMGHevJ5JGc5kkdj3JY16L8O9CSytf7avF/fOCLZWPQd2/HtXTgsLKrNJfMVZqnFybOy8Rao0OnpC5Ak2/PtPf0FT+BrOM6Ylwch5WLsMdugrgPE9/Lc3CW8GWnlcIoHvXr2k2q2ljBDGuNqAGvrvZxoUlCOh4vM6knJl5mVcLnA9KkiTcoC9KgKBl46+9SW6yKdxbaO5NQMe0YX5icYqWIZZXmGAOVX+pqLlzvY5A+6P6mnhiT82SKQE7XLOAF4FSRMI498jFVHJJqDgYAHXpVbxJKY9MMMbhHmIjyew7n8qaQ2UZ7h5ohM5AMrF1BHQdh+VV0uWtpUOMr39xUNxf29xJFDbyAtGuMfSku1LRKcYFOxLLfiHUvtFtEkalQWB61PZT/abZHJycYb61iTK0jRL3HNX7ImORgFI3KeP9qhxshp6l69ga6tm3EKy9CDzXB+Io5IoZlckg9c9676CQkqzcBuDWD4msvOhkAHNQ9Ck7nz74lt/KlElvGiS5yHA5FWfD+qm7j8idgJ0HP+0PWtPxFZYdt2eK49ka31OKWDOQCDXDWoe206nXRrez16HaM/Iz0omuo4UOT83bA61Rt7nzowP4vSonWQygg7mzwtfMYilKnPkkj3qUoyjzJ6E2nXUl5qy208LQK4O2Vjwcdq9I+HHgyOdpNT1SINEx2xRE/e9zWNoGgwf2et1eAvclsgZ4T8K9i0yIW+nWsSjAWNfzxXY6P1elGdrSZw1a6qScI6otQxRQKEgjSNPRFxUoJB4NMFOFc1zM8w8SeEvEWqeIpLrzkki3nymd8CNfQCui0DwZDZSLPqcq3s6fcXbhEPr711w6UUuVXuaurJrlClpKWmZBRRRmgYUUUUwPlbwho763rcMOM20ZDzN/sjt+NeoeI7xbK1bbtWNV2xqOwHaqXg/S18P+HhJNxdXIEknsMcCuc1y9k1C9EMQLFm2qPrX1+XYX2cbvfqeVi63PKy6Gr8PLD7frE2rXS7orc7Yge7n/AV6nZXj+Zh1yg6kdqxvDWjrYaZBbg4RBlm7sx61vpAXUL/AKuP0xya6KsuaVzGKsi39riLbYRk+1ISZ2G0/IOx7miO3PEcaBUP3j3rQSFUjAAAAFZ7Dtcroh/iqRRhvYCptmOvWmMOGwe1IYyFd0+ewPFcV8QNSkOpw2yH90i/Nj+8a7CNxF50xGAoPevOpUkujcTytuaSUuM9s9q2hHqS2VNMuVXUFIOCprq1dn3Fz8vYdhXnTyG31DPTmu1a8K26un3WQE5q5R2JTNCzbfehs/KoxU17qMNs4aQ554wOlc/NrkVjZbgd0z9FrCWe5vLhJbhicsML2FZ8vMyr2PV9NCTIplXIPYGquooryyIvK9ADU+nPstlY8BVyaybi6O92B57Cs5IqJ534t0/Y7sBXn93YOs/K/jXtusQxX0O4AFxgkVzV/wCHxO+U4asUrSuW3ocLb2Jwp7itnTbRUlU4Gc9cVux+HzFGc7i47YqvBCFmKr9K58Q1zGtK6RtWrAWcaj+Ntqj3Jr05RtAUdgBXnWhQLPq9rbdUiw5/DmvRAc15OYvWMTpodWSA04Go6UcCvONyQE0YpgNOzTAWlpKM0wFpaSjvSGBo59qTPNHHpTA8R8Tak8kjRq31xVbwDbQzeIhLcjcIlLqD0z6msy8Ys7MeSa2/CFn5gldhlndUUe3f8K++qNU4NI8GCvI9Ui1COO3MpKhOxA/lVX/hJNLY4leVWHcA5qWDTYLpUF0gcKMKuakl8M2BGRCiD2rng4L4i3zdBsWu6XIPk1Io3bzFqxHqYf8A1Wo2Unpltpqva+FbBJAzxeYOwPStU6HpaKM2UHA/u1TdPzFaRAuozZw6Iw9UkBqSS+iwThwcdxike30y2XK2UTD/AGUzimx6taRb/LjTCDO0evpU2i9kPVblHUrvdatEeBKNvp9a5a9iNrp0uOcMCPpWDrGsanNq88l+zozOWSLPyoOwH4VbXUXvtPmgd9zbDtro9jJK/Qz5lexzmoTiXU1K4yBzinah4gaC1+ztjyweoHzVzF5qZtwGiUyXLnCqP1zVrR9MlklF1qsysW5EYPArdwS0Yk3ueh6DocF9El68jTCRRtI6L7Vt/wDCOucGIqQvPpXP6JrUemokcRAjH8NdSvjTThbt+6kebGAoHDH61yzhJPQtNNamlqk32XT0jzhn/kK5trkhi2eT2outSlv1WaVQhIwFB6Uy0tZbhlAHU81zVJcqbkbQjfRFixR5roKqls8YrYksETG8qMVe061is4+B82OSaq6wrywN5IJb2r5fGZvO7VDRHsUMDH/l4QxX0Fg7ZKZKkbsZIrib6VY7yW4eJkWRztBGKhj1iaDWT/aNvuQHAQHBB9a09TjstXjQw3UkDg5xKmR+YrxP7VrUZ33b6s661CMkoxWgvg+8gttUlmu5Ng2YUn1Jrv7a9trgAwzxv9G5rzu10l41kxd2TswwP3uP51Xk0i83bomg3dmWdQf51NTN6lafNUS+Rzxw6grI9WzSg1zXg/8AtNbZ11KWOVAcIQ4Yj2JFdIOldtKoqkeZGclZ2HAinVGDinZzWohwp1R8E07NMB1FJxRnFAC0U3NGaaGfPgiMs5A/Guy8NRCG03cBVJJNVINJS2UouWbucdavW9rNcmOwtflB+aV/7or7iq1LQ8OOhoLrEhlWKxDSS5xxzXQLq0tnZg6gVaftGp/nXLvcvpLG20u3G4jBm6u/+FULix1GVDPfXSWcfUl+TVRpprXREubOpn8WqAc4Qemaxr/x/aWwbzbhBjturjhd6RudB5942f8AWu3BPsBW/rvh7TGWOS1gVC8asVx3IqnCnDdAnJlq1+ItleR7YnUvnAy2Kk/tE3SiRJExnJ9fzrzrU9HtIw48pfN/hUDkmq+hPrGiQlLyGSe1YkqVXmP2NUowfwA79T1e9tLXWbEo7KtwB8j9wf8ACuLtbTVLK+CSwOVzjzF5X61AdP8AE2u2aS2kzadFnIhH3nH+0e34V1+l+G9b1LRHtby6hgLLsBVSTjvzVwfsk02JrmPEpd/9pzu7AorlQV6detdp4e0jUL9FMFlcyoejBDivYPBvg7SdL0ySCewt3YONxK7skd8muxjdQmyBAqDgYGAKynieXRItQueInwvqcSlnsZlA5OR0qTTtOkkuliigZ5TxgDkV6/dRnzCACyOMFc4z+NVNNto4PPm8rZMH2vu7jtzUPEu2oKnqcfa6LerJ5U0LJt7t0NdDb2iWkWMjf/e7Vc17VIkiiI2iXONoPaudu9Yz8pNfG5xj6vO6D0R72Bw0OVVFuaUswP8AGDVY3scR/wBYB9axJdQQqeefWqM1/H/E3NfP8x6fKdFdrYamvlzxxuT/AB4AI+hrNm8NiJgba5UIf746VjPckjfHOEA71l3/AIse0gKs7yAcbiKPZqro0NKx0Nzo1ykmFeNxjqDVe006drpYnjIJbArA8M3+q+J794LO48sKhYtIDgCvRvDmhXGnv5+oXfnzjO1VGFX/ABNUsvVzGrVilbqb1nAltbpFGAAo7VPmmA4FLnn2r04pLRHnD+9LUeaN1VcCTNLmo91GaYiTNLnios0u6i4x+aXNR5o3GmmM5OSDcMgDOKhjnWzsJjHjcx5b1NOuHYRyJyCQQK5DxZq8lokGnWSGW7k+VEHdj/SvsppuSijxYtWuamo+KrPT4UFvAxu3HA+87H2HpWSmi6t4gb7V4guBa2eciHdjj3NVdKgg0e8MeVv9bkG6aVuY4fb2+lXZZvOuBJcu08nq3QfQVu5KHqRa5duotAs7YwW0UlywHWNePzqvbz3mpRSRszWCDCrJIucr7HtWlp6RQjMqFmfoFGa0kjURN9pkSGI87G+8fwqOa+4C6T4dsraJJU23MjAEy7txNN8Q3EOnwpDFayTyOCxWIdFHcmqwKabG0unPPHI5+VTghz9KWI3S3VxfajtE0kIjVV+6OeuKtR15mF+hP4a8W2JHlvYToD1bIb9K62HWrVkLw7GQdcHB/KvNdJj8jWXc4Ct81diyaffxkb4xcAYBU4YVnOUW7lRTSG23jWINdQw2T3dxG5YohAwPXms+6+JF8ylbSwt4n6ASEsR+HFchNbzaF4sRxI7BuAT6GtnX5bO7m/dxiK8VdxkH3T9RWrUHbQlNmnH4n1uWGOeW7iVieI44wB+uas+J9Une0Ui6nVnGXRCABjr71xtvqYt0H27gQsW+UZ3DHGKv6pqFvJpRvSduBxk9jWM00WmV9V1JYNPie2V0ZpMvI7ZZuOKxptTldQWfr3qDxPfxWehWkzM8qyygZGMdDXNJqyTR71hkVB/Ea+ZzTAVK+Ic4o9rBYmFOioyep0smovjG4nHU1Xe+mbjdxWEuqwMcYYMemRUF3raxWjyiM7gwVQe9cVPK6kuh0yxsF1OkS5J+/IdvpVxJknKRWkSySMQPmHFchbaq13GuxQFb05Ndn4NYR6lbPKoZA4P0969Clk6s5VOnRHLVzDVKH3nWaFpsmnAuzBLo/eKDAHtXbadOZ7VHc5bofrVGW0+0XLSRyII25OOTmr9tGsCbAc98msa8qLoxjHdGUedzcmWc0uciotx/CjPvXAakmaM81HupN1MCXNAaot1G71p3AlDe9PDVAGpQeKQE+aMios07dVAczrYMCySjoqliPpXnlhaSTSXGpSyhLqUkK56on+z716Tq+JLaTOPmUjFefTpwsan5F4+tfac9lc8axXt0jhzDbDhjudyclz6k1pQCOIB3wSOgNVVCp90YNHzSthTxnqelTzX1AvPqNxz5OEz1bv8AhVy3KQ4ubx+SMhXOSf8A61Z0E9varvb99IDxkcVFKzXkxmlXag/hJ6/WtE1Fakas3IdUAkacqCxGFdh0HsO1Rz3jXFtK4OTkAmsKd3cYFalusYsx+9UHqVrOVRyLUbCpGy/OzfMRVSO6aOXep2kHg1PLdRKDvkVM/wB41kT3EaFmMqBR3LDFLVu49jcvmGrxxOcfaojwfUVj+ckkt0UkVpN+G56Yrmdd8VJBbyW2m5kncbTKDwn0964+0iunyBO0SsPm5PNbJaWFbqd7f6vawTIHmHy/3Dn8KybjxHdz201lZwKYJMqpdckA9qoW+n2cEe6SUu9bumLDERJNtjBXKg8ce9aKOmoupHp/hieVLc3d2XtUQmON+QrHvipb7w5Bt/eXZ2jnaowKi1DxbZ27eVbB7pxx8nQfjWQ6654gcGNDb2zdh3+prmqas0jcbeNpliSkSm4mHTJ4rJnjOoTK00gVRwFRcACutsfBbkf6RIPfFa0PhWCFdseS3qazS5R8xyOkadHExWKRwW7kZxXfeFbQ2kjzPMZWK4UMMYpLTw2I2Umt+DT0jXap+arSurMV9bmmt+IPLZX2tnJ9K149f08qN9zGG781zsFlIZRk7kx0rc0rRrTzM3FpC0uPvFa5K+Co1V7xpCtKOxci1exl4juYyfrVtJkcgJIpJGcA81IthbxtuWCJV7gIKhv9MDyJcW4WOZBwVGOPSuT+yactpNGv1qS6EuaTdUjqBAryfI+Ofeq5YGvJr4adB2kdUKimrofu5ozmoifegHmucsmB4pwPSog1OVqAJgaWo1PNLuqgOWu78C3cSg5xwRXEXjuk37oAD0auguLhVzv6etc3fyh5WIPBPavsNdjxyvLfOv30GPVTmqh12xSby55HV842spxU5UORnkVjeJLAPtlQfMO9Ceths6A6rZA4eeNCP73FWBqNu6YS4jYeziucsnS8tVS8iDdskUx/DlixLKWXd0CjpV8pJuT6tZWylpLiP5e2a5rU/GNzMTHpcPy9PMcY/IVo23gdDiUEOuM/MKvJoEMJAKrnuQKuMYhc89vZbie6Rr2SR3PO4kgDPoKuR6U87l2d/K7ZPWtnxJFbtPHbwJuPRziq1lvgaSznOGHzIT1I9KtRutA5itFaRiURRITg84Fb1lp6lcTEKScBQOntV7QtPW2sXu5UDO5yrdcD2qdRHEyySOqKOeT0zWiiS2ZV/pxtI/NFs0wXkFOv5Vi6zYXl1YRXbZSFjsZAeRn1rqNT19oLcDTYDO78BsfL/wDXo8OW0l24fWHOWbAjbhV/CpurNDTd7mf4L8JJcSCW4X90vIXHX/61ekLZpAiLHGFQDGAOlX7Gyit4gIlA47VJcoRtx0rmvqWZYhVzjbg1PFagNnHHrViKAl+BzV+K3AOOuKGxIpCBsgLmrFvZF23KATnrVmKPzJfKQEgffI/lWtBCEwqjgVMpWGkQWmm4IPFbENqowSckUkSAVZDKo54qblWFESkYIzStECOaBIMZFODAjg0XGZ9/FvTaenaskK0YKk9Olbd9xFuA5HasmeQGP5hzXJjaXtKbRrRlyyIy3NIG4zUZb3o3etfMnoE6sKerVWDZp6vTAsg07NQI3NO3UxHmN2QEPzk561lnLrjip55fpk023t2kAcnAz0r7OSsjxkNij5znPHep3sPtMLKe/Q1JHHg9OladkudorKxRx9vZPAzxYyKu2sKnqea6G9slF1uUcEVmQW+LkrjvXSmQzooDHFpaPI2F29a57UL6KaNxaZY9N/at+4sVu7OJGJMO3BUetQroC+UViGxR0HrVKOgXOQ0zRjNcebICSTWD42jktfETGKM4RFC+hNeoRwxWERa4KoRzhjiuH8T67pdxOY4IRcXXXzM/KPxrek7Mlm6IifD2mRoQGeFF/HvUh0S3aZpHXezAcMfSqehrcXOnWzS43QgbVX0Oa6hEDhPpioqSVrIFuFpYW8VqA8aAD2qhcWInRzHHtVTnd3NbFwpIVV4xTWIRQucDvXKrmjKOjai9u/kXOTGOjeldX5aSxqykFSOCK5i7hjeMlQN3rTtJ1GaxkVHBeHuvpVN8wlodHFAYz61K68hV+8fvH0qUzI1urxkYbv3qBmBBCHHrUXKsW7MQxOqbsE1qogArnUIVxn161t2k3yjJ4NTLXUaLakDvTJDmkZ1GTUHmhpMKRj0qRkwkwevFQz3ZjUlGwajnkC/xDnvWNfXRZjGnQ9TTQjas9S85jDcBdw6MO9RalGBC7L16isKFtrDBwR3rSF2ksZimkAJ6HNOUL7BGVipCzZIAymOPapN1N27BtPWkzXy2NlGVV8p6lJNRVyQNTw3HWoAacprmNCwrUu+olb1p2aoDyvGTmp7RyJCpPBOKc6bAc1HCT5h6da+2aueGXgCCw9+tW7Z8OFHfnNVIiOp4qxERuHIwKxKNsxBogSMkVjXMQS7Jx71u2ZWSI7ear3liZ1yBhxzVReuomJpE+0+W33c8VvtHFHH5rN+Fcem+EsrcEetWJNRm8pVZ8qOK3i7kjPGmnprensA2yZOU9/Y141HAYrhkZcbTgivW2vgrnc351w/iK3j/ALUeSEAI+Dir1ixXub/g68WMLHJn0U120agnGOeteY6STER168V3mkXpl2Bz8w9azrR6ocH0NpogR2qG7t1KZxyO9XVAMec802RCwOeayWxZkEYUcDOaRVRRuarEy7Tg9Kq481sKflFC0QmLBezQShl+ZM8oeldHp80F9GWgO1x95D1Fc/tUDGKYvmW8glhYq45BFS3ca0Ni7keFyjD6VNpV4ysVc5U9B6VDBqUV8ggvFEc/QP2as9i9tebXPHY012YXOvnuIwg3SAZHTNUHkRGLwzqD3GetZ80JuIRIDllH6VmSo6g/zpNWHc0rq9DsfmPHTFVS2cEE5NVkPyjp9anXAXPQDuaGkA+Riq4HXFZs5ffwxI+tWLicBgFNVm+tUpCNnSpTLbbGJZ07k9qtbvasjTJxBcBux4IrZnQI+B0PIrwc2wvJL20dnv6ndhavMuR9BgPIp4PpUWeeKdu/KvHOwl3cU3f7VGzfjURZs1SAxIdJabPmqQO9U9R01Lbc1uDwea65mAkMYHQ1Qu4N7yKfumvt1fc8NnJxrlMMeQeKnVVUElwB60l1H5Ltu4HTNZs84B2g5AqnTu9CUzodM1KG3kCyyDYe+OlXLzXYUyLf5vfFcSbgADHWmNNI5AFWqaW4OT6G3eao0zbpCox2FUprw7SQc5qisUsn3QTV6HSp5AMqQKfNCGwrNlKSUl8luPSqeoxecyMO/FdInh9nQFjgD9abPpOxwI23Adq0lOMo6CSaZjWtvtAx1FbFlIYZFYc4qWKyIXBHzetRzW8icqORWPN0ZVux1+mXKzw9s4q1Gw3EE8GuS0m+MMoVuAeua6xFVUMmcjGR71k42LTuV7y3EuArYOeajSx2JweDVtx8m4cGn2770wfxqWrDM8W7gkdjUwsXkGAAPrWgoXkenSpomBAyOelSBlvYNGAsyZB6EVWu4PLjDOWKjgE9q61UDAI2CAKjnsEmQqwHIpRdtwaMPSJfkMZ6Y6Ul/GUyygbcdcUx7WTTboEgmEnGfSr0iiUbTjGK0VmIwjuCnmkjeTGMgA+2atTQGGQ7ufTFRMOeMYqWMolNjkv83+16U0+g6fzq/wCSXztAxVGZBHLj+EfpSGOjbDDFdFbkz2i/3l6VzJIABzV6x1y1s/kd9x9u1Y4udJ0nGo7Jl0Yy5rxRp5waC1UF1W0kYkSqM9ialF1E/wB2RT+NfIaHrE7H3pmabuBPUGk3D3qkBbvoZXkLQsAw5qG1u7af5JnCy5waZNfK+VRhg/rWRe2Em4yQ52nnPoa+2UrHiNFrXfD098Q1nMm3qR61zFxodxbZ86NzjuOlbllq09u+xiSR2NblvrEE4AnQZ961VR2sTyo4JbPCj92c/SrcFijY3DFd39itbnLRsoPpUEmleVzsH1paSDVGDBbwxgYAzVsyAABBV5rRf7tNFqgI45oVNIOZlFTIWP8AdqZYFIyoz9atNACPl609IN3A59a1i7aMhme1uCSQPl9qPsW8/KM1rrAAuAMD09au2tsVO9E7UppbjRx19oM7x74lAYc5q1ZXDwbLO53DA+Vm712LDzIyCKzxp0Vw3lTocL91u+KyjLQtoqRBihDcgdPeo7Y7ZCDxW9BZwRptTLY7k1kXtq1vcCRATGx/KofmO5Ip+fGe1OiYgKCKh2/Nk8elTQknCtS6DNPdnbj061IJCMbuRVdCqjBPaori48teKyZRNe3sKRMJEDrjoa5yG8ZJy3Pln+H0FF3PvJ7j3qqu1264FWtNhPU1plDxhlIYHoaoiPDc9M0y2uDC+x+Ys8+1WpgqsM8gjINXuhDbhhDHuDDnsBzWFdzKgeRsgVeup85GQB61jXg84qF5XrXDjcQqFNy69DajT55WZWTzbuQjJA9KouCM5GMGuj0+28rBPNYuoJ5d1KvvkV8pUqSqPmk7s9SEUtEUyeDTdzA8Mw+hpW7+9M71CRZOt5Og+WZ/zp39pXn/AD3f86qE03P1p6iOhSTHKPjFaUOrSqqrIAyjiuWWdlHJqxFeEAccV9kpNHj2Nu5SO6+ZMK/bFZkjTwE5BIpY7xSeTgipJJvMTOd386tTJcSS11gwkfMUNdHp3iHOFmIZfUVxkiREknk1GGkU4hG2rU+5Nj1OG5s7xcI6qx96V7PD/KAQe9edWlxNCwYyc+1blp4lkiwrEMB2Jq4z7MTR0ctuYycgZqe2gY4IXHvWXb67E23CKCe55q6urKVGW6+lU2xJI0khVGyeT3NWdyJjkbaxvt4bBB/Kpo7lCMNz9KE3sw0NFtok4A2sKGReeOKpiQuCp4A/Spoplfhj8w4IrOaa2LWo/G0cACiSISwsD9RSzHKfKKSJsECpTugaMiTAYjvTAMP6VNqURS4BHQ8iovvVpe6JtqSySgKOee9Zt5c9QDTb+cICBkkVlSuz85NZ3sWDzEg5bk0seOB0FRbOfpQjkNxUtjsWWVQc5p0V2CGSTJx932qs78gc1Ulk2yhVOXP6VnUrKlHmk9Cow5nYnkAd8nk+/SnQwZckinRjgc1chUdT0r5bFYmWInzPboelTpqCshRGAnpWLqmnvPOZIyORW9IRs46VDEcsRXPFXdizj5dPuFY4XOPSoJLedesTflXbNGpzlRUMlvGf4cVfIFzh5A69UI+oqEuc9K7aSzVv/r1AdOTPRP8Avmm4sLnPCLoDUi2xJGKejoo7k1OGduhwK+tseSMW0UAlmx9KCUjGEJJqUR5PLZNL5YHBHNJAysQeSD1pDIwWrTJxURjGSB0IqiSs8rjrnFROd3POatvGfSmiPJoV0MhivJY+N2R6GtCHVXOFY7fSqLw96YY8H3xVqbQrHRwahIoHOR7Veh1JsAKea41Lh7d8AkrWnbzrL9xtpqlUFynYQaqxA3nAFXRfK37yMg461xqsy4JbIqxFchGJGfetVOMlqTZo7W31HedsmAavRPkjBBzXCxX24Zzgr/KtGy1cRN8zZWot2KOk1VAYkfuDg4rJuH8tD61eF7DeWbBHG7GcZrnr+9BcKvOOM0nogtqQ3UrEtmqqsdvHXv7UrsTy3PtQGHYYqOZFWFDbR7mmMepoc/OPWq9zcqh25G/0rKpOMIuUtkVGLbsgnm8pf+mh/SobcZkyeSeSaoyy73xnJq9acgH0r5nF4mVeV+nRHoU6agrF8MOnepoyTgdqrgjqRmrMJBBzx7VxmxMT+7AqFG2yKexNOmOFGKi3AnFUhF4CmMoqUDIpGXnqK6EQVypxTcVORgUzApjOGjfd1HNW45PlxWXG5BGCKtRSZwc/hX0ildHmWNGNhjNTqQ3U1nI57GplfmrTE0Wj6YpjDdkAUwPipBu3Z4FVcREck4p2wY5PNLLy2RwDQrAHmgQwpgHuKiZBnpzVtVU+9MZeaYFGaPOc96rgmI8GtGRe3eq0iDPT3otbULj7e9K8OQRV+ORZEBQ1kPFkE9/SmQGSJsjp6UXA2k3RyEins2wg84NUobtmG04JqdZCciToe9O9x2LcErLyDt/GlM+WwnzHue1QJEMD5srVhRgcAADp71DuNDgxIGTT0fnmmbe+KxvFGuW2gac9zcuDIQRFH3dqRRF4t8UW/h+zd3Ie6cHyox1J9fpWbod8byyS5km3vMNxb09q8c1bVLnWL+S7vH3Suc47KPQVt+EtVltmMG4+UeVHoa4McnUhyx6HRRSi7s9biVVwd4NbFmP3YI71wlpqcd1KsZciT0rubFStvGo9K8GpFx3OtMs7sdOKkhl5HU84yagmxGoLHFRfaYVYKu7eenFZWGaErksKcVxHhcFjUckTsyszBF9+tK8mE2r0/WqW4GkjAqOaVjxxVeNtqL9KdvrpIHsRURNI74qHzaYHn8fSrEFFFe9S+FHBLdllanXtRRWqIJB2qY/w/SiirRLFf/Vj/epkn3TRRVMQ+L7tHcUUVYhsnX8Krj75+tFFJgI33TUB6miikMSD/WD61bn6CiiiO4y5Y/6ofWrx+4PpRRQxoX+EV458bf8AkIab/ut/Oiis5GsNzz23+8fp/StPTOif7w/nRRXNUNludsn/ACMFrXqNp/qEoorwcR0N4dR1x99K0Iv4f92iiuePUtkk/QfQVXPX8aKKrqBcoPSiiugkifpUVFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To stop a nosebleed, sit or stand while bending forward a little at the waist. Then pinch the soft area towards the bottom of your nose, below the bone. Squeeze both sides of your nose shut for at least 15 minutes. (In children, squeeze for only 5 minutes.) Do not check to see if the bleeding has stopped until your time is up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_21_16735=[""].join("\n");
var outline_f16_21_16735=null;
